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ABSTRACT OF THESIS
The expression of the androgen receptor gene in cell models of prostatic
epithelia and its relationship with the apoptosis inhibiting oncogene bcl-2 was
examined.
The inability of the metastatic prostate cancer cell lines DU145 and PC3 to
respond to androgens is well documented. However, the LNCaP cell line displays
marked growth stimulation in the presence of the androgen dihydrotestosterone
(DHT) at concentrations between 0.001 nM and 10.0nM. Paradoxically, LNCaP
demonstrate growth stimulation in the presence of the non-steroidal anti-androgen
hydroxy-flutamide with significant (p<0.05) effects being observed at concentrations
of 1.0nM and 10.0nM 4days post-administration. Primary cultures of prostatic
epithelial cells derived from both benign hyperplastic (BPH) prostates and from
prostate cancer (CaP) tissues, in common with DU145 and PC3, do not exhibit
growth response to either DHT or to hydroxy-flutamide at any of the concentrations
employed.
Northern analysis of total RNA samples, using a 1kb PCR probe
complementary to the 3' portion of the androgen receptor (AR) cDNA, demonstrates
that of all the cells examined only the LNCaP cell line displays detectable AR gene
transcripts. Increasing the sensitivity of AR mRNA detection through the use of
reverse transcription-polymerase chain reaction (RT-PCR) enables detection of AR
gene expression in LNCaP, PC3 and both BPH-derived and CaP-derived primary
epithelial cells. In contrast RT-PCR, coupled with Southern blotting, was unable to
identify AR mRNA in the DU145 cell line. This apparent complete down-regulation of
AR gene expression cannot be blamed on any gross rearrangements or deletions
within the gene since all 8 exons were detectable by PCR. Indeed the only variation
in the AR gene between the established cell lines was in the CAG repeat region of
exonl, and since in all cells the size of this repeat was observed to fall within what is
generally accepted as the normal range, it was deemed irrelevant in terms of AR
expression and function.
Transfection with the steroid receptor reporter plasmid pMMTV/SPAP
demonstrated that the extent of AR gene expression in the primary epithelia and
PC3 is insufficient to furnish these cells with a functionally-significant level of
receptor protein. When supplemented with either DHT or hydroxy-flutamide,
pMMTV/SPAP-transfected PC3 and primary epithelial cells do not exhibit significant
alterations (p>0.05) in the extent of alkaline phosphatase secreted compared with
cells transfected with the control vector pRc/CMV. pMMTV/SPAP-transfected
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LNCaP cells exhibit an approximately 200% increase in SPAP production compared
with control cells when supplemented with 10.0nM DHT. Similar levels of SPAP
production are observed following the administration of 10.0nM hydroxy-flutamide to
pMMTV/SPAP-transfected LNCaP. Furthermore androgens and anti-androgens are
observed to act synergistically to activate AR-driven gene transcription in this cell
line. Such unusual co-operation was abolished upon the introduction of normal
androgen receptor into LNCaP cells via the expression vector pCMV/ARcom.
The bcl-2 oncoprotein has been implicated in the transition of prostatic
adenocarcinomas from a state of androgen-dependence to one of androgen-
independence during androgen ablation therapy. RT-PCR indicated that the three
prostate cancer cell lines and all of the primary epithelial cell cultures examined
contain measurable levels of both the bcl-2a and bcl-2p mRNA transcripts.
Furthermore, Western blotting using an anti-bcl-2 monoclonal antibody illustrated
that of the three cell lines, PC3 express the highest level of bcl-2, with conservative
densitometric estimates placing this level of oncoprotein at -2.7 times that
observable in the LNCaP model, bcl-2 Expression in primary epithelial cells is
equivalent to that in the PC3 cell line.
The possibility of a relationship between AR expression and that of bcl-2 was
examined through transfection of PC3 with pCMV/ARcom. Levels of bcl-2
oncoprotein are not reduced in AR-positive PC3 cells and indeed DHT
administration induces a pronounced increase in oncogene expression. It is
therefore unlikely that AR loss and bcl-2 elevation are concomitant events in the
acquisition of an androgen-independent phenotype.
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Carcinoma of the prostate (CaP) is currently the most commonly diagnosed
cancer in men in the U.S.A., excluding skin cancer, and is the second leading
cause of cancer death. Data compiled by the American Cancer Society in 1992
predicts that approximately 1 of every 11 men will develop CaP during their lifetime
and that 25.7% of this population will die as a consequence (Coffey, 1992).
Translated, this data indicates that the United States possesses an age-adjusted
death rate for CaP per 100,000 population of 15.7. World-wide the death rate
ranges from 22.0 per 100,000 population in Switzerland to 0.5 per 100,000
population in Korea. If one considers, that of all cancers, the prevalence of CaP
increases the most rapidly with age, such figures must surely increase, with
continuing shifts in the world-wide demographic patterns toward an older-aged
population. Indeed, in the United States it has been estimated, that during the
years from 1985 to 2000, there will be a 37% increase in the number of prostate
cancer deaths per year and a 90% increase in CaP cases diagnosed.
1.1 The Prostate
The prostate is a fibromuscular, glandular organ that surrounds the prostatic
urethra, and is located between the neck of the bladder superiorly, and the
urogenital diaphragm interiorly. It is composed of acinar units and ducts, lined with
epithelial cells, arranged within fibromuscular connective tissue and enclosed within
a dense, fibrous capsule. The entire organ is sheathed in a heavily vascularised
cover derived from pelvic fascia. It functions to secrete a multifaceted alkaline liquid
into the seminal fluid at the time of ejaculation, in order to optimise the environment
of the spermatozoa for their potentially hazardous journey to the vagina. The two
major diseases of the prostate are benign prostatic hyperplasia (BPH) and
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carcinoma (CaP), the former characterised by enlargement of the gland leading to
the obstruction of urethral outflow.
1.1.1 Anatomy
McNeal's model of the prostate demonstrates four distinct zones that differ
markedly in their tissue composition and highly significant differences in their
susceptibility to the different pathologic conditions (Figure 1.01a.) ( McNeal, 1981 )
. It should be noted, that despite obvious histological differences, these various
zones do not represent discrete compartments.
The peripheral zone constitutes almost 75% of the glandular tissue of the
adult prostate and forms the postero-inferior portion of the prostate. It possesses
long, branched glands, whose ducts curve posteriorly to open mainly into the
prostatic sinuses, although a number open on the lateral urethral walls. In a study
of 104 prostate glands obtained at radical prostatectomy for adenocarcinoma, of 88
cancers whose probable zone of origin could be identified, 68% were seen to arise
in the peripheral zone ( McNeal et al., 1988 ).
Those ducts that branch proximally into the mesenchyme surrounding and
following the ejaculatory ducts are referred to as the central zone. Their orifices
arise on the convexity of the verumontanum immediately surrounding the
ejaculatory ducts. This region accounts for approximately 25% of the prostatic
volume and presents with a mere 8% of adenocarcinomas.
In addition to the dramatic anatomic delineation that exists between the
peripheral and central zones, striking histologic differences are observed between
their glandular tissues which might suggest important differences in biological
function. Such dissimilarities might explain why carcinoma commonly arises in the
peripheral zone, while the central zone exhibits a degree of resistance to
tumourigenesis. The acinar tissue of the central zone consists of large, irregularly
shaped spaces into which numerous septa project. In contrast, the peripheral zone
possesses long narrow ducts that branch into small, regular acini that are round in
appearance and exhibit smooth non-septate walls. The epithelial cells resident
within the glandular tissues of the peripheral zones are columnar in appearance,
with readily distinguishable cell membranes and basally located small, dark nuclei.
In contrast, the cells of the central zone exhibit variable lengths and appear more
opaque, with a granular cytoplasm and less well-defined borders. They exist at a
significantly higher cell density than the cells of the peripheral zone and possess
large nuclei displaced to variable levels from the basement membrane.
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Figure 1.01 a. The anatomic zones of the prostate, showing the central, transitional,
peripheral and anterior fibromuscular zones in sagittal section. The position
of the verumontanum is also indicated, (adapted from Algaba, 1992).
b. The normal architecture of prostatic ducts, (taken from Tenniswood,
1993)
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The transitional zone constitutes a small group of ducts, comprising a mere
5-10% of the total prostatic volume, arising at the junction point of the proximal and
distal urethral segments. It exhibits two lobes, positioned on each side of the
urethra, in the angle between the peripheral and central zones, with ducts opening
onto the lateral urethral wall. Compared with that of the other main glandular
regions of the prostate, the ductal branching of the transitional zone is observed to
be considerably simpler, which may underlie the inability to assign any functional
significance to this region. It does, nevertheless, have great relevance in adult
pathology, presenting with 24% of prostatic adenocarcinomas and in combination
with the other peri-urethral glands, being the exclusive site of origin of benign
prostatic hyperplasia.
The fourth main anatomic region of the adult prostate is entirely
fibromuscular, with no glandular structures. The anterior fibromuscular zone
constitutes approximately 1/3 of the total prostatic volume, and forms the entire
anterior surface of the prostate. The full significance of this region in prostate
function and pathology remains to be ascertained
Prostatic acini drain via the ductal systems into the prostatic urethra. Micro¬
dissection of the acinar units indicates the presence of three separate
components - the proximal region (secretory), the distal region (non-secretory) and
the proliferative distal tip (Tenniswood, 1993)(Figure 1.01b.). The glands are lined
by tall, columnar epithelia separated from the basement membrane by a layer of
basal or reserve cells. The ducts are lined by more cuboidal cells again with a basal
cell layer. The basement membrane isolates the epithelia from the prostatic stromal
tissue which is composed of fibroblasts, smooth muscle cells, endothelial cells,
nerve cells and assorted infiltrating cells including mast cells and lymphocytes.
Clearly ,the proximity of the stromal compartment allows alteration of the epithelial
micro-environment and it is evident that the basal and glandular cells receive
growth factors, trophic nerve factors and androgens that have traversed the
basement membrane.
1.1.2 Function.
At the moment of ejaculation, sperm which entered the prostate via the vas
deferens and through the seminal vesicles into the central zone, are expelled into
the urethra at the verumontanum. At this point the sperm is exposed to the
combined secretions of the seminal vesicles and central zone. They continue along
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the distal prostatic urethra, where they are combined with the secretions of the
peripheral zone, prior to moving through the phallic urethra and into the vagina.
The secretions of the central and peripheral zones, which represent approximately
15-30% of ejaculate volume ( Mann and Lutwak-Mann, 1981 ) contain a multitude
of both protein and non-protein components, many of which, have as yet to be
assigned an irrefutable function.
The epithelia of the normal adult prostate produce a fluid of approximate pH
7.28, that is rich in electrolytes, notably zinc believed to be involved in the
stabilisation of sperm chromatin. Other non-protein constituents, include citric acid,
cholesterol and the polyamines; spermine, spermidine and putrescine. The protein
components of the prostatic secretions are many and varied. Growth factors (e.g.
epidermal growth factor), immunoglobulins, transferrin, prostatic acid phosphatase
(PAP) and the exclusively prostatic in origin, prostate specific antigen (PSA) are all
detectable. The prostate also express very high levels of annexins 1, 4 and 5
( Haigler and Christmas, 1990 ). Some of the more interesting facets of prostatic
function arising from contemporary research will be discussed.
The annexins, of which there are 8 different forms in mammalian cells
( Crumpton and Dedman, 1990 ), are a family of structurally related proteins that
are known to bind certain intracellular phospholipids in a Ca2+-dependent manner.
It has been proposed that annexins also have an extracellular site of action, due in
part to their detection in peritoneal exudates. However cDNA sequence analysis
would seem to indicate the lack of a hydrophobic signal sequence directing
secretion ( Pepinsky et al, 1988 ), and in addition, the N-termini of mammalian
annexin proteins are observed to be blocked by acetylation. These observations
are consistent with those of other intrinsically intracellular proteins.
Haigler and Christmas (1990, 1991) have demonstrated the presence of
annexins 1 and 5 in seminal plasma. Analysis by immunoblotting demonstrated that
annexin 5 and annexins 1 & 4 locate exclusively to seminal vesicle tissue and
prostatic epithelia respectively. Thus, it would appear that although annexin 1 and
annexin 4 both localise to the ductal epithelia of the prostate, only the former is
secreted as part of the prostatic fluid.
The existence of annexins 1 and 5 in the seminal plasma, indicates that
proteins without recognised secretory signalling can function extracellularly.
Furthermore, the secretion of annexin 1 by prostatic epithelia suggests the
presence of a selective pathway for its release from the cell, and potentially, a
specific requirement for this protein within the prostatic exudate. As yet, roles for
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annexins 1 and 5 in the seminal plasma have not been suggested, but the high
concentration of calcium within the prostatic fluid might indicate that these proteins
will, at least, be functional within the semen .
Spermine, spermidine and putrescine have been postulated to induce the
formation of the seminal clot, following ejaculation, catalysed, potentially, by
transglutaminase. The clot, principally composed of a polymerised gel formed from
seminogelin and fibronectin, is broken down 5-20minutes post-ejaculation through
the activity of PSA, secreted into the prostatic component of the seminal plasma.
PSA is a 34kdalton glycoprotein, functioning as a kallikrein-type serine
protease, that is expressed specifically by prostatic tissue. The concentrations of
PSA in blood serum are commonly used as diagnostic and prognostic indicators in
prostate cancer. Serum PSA levels are known to be proportional to the volume of
intra- and extra-capsular prostate cancer ( Stamey et al, 1987 & 1989 ) and are
also used to follow prostate cancer patients after radical prostatectomy,
radiotherapy and anti-androgen therapy.
Lee at al (1989) analysed the composition of the seminal clot and the
involvement of PSA in its disruption. Using 2D gel electrophoresis a group of
proteins, ranging from 28kD to 68kD, designated seminal vesicle-specific antigen
has been identified in both seminal vesicle fluid and freshly ejaculated semen. The
addition of PSA or prostatic fluid to seminal vesicle fluid completely removes
seminal vesicle-specific antigen from the 2D profile. It is proposed that the
structural component of the seminal coagulum is seminal vesicle-specific antigen,
and that the digestion of this complex by PSA leads to liquification of the clot.
The primary function of the seminal plasma is to sustain the spermatozoa
and to maximise the chances of fertilisation. To achieve this, the immune system of
the female reproductive tract must be impeded.
The levels of antibodies in women directed against sperm is low ( Bronson
et al, 1984 ), due, in no small part, to the presence of powerful immunosuppressive
agents arising within human seminal plasma. Among these agents are the
prostaglandins; PGE-|, PGE2, 19-hydroxy PGE-| and 19-hydroxy PGE2
(Templeton et al, 1978 ). In addition, Kelly etal (1991) have demonstrated the
immunosuppressive capacity of microparticulate prostasomes derived from seminal
plasma, and suggest that they cooperate with the prostaglandins in this function.
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Prostasomes are submicrometre organelles that locate to membrane-bound
storage vesicles within acinar epithelial cells of the prostate. They are released into
the glandular lumen, either by translocation of the storage vesicle across the
plasma membrane, or exocytically, through fusion of the storage vesicle membrane
and plasma membrane ( Ronquist and Brody, 1985 ). Ronquist and Brody (1982)
were the first to isolate prostasomes from seminal plasma using a combination of
ultracentrifugation and chromatography, and proposed that they function to
promote motility of spermatozoa.
Kelly and colleagues (1991) have demonstrated the inhibition of
phytohaemagglutinin (PHA)-induced proliferation of human T cells and the arrest of
phagocytic activity in a mouse macrophage cell line by pure preparations of
prostasomes. The mechanism of the observed immunosuppression is not fully
understood, but it has been suggested that it arises from phagocytosis of the
particles themselves. It could be envisaged that prostasomes, which are observed
to associate with spermatozoa ( Ronquist et al, 1990), are preferentially
phagocytosed, and subsequently release inhibitory factors within the macrophage.
In this way, a degree of protection against macrophage action can be offered to the
spermatozoa.
1.2 The Endocrinology of the Prostate.
A number of steroid and peptide hormones exert influences upon the
prostate. Figures 1.02 and 1.03. summarise the hormonal network that exists
between the endocrine organs and the prostate. Androgens e.g. testosterone and
dihydrotestosterone play a key role in the growth and development of the prostate
from embryogenesis to puberty and on through adulthood. The synthesis and
release of androgens from both the testis and adrenal cortex relies upon the input
of the gonadotrophins and adrenocorticotrophic hormone respectively, the
production of which, within the pituitary, is regulated by hypothalamic releasing
hormones. In addition, under the control of the hypothalamus, the pituitary releases
prolactin, a relative of human growth hormone, which acts upon the prostate in an
as yet undefined manner.
1.2.1 The Hypothalamo-Pituitary-Gonadal Axis.
In response to neural inputs, the median eminence of the hypothalamus
liberates a number of factors that exert both stimulatory and inhibitory influences
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upon the cells of the anterior pituitary. In response the anterior pitiutary produces
and secretes tropic hormones that target the adrenal cortex and the Leydig cells of
the testis with consequent liberation of androgens and other steroid hormones into
the bloodstream.
1.2.1.1 The Hypothalamo-Pituitary Unit (Figure 1.02).
Peptide hormones and neurotransmitters are secreted into the median
eminence via peptidergic and bioaminergic tuberohypophyseal neurones
respectively. These factors enter the bloodstream via capillary beds within the
median eminence, and are subsequently delivered to the anterior pituitary
(adenohypophysis) along short and long portal vessels. Hypothalamic products
reaching the anterior pituitary in this way include; dopamine, y-aminobutyric acid
(GABA), vasopressin and the releasing hormones, luteinising hormone-releasing
hormone (LHRH), corticotropin-releasing hormone (CRH), growth hormone-
releasing hormone (GHRH) and thyrotropin-releasing hormone (TRH).ln terms of
the activity of the prostate and its dependence on androgenic input, the most
significant of the releasing hormones is LHRH.
LHRH, released by the hypothalamus in a pulsatile fashion, binds to specific
cell surface receptors on gonadotrope cells within the anterior pituitary, inducing
2nc' messenger responses which ultimately result in the release of the trophic
hormones; luteinising hormone (LH) and follicle-stimulating hormone (FSH).
Similarly, CRH in combination with vasopressin etc. stimulates the release of
adrenocorticotropic hormone (ACTH) and an ill-defined peptide from corticotrope
cells which target the adrenal cortex.
In contrast to the gonadotrophins, corticotrophins and growth hormone the
hypothalamic secretions predominantly inhibit the secretion of prolactin. Dopamine
and GABA are mainly responsible for this suppression and are consequently
referred to as prolactin inhibiting factors (PIF's). However it has been proposed that
several factors of hypothalamic origin can act as prolactin releasing factors (PRF's).
These include; TRH, vasopressin and oxytocin.
1.2.1.2 The Adrenal-Testis-Prostate Network (Figure 1.03).
The factors liberated by the pituitary gland exert their influence upon the
prostate in both direct and indirect fashions (Figure 1.03).
LH, FSH and ACTH stimulate the release of androgenic steroids from the
Leydig cells of the testis and adrenal cortex which subsequently target the prostate
8
Figure 1.02 The Hypothalamo-Pituitary Axis - Factors Relevant to Prostatic Metabolism.
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Abbreviations : Prolactin Releasing Factors (PRF's) e.g thyrotropin releasing hormone, vasopressin, oxytocin,
peptide-histidine-isoleucine-27 and neurointermediate lobe factor.
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gland. In contrast to this characteristically indirect action of the trophic hormones,
growth hormone (GH) is believed to act directly upon the prostate, owing to the
detection of endogenous GH in BPH and CaP (El Etreby and Mahrous, 1979) and
the identification of cell-surface GH receptors in prostatic tissue (Sibley et al, 1984;
Prieto and Carmena, 1987). The exact function of GH in the prostate remains to be
elucidated. However, Reiter et al (1992) have demonstrated that the responses of
the rat prostate to GH are analogous to those observed with prolactin. These
responses are manifest as up-regulation of AR and insulin-like growth factor-I
(IGF-I) and IGF-I receptor.
Prolactin, in the context of the prostate, is perhaps the most intriguing of the
pituitary factors in that it elicits both direct and indirect effects upon prostatic
metabolism. Direct action is mediated by a specific cell surface receptor - cloned in
the late 1980's by Boutin et al (1988 & 1989) - with the indirect effects being
manifest as an elevation of testosterone synthesis in the testis (Hafiez et al, 1972).
Human prostate membranes are rich in receptors for prolactin (Leake et al,
1983). More recently prolactin receptor mRNA transcripts have been visualised in
epithelial cells by in situ hybridisation techniques (Ouhtit et al, 1993). It has long
been known that prolactin, via this cell surface receptor, dramatically increases the
uptake of testosterone by prostatic tissue (Jacobi et al, 1978; Farnsworth, 1981). In
addition to these observations, it has been demonstrated that there is a strong
correlation between plasma prolactin and androgen receptor (AR) expression in
patients suffering from BPH (Odoma et al, 1985). Reiter et al (1992) have shown
such upregulation of AR protein in hypophysectomised rats in response to prolactin
and determined that it correlates well with increases in AR mRNA. It would appear,
in the face of such evidence, that prolactin has some direct role in the regulation of
AR expression in vivo. Outwith the androgenic network, prolactin has, in addition,
been observed to have upregulating influences upon the production of both citrate
and mitochondrial aspartate aminotransferase by prostatic epithelia, independently
of androgenic inputs (Franklin et al, 1990 & 1992).
Oestrogens too have been proposed to have both direct and indirect effects
upon the prostate. However if one examines Figure 1.03 closely there is a question
mark included alongside the input of oestrogen to the prostate. The reason for this
being that the role of oestrogen within the human gland is very unclear despite a
certain amount of evidence in animals. Oestrogens derived from dietary sources or
from the action of the enzyme aromatase - a protein structurally typical of a p450
enzyme (Corbin et al, 1988) - has been postulated to have a role in the
pathogenesis of BPH, synergising with DHT to enhance prostatic growth
10
Figure 1.03 Endocrine inputs to the Prostate.
Abbreviations : 5 aReductase (5aR); Dihydrotestosterone (DHT).
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in the dog (Walsh and Wilson, 1976; Aumuller et al, 1982). Such synergy is
believed to result from upregulation of the androgen receptor (Moore et al, 1979)
resulting in prostatic epithelial hyperplasia. There is, however, little evidence to
suggest that these effects occur in the human prostate where stromal hyperplasia
predominates. Indeed, the hyperplastic human prostate expresses significantly less
oestrogen receptor than does the normal prostate (Robel et al, 1985).
If direct action within the prostate is debatable, there is little doubt
concerning the indirect effects of oestrogen on the human prostate. Figure 1.03
demonstrates that both testosterone, released by the testis and derived from the
metabolism of adrenal androgens, and oestrogenic compounds act upon the
pituitary and hypothalamus to inhibit the synthesis and secretion of the trophic and
releasing hormones with concomitant down-regulation of androgen synthesis. Such
oestrogen-induced negative feedback is hugely significant in the context of the
treatment of androgen-dependent prostatic neoplasms.
1.2.2 Androgens and the Prostate.
As long ago as 1792, John Hunter established the influence of testicular
secretions on the growth of the prostate. Subsequent to this, following the isolation
of testosterone by David et al in the mid 1930's, the further involvement of
testicular testosterone in the progression of prostatic carcinoma was demonstrated
by the trailblazing work of Huggins and Hodges (1941). These pioneering
observations have spawned a profusion of treatment protocols based upon
androgen ablation.
Adrenal androgens have also been demonstrated to have an effect on
prostatic metabolism. Davidson and Moon (1936) observed growth of the rat
ventral prostate following treatment of castrated rats with ACTH. However it was
subsequently shown that removal of the adrenal has no significant effect on the
prostate in non-castrated individuals (Mobbs et al, 1973) and indeed
adrenalectomy merely offers palliation in the treatment of CaP following castration
(Huggins, 1945).
The major sites of androgen biosynthesis are the testis and adrenal cortex,
the latter accounting for approximately 10% of the 3-10mgml~'1 of plasma
testosterone in the adult male (Williams, 1992). The synthesis of androgens in the
testis and adrenal cortex, illustrated in Figure 1.04, is based upon the conversion of
cholesterol and occurs through a series of enzymatic pathways (Ghanadian,
12































1982). Stimulation of the Leydig cells of the testis with LH initiates the conversion
of cholesterol to testosterone via pregnenolone, progesterone, hydroxy-
pregnenolone, hydroxyprogesterone, dehydroepiandrosterone (DHEA),
androstenedione and androstenediol (Figure 1.04a.). The testes also secrete low
levels of DHT. The major androgenic products of the adrenals are DHEA and its
sulphated conjugate DHEAS (Figure 1.04b.). The adrenal cortex is also the main
source of circulating androstenedione. DHEA and DHEAS influence prostatic
growth through conversion to androstenedione and subsequently testosterone in
peripheral tissue e.g. adipose tissue, the adrenals and the prostate itself.
98% of plasma testosterone and DHT are bound to plasma proteins
(Vermeulen, 1977; Dunn et al, 1981). The literature suggests that there is variability
in the percentage testosterone bound by each protein. Vermeulen (1977) reports
that the binding distribution of testosterone per protein is as follows : testosterone
binding globulin, TeBG, (56%); albumin (40%); transcortin or corticosteroid binding
globulin, CBG, (2%). Free testosterone, therefore, represents only 2% of circulating
androgen. For many years it was this free testosterone fraction that was regarded
as the biologically active portion (Vermeulen, 1977), however, it became clear
during the 1980's that the active fraction is larger than the free fraction owing to the
dissociation of protein-bound testosterone within capillary beds (Pardridge and
Landaw, 1985). Subsequently, Pardridge et al (1986) demonstrated in vivo, that
almost all albumin-bound testosterone was available for tissue uptake and that
consequently the levels of bioavailable testosterone was equivalent to the sum of
free plus albumin-bound i.e. -50% of the total circulating hormone. The levels of
testosterone available to the prostate may well be higher owing to the presence of
specific membrane TeBG receptors (Hryb et al, 1989).
Testosterone released into the prostate is converted to DHT through the
activity of the enzyme 5areductase (A4-3-ketosteroid-5a-reductase), an enzyme
believed to locate exclusively to the nucleus (Houston et al, 1985) and of which
there are 2 known isoforms (Habib, 1994). It is DHT that is thought to be the
biologically active androgen within the prostate and indeed the importance of DHT
in prostatic development is borne out by the lack of a functional prostate in
individuals with 5areductase deficiency syndrome (Imperato-McGinley et al, 1992).
The activity of 5areductase does not represent the end-point of androgen
metabolism within the prostate since DHT is subsequently further metabolised to
androstanedione or to the 5aandrostanediols, as outlined in Figure 1.05. These
enzyme-catalysed reactions are reversible but it is clear that the diols in the normal
prostate are significantly in excess of DHT (Geller et al, 1976). Isaacs et al (1983)
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Figure 1.05 Androgen Metabolism in the Prostate Gland.(Adapted from Habib, 1990)
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showed the importance of the DHT metabolising enzymes in prostatic
pathogenesis by demonstrating that the elevation of intra-prostatic DHT associated
with BPH (Geller et al, 1976; Habib et al, 1976) - a finding refuted by Walsh et al
(1983) who did not observe any difference between the T/DHT ratios in normal and
BPH tissue - arises not only from an increase in 5areductase activity (Bruchovsky
et al, 1979) but also from a reduction of 3p-hydroxysteroid oxidoreductase and
17p-hydroxysteroid dehydrogenase (Isaacs et al, 1983).
The metabolism of androgens within the prostate is obviously well
understood, nevertheless, the question still remains as to how the intraprostatic
androgen pools control the growth, development and function of the prostate
gland. A strongly held opinion is that DHT and, to a lesser extent, testosterone act
mitogenically within the adult prostate, regulating the expression of growth factors,
growth factor receptors and other prostatic proteins. And indeed, there is some
evidence to support this theory.
A number of groups have demonstrated upregulation of the epidermal
growth factor receptor (EGFr) in response to androgenic stimuli (Schuurmans et al,
1988; Wilding et al, 1989). Wilding et a/(1989) also established that the production
of TGFa is increased by androgens in the hormone-sensitive prostate cancer cell
line LNCaP, and postulated that concomitant increases in EGFr may arise from
such elevation of TGFa or indeed EGF, as is observed in other systems (Kudlow et
al, 1986). It is worth noting however, that such up-regulation of the EGF receptor
with androgen stimulation has not been observed by other groups using androgen-
sensitive human prostate cell lines (MacDonald et al, 1992), and furthermore, in the
rat, EGF receptor is markedly reduced in response to androgens (Traish et al,
1987). Clearly, the relationships between androgens, EGF and its receptor is a
complex, perhaps even species-specific, one and requires further investigation.
Fibroblast Growth Factor (FGF) in its basic form is known to stimulate the
growth of both prostatic fibroblasts and epithelial cells (Story et al, 1989; Zuck et al,
1992). Androgens administered to cultured LNCaP cells induce an upregulation of
bFGF acting in a paracrine fashion to enhance the growth of a FGF-dependent cell
line (Zuck et al, 1992). Clearly androgens promote the production of autocrine and
paracrine acting growth factors leading to enhanced prostatic cell growth.
In addition to these influences upon growth factor networks, androgens also
govern the expression of the epithelially produced proteins PSA and prostate-
specific membrane antigen (PSM), the latter, recently cloned by Israeli et al (1993),
displaying negative responses to DHT and testosterone (Israeli et al, 1994). In
LNCaP, PSA is upregulated by androgens at both the RNA and protein levels
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(Young et al, 1991; Montgomery et at, 1992). Interestingly, the PSA gene has in its
5' region a putative androgen receptor-binding sequence or androgen response
element (ARE) which is believed to confer androgen-responsive gene transcription
by granting direct interaction of liganded androgen receptor (Riegman et al, 1991;
Young etal, 1991; Murtha etal, 1993).
1.3 Carcinoma of the Prostate.
According to the Scottish Health Statistics (1993) supplied by the National
Health Service in Scotland, the number of deaths resulting from carcinoma of the
prostate (CaP) in 1992 in all age groups in Scotland was 693. This equates to a
death-rate per 100,000 population of 28 and demonstrates an approximately 100%
increase in CaP related mortality since 1975. Indeed, CaP is the second most
prevalent malignancy in males in Scotland with only lung cancer exhibiting a higher
incidence. Prostatic disease is relatively uncommon in young males but there is a
dramatic increase in incidence with age. The Scottish Health Statistics bear out the
age-relatedness of CaP with only one case being diagnosed in individuals below
45. However, between ages 65 and 84 years old there is a dramatic increase in
CaP sufferers. Consequently, and as previously eluded to, shifts to an older-aged
population in Scotland, will necessarily involve rapid increases in CaP-related
death.
The vast majority of malignant prostatic tumours are adenocarcinomas
arising from acinar epithelial cells within the peripheral zone of the prostate . Ductal
epithelia give rise to -10% of carcinoma (adenocarcinoma and transitional cell
carcinoma)(Busuttil, 1990). Other malignancies observed include non-epithelial
carcinosarcomas and sarcomas (Rhabdomyosarcoma and leiomyosarcoma)
derived from the fibromuscular stroma, both of which occur very rarely.
There is wide variation in the clinical aggressiveness of prostate tumours
and it is evident that the behaviour of the neoplasm relates to stage and grade at
diagnosis. The generally accepted staging protocol is the TNM system proposed by
the UICC (1978) which can be summarised as follows : TO - no palpable tumour; T1
- incidental tumour; T2 - organ confined tumour; T3 + T4 - locally invasive tumour,
NO-3 - regional lymph node metastasis; M0-1 - distant metastasis. Several systems
for the classification of histological grade have been recognised notably those
devised by Mostofi (1975) and Gleason (1966). Gleason's grading technique, which
assesses the pattern of tumour growth as the relative state of differentiation based
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on its ability to form glandlike structures, scores the tumour from 1-5 as it becomes
less differentiated. As long ago as 1963, Vickery and Kerr observed that well
differentiated tumours have a better prognosis than tumours of poor differentiation
which exhibit a rapid course. Gleason's system results in a histological score that
correlates well with patient survival.
Prostatic carcinoma presents with an inordinately high incidence of latent or
dormant cancer, which will, in all probability, never become clinically manifest
(Franks, 1954). Approximately 10% of all men 50-59 years old and 50% of those
70-80 years old have histological cancers in their prostates, however, the majority
of these histologically localised cancers will remain sub-clinical and never require
treatment (Isaacs, 1991). The greater excess of CaP patients already present with
the symptoms of metastasis at the time of diagnosis (-2/3) and this relates to a 5
year survival rate of -50% in Scotland. In view of this, there is a strong case for
aggressive screening of men as they age such that tumours can be diagnosed at a
curable phase of their natural history. However, with such a high prevalence of
incidental prostatic cancers there is an obvious requirement for a consistent
predictor of which localised tumours will progress and therefore require treatment.
Such a prognostic indicator is as yet unavailable.
1.3.1 Treatment of Prostatic Carcinoma.
Radical prostatectomy and radiotherapy are commonly employed in the
treatment of organ-confined prostate tumours. Lepor et al (1989) demonstrated a
15 year disease-specific survival rate of 86% following radical prostatectomy with a
mere 14% of patients dying of metastatic tumour in the first 15 years post¬
operatively. The prognosis of the disease following radiotherapy is poorer with a 15
year survival rates of 66% observed after combined external beam and interstitial
radiotherapy (Lemer et al, 1988). However, as previously discussed, the majority of
CaP patients present with symptoms of metastatic disease and hence the above
treatments are inappropriate. These patients consequently undergo androgen
ablation therapy.
The concept of hormonal therapy for prostatic cancer was introduced in
1941 by Huggins and Hodges who reasoned that since normal prostatic epithelium
is androgen-dependent, prostate tumours should be similarly dependent. They, and
other groups subsequently, established that human prostate cancer could be
induced to regress through the administration of pharmacological doses of
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oestrogen or by castration (Huggins et al, 1941; Spirnak and Resnick, 1983).
Regression of tumours was associated with impressive palliative effects in patients
with symptoms, and it was assumed that this excellent palliation was also
concomitant with increased survival. However, the Veterans Administration Co¬
operative Urological Research Group (VACURG)(1967) failed to establish any
survival benefit in terms of pain reduction, urethral obstruction and neurological
symptoms. In spite of these obviously disappointing results, hormonal therapy
continues to play an important role in the treatment of advanced prostatic
carcinoma.
1.3.2 Principles of Endocrine Therapy.
All types of endocrine management of prostate cancer utilise mechanisms
that are related either to hypothalamic-pituitary-testicular feedback mechanisms or
to the ability of anti-androgens to counteract the effects of androgens on prostatic
epithelia.
Surgical castration (orchiectomy) can probably be considered the standard
treatment for prostatic carcinoma. Ghanadian et al (1979) demonstrated a
reduction of serum testosterone from 645ng/100ml to 11ng/100ml following primary
orchiectomy. These findings are very much in keeping with those of other groups.
In general, such dramatic reductions in circulating testosterone are observed within
24hours post-operatively and prompt significant diminution of prostatic size and
palpable tumour mass within 3 months, in almost 100% of cases (Carpentier et al,
1986).
Interference with hypothalamo-pituitary feedback mechanisms offers a less
radical approach for the suppression of circulating androgens. As previously
discussed, LHRH secretion is dependent on negative feedback with androgenic
and oestrogenic hormones. Consequently, the commonest and certainly the oldest
method of quenching LHRH secretion by the hypothalamus is through the use of
exogenous oestrogens. This approach was first employed in the successful
treatment of prostate cancer by Herbst in 1942. Synthetic oestrogens, of which
there are a number, notably diethylstilboestrol (DES) and estramustine (estracyt -
an oestrogen-mustard complex), are commonly used, with the former reducing
serum testosterone to castrate levels at a dosage of 3mg daily (Shearer et al,
1973). The use of such oestrogenic compounds, in particular DES, is, however,
associated with cardiovascular thromboembolic side effects and significantly
increase the death rate from such diseases (VACURG, 1967; de Voogt et al,
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1986). Reduction of testicular testosterone synthesis without the side-effects
characteristic of oestrogen administration can be achieved using LHRH agonists.
These agents e.g. leuprolide and buserelin, were first described in the early 1970's,
and offer more selective suppression of LH secretion.
The suppression of serum testosterone using androgen withdrawal regimes
results in loss of libido and often impotence in the patient. Significant reductions of
these side-effects and those associated with oestrogen treatment have been
observed through the use of anti-androgens that counteract androgen action at the
cellular target and latterly with 5areductase inhibitors e.g. finasteride, that block the
conversion of testosterone to DHT in prostatic epithelia. The most widely used anti-
androgens are the steroidal compound cyproterone acetate and the non-steroidal
androgen antagonist flutamide. The latter binds to the androgen receptor
competitively as an activated a-hydroxy metabolite (Neri, 1977; Simard et al, 1986).
Subjective improvements have been observed in 90% of patients given flutamide
(Sogani et al, 1984), however, resulting inhibition of androgen feedback induces a
secondary increase in plasma testosterone (Knuth et al, 1984) and has
discouraged many clinicians from using flutamide and other anti-androgens as
monotherapy. Consequently, non-steroidal anti-androgens are commonly used in
combination with castration or LHRH agonists to achieve what is termed "total
androgen blockade" allowing simultaneous obstruction of both testicular and
adrenal androgens. Debate continues as to the benefits in terms of duration of
response and survival of such combination therapy (for review see Labrie, 1991). In
view of this, and the fact all treatments necessarily involve a certain degree of side-
effects, endocrine therapy is in general limited to patients with metastatic disease,
usually associated with symptoms.
Owing to the age-group involved, a large proportion of the patients with
prostate cancer will die of unrelated, concomitant disease during androgen ablation
therapy. Those surviving patients, in virtually all cases, will have a relapse due to
tumour progression that can no longer be influenced by endocrine manipulations
(Sinha et al, 1977). The mechanisms that underlie this switch to hormone-
independent growth or "hormone escape" are ill understood.
1.3.3 Effects of Androgen Ablation upon the Benign and Malignant Prostate.
After -20 years of age, growth of the prostate ceases and a period of
maintenance ensues, in which the rate of prostatic proliferation is in equilibrium
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with the rate of prostatic cell death (Isaacs, 1987). In the adult male rat this rate of
death/proliferation is in the order of 2% per day. Androgens play a pivotal role in
prostate maintenance, acting both agonistically and antagonistically on prostatic
cells through simultaneous stimulation and inhibition of the rate of proliferation and
death respectively (Bruchovsky et al, 1975; Isaacs, 1984). Consequently, the rate
of cell death is promoted under the androgen limiting conditions resulting from
castration, and culminates in the involution of the prostate.
It has been demonstrated that it is the secretory epithelia not the basal
epithelia or stromal fibroblasts that are lost during androgen ablation (English et al,
1987 and 1989). Indeed a 66% decrease in glandular epithelia has been observed
following castration. The death of normal androgen-dependent non-malignant
epithelia is not believed to be necrotic, but rather, is brought about through the
initiation of programmed cell death (apoptosis)(lsaacs, 1984; Kyprianou and
Isaacs, 1988a.). Programmed cell death is also typical in malignant prostatic
epithelia. Kyprianou and co-workers (1990) observed that in the androgen-
responsive prostate tumour, PC82, grown as a xenograft in nude mice, androgen
deprivation leads to an alteration of cell proliferation and death rates from 3.5% to
0.5% and from 0.5% to 4.7% respectively.
So if androgen ablation successfully induces programmed cell death in
malignant epithelial cells, why in nearly all cases do prostatic tumours relapse and
escape from androgenic control? Debate continues as to the answer to what is
arguably the biggest question in prostate cancer research.
There is evidence to suggest that metastatic prostate cancer is a
heterogeneous tumour comprising clones of both androgen-dependent and
androgen-independent cells (Schulze et al, 1987). Controversy surrounds the
potential mechanisms underlying this heterogeneity, nevertheless, what is clear is
that once hormone-independent cancer cells are present within individual patients,
these patients cannot be cured by endocrine management alone. This regrettable
situation arises because partial or total androgen blockade only induces cell death
in the androgen-dependent epithelia such that there is outgrowth of androgen-
independent clones (Isaacs and Coffey, 1981; Schulze et al, 1987). Such clonal
selection may well be the critical feature of hormone escape in prostatic carcinoma.
Rennie et al (1990) in their analysis of tumour recurrence in the androgen-
dependent Shionogi mouse mammary carcinoma observed a proportionate
increase in the number of tumourigenic stem cells from 1 per 4000 progeny (end)
cells to 1 per 200 progeny cells - a 20-fold increase in the size of the stem cell
population. This was concurrent with the complete elimination of nearly all
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androgen-dependent progeny cells and an approximately 500-fold increase in the
number of androgen-independent (Al) stem cells. These Al stem cells, which
necessarily give rise to Al progeny, Rennie believes, arise from adaptation - not
selection, as proposed by Isaacs and Coffey - of initially androgen-dependent cells,
owing to their extremely low incidence in regressing parent tumours.
Cell-cell interactions have also been implicated in the transition from
androgen-dependent to androgen-independent epithelial cell growth. Tenniswood
(1993) suggests that the proximity of stromal cells attenuates the programmed cell
death of prostatic epithelia following castration. In support of this claim he reminds
us that in the normal adult prostate, it is only the epithelial cells at the distal tip (see
Figure 1.01b.) of the acinar unit, which are separated from the stromal
compartment only by sparsely distributed basal epithelia, that are induced to
undergo apoptosis. In the proximal region basal cells form a continuous layer that it
is intercalated between the stroma and the luminal epithelial cells.
Despite these theoretical differences, in all cases the end-product is an
androgen-independent, apoptosis-resistant and potentially lethal epithelial cell.
Undeniably, in terms of effective treatment protocols for advanced metastatic
tumour, there is a desperate requirement for therapies that target both the
androgen-dependent and androgen-independent epithelia. This will involve the use
of total androgen blockade coupled with chemotherapeutic agents which will target
and induce cell death in the androgen-insensitive cells. As yet, there are no such
agents with the ability to control the growth of hormone escaped prostate cancer
cells.
1.4 Programmed Cell Death (Apoptosis) in the Prostate.
Necrotic cell death is a passive cellular process , characterised by
permeabilisation of the plasma membrane leading to osmotic lysis of the cell and
its internal membranes. In contrast, programmed cell death involves active
participation by the cell in its own death. The initiation of this energy-dependent
process leads to a number of biochemical and morphologic alterations notably DNA
fragmentation that precedes eventual breakdown of cellular membranes (Kerr et al,
1972; Wyllie, 1980). Fragmentation of genomic DNA is an early event in the
apoptotic pathway that necessarily commits the cell to die. It is believed to result
from the activation of Ca2+/Mg2+-dependent nuclear endonucleases. Cleavage of
the DNA initially releases 50bp chromatin loop domains (Oberhammer et al, 1993)
prior to liberation of stereotypic 180-200bp internucleosomal DNA fragments
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(Wyllie, 1980; Wyllie et al, 1984). Nuclease activation is triggered by sustained
elevation of intracellular Ca2+ concentration initiated early in programmed cell
death (McConkey et al, 1989a. and b.). The increase in intracellular Ca2+ is
derived from the extracellular Ca2+ pool (Furuya and Isaacs, 1993).
These events are characteristic of a number of different cell types, including
the prostate, which undergo programmed cell death, however the precise cellular
mechanisms which underlie not only prostatic epithelial apoptosis, are only now
becoming clear.
12 to 24 hours post-castration the rat intra-prostatic DHT level plummets to
~5% of that observed in intact animals, with concomitant reduction of androgen
receptor retained in isolated ventral prostatic nuclei (Kyprianou and Isaacs,
1988a.). These changes in the level of nuclear androgen receptor lead to
expression of a number of genes which are normally repressed in the prostate.
Notable amongst these genes are those for testosterone repressed prostate
message-2 (TRPM-2; Montpetit et al, 1986), glutathione S-transferase (Chang et al,
1987), TGFpi &theTGFpi receptor (Kyprianou and Isaacs, 1989a. and 1988b.),
C-CAM (Hsieh and Lin, 1994) and c-myc, hsp70 & Ca2+-responsive c-fos (Buttyan
et al, 1988). This epigenetic reprogramming is believed to induce initiation of the
programmed death pathway with consequent DNA fragmentation and cell
breakdown into apoptotic bodies (Kyprianou and Isaacs, 1988a.).
TRPM-2 [also termed sulphated glycoprotein-2 (SGP-2), clusterin,
complement cytolytic inhibitor and SP-40/40] is expressed by a number of tissues -
including the prostate during androgen ablation - undergoing programmed cell
death and although as yet not fully characterised, provides a useful early marker
for apoptosis (Buttyan et al, 1989). [It is worth noting that the homology of TRPM-2
to a factor whose function is to inhibit complement-induced cytolysis of epithelial
cells (Jenne D.E. and Tschopp J., 1989) may suggest a protective role in surviving
cells]. Additionally, both c-myc and TGFpi have been demonstrated to induce
programmed death, the latter in rat ventral prostatic epithelia (Bissonnette et al,
1992; Fanidi et al, 1992; Martikainen et al, 1990). Kyprianou et al (1989) observed
that 4 days after castration both the expression of TRPM-2 and TGFpi reaches a
maximum in the rat ventral prostate. The suggestion that TGFpi expression
parallels the onset of programmed death lead to the demonstration that apoptosis
can be induced in the rat ventral prostate by this growth factor, even in the
presence of physiological levels of testosterone (Martikainen et al, 1990). In human
tissues similar results have been obtained. Muir et al (1994) have shown that
prostatic TGFpi is highly expressed in patients receiving androgen ablation
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therapy and that the increased staining localises to the extracellular compartment
of the stroma adjacent to the tumour. These findings suggest that stromal-epithelial
relationships have a vital role in the programmed cell death of secretory epithelia.
The precise role of the elevated TGFpi expression following androgen ablation is
not clear, however, there are indications of involvement in the raising of intracellular
free Ca2+ (Furuya and Isaacs, 1993).
Furuya and Isaacs (1993) have recently analysed the expression of a
number of genes potentially involved in the biochemical steps of prostatic epithelial
cell death. Perhaps most significant among these are the gene for the Ca2+-
binding protein, calmodulin, which demonstrates post-castration increases in
expression and the genes encoding p53, ornithine decarboxylase, c-fos and H4-
Histone whose expression is unchanged after androgen ablation but rises
dramatically after testosterone replacement. It has also been demonstrated that c-
myc is up-regulated in both cell death and cell proliferation.
Calmodulin is involved in the calcium-dependent regulation of a number of
enzymes (perhaps nuclear endonucleases) and interestingly is implicated in
dexamethasone-induced cell death in lymphocytes where its expression is
increased -10 fold after dexamethasone treatment (Dowd et al, 1991).
Cell cycle events have been suggested to regulate prostate cell apoptosis.
Colombel et al (1992) at the 9^ congress of the European Society for Urological
Oncology and Endocrinology (E.S.U.O.E.) proposed that castration induces re¬
entry of epithelia onto a defective cell cycle in which they never reach mitosis.
These cells have been proposed to leave the normal cell cycle onto this defective
cycle either in the S-phase or G2-phase. They base this theory upon observed
increases in bromodeoxyuridine into epithelial genomic DNA and increases in the
expression of proliferating cell nuclear antigen (PCNA) and the G-| proteins c-fos
and c-myc. In addition, Colombel claims an up-regulation of the p53 tumour
suppressor following castration and postulates that this may lead to initiation of
apoptosis. These observations are in conflict with those of Furuya and co-workers
who exhibited no increased expression of genes required for entrance of cells into
the S-phase of the proliferative cell cycle (i.e. p53, histone-H4 and ornithine
decarboxylase) following androgen ablation (Furuya et al, 1993; Berges et al,
1993). Further to this, Berges et al (1993) demonstrated that programmed cell
death consequent of endocrine management does not require entry onto the cell
cycle with cells dying out of cycle in G0 (interphase).
Programmed cell death in malignant epithelial cells would appear to be the
major ally of the clinician in the control of prostatic neoplasia. However, it could be
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argued that apoptosis in androgen-dependent cells merely allows unhindered
progression of the tumour to a more aggressive state ultimately fatal to the patient.
As discussed in the previous section, androgen ablation therapy leads to the
outgrowth of epithelial cell clones which are resistant to androgen ablation
therapies and therefore do not undergo apoptosis under such circumstances. It has
been proposed that it is the proliferation of these cells that leads to tumour relapse
and eventually death from the disease. This does not mean that the situation is
completely hopeless, and indeed it has been demonstrated that androgen-
independent tumour cells can be induced to undergo programmed cell death
through administration of cytotoxic drugs (Kyprianou and Isaacs, 1989b.). This
group identified the major problem associated with this form of therapy as being a
requirement for a relatively high rate of cell proliferation. A high proportion of
prostatic tumours are slow growing and contain a high population of non¬
proliferative androgen-independent cells. In respect of this, Martikainen et al (1991)
have analysed the response of the hormone-independent rat prostate cancer cells,
AT3, to compounds that increase the intracellular Ca^+, since they have proposed
that the lack of apoptosis in androgen-independent cells following androgen
ablation is due to a repression of changes in Ca^+. Using the calcium ionophore
ionomycin, elevation of intracellular Ca^+ 3-6 fold above basal levels was observed
in AT3 cells in vitro. This led to programmed cell death in these cells after 48-72
hours. Clearly Ca^+ offers an exciting new alternative target in the treatment of
androgen-independent CaP.
1.5 The Androgen Receptor.
In the human male, sexual differentiation and development is under the
direct regulation of androgens, specifically testosterone and its more biologically
active metabolite 5 a-dihydrotestosterone (DHT). The influences of both
testosterone and DHT are believed to be mediated by the same androgen receptor
protein (Evans, 1988) functioning as a transcription factor within the nucleus
(Rundlett et al, 1990). This androgen receptor exists as a member of a superfamily
of nuclear regulatory proteins, thought to have evolved from a common ancestral
gene, that exert control over the expression of specific eukaryotic genes (for further
review see Beato, 1989; O'Malley, 1990.). Amongst this family of nuclear receptors
(NRs), the androgen receptor is relatively under-studied and much information
about its function has been obtained by extrapolation from its co-members.
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1.5.1 The Nuclear Receptor (NR) Superfamily.
This group of phospho-proteins that includes, amongst others, all the
steroid hormones in addition to the thyroid hormone, retinoic acid and vitamin D3
receptors, all direct the expression of target genes mostly in a ligand-dependent
fashion, through direct contact with upstream DNA sequences termed hormone
response elements (HRE's). The activated receptor binds to its HRE either as a
homodimer (e.g. the steroid receptors), a heterodimer (e.g. the retinoid and thyroid
hormone receptors which form dimers with the retinoid X receptor) or even perhaps
as a monomer (e.g. NGFI-B). In addition to the hormone receptors, the NR
superfamily contains a subset of ,as yet, poorly characterised proteins termed
Orphan receptors (for review O'Malley, 1992). Orphan receptors - which now
constitute the vast majority of NR's - clearly belong to the superfamily, due to the
presence of distinctive amino acid homologies, but in the main have no assigned
function or indeed ligand specificity.
The members of the vertebrate nuclear receptor superfamily are listed in
Table 1.01.
Table 1.01 Nuclear Receptor Superfamily.












Through their DNA binding properties the NR's provide direct links between
extracellular signals and transcriptional responses, manifest as both up- and down-
regulations of gene expression. The precise mechanisms underlying such
alterations in gene transcription are not fully understood, however, four discrete
steps are believed to be involved : 1. ligand induced allosteric activation of the
receptor; 2. specific binding to the HRE; 3. stable complex formation at the HRE;
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4. recruitment of other transcription factors and RNA polymerase II for transcription
initiation (O'Malley, 1990). The exact role of the NR in the receptor-transcription
factor-RNA polymerase II is, unsurprisingly, not yet fully understood, although
theories range from stabilisation activity to stimulation of the assembly of the
preinitiation complex composed of general transcription factors. The latter function
may necessarily involve the alteration of the chromatin structure adjacent to the
HRE such that the binding sites for other co-operating transcription factors are
exposed.
The cloning and sequencing of the genes and cDNA's for a number of NR's
during the 1980's, notably, the oestrogen, progesterone and glucocorticoid
receptors, led to the disclosure of common functional domains shared by all
members of the superfamily (Krust et al, 1986; Kumar et al, 1987). The domain
structure of the NR superfamily, comprising 6 separate units lettered A-F, is
represented below (Figure 1.06).





This model is merely an approximation of the typical structure of a member of the
NR superfamily, since each individual protein possesses its own unique structural
characteristics. However, it does demonstrate the major functional domains
(domains B,C and E) common to each receptor and summarises their roles within
the molecule. It is evident that the receptor molecules demonstrate a hierarchy of
conservation among their functional units, with the DNA-binding domain exhibiting
the least amount of variability in length and amino acid sequence between NR's. It
is the conserved nature of the DNA- and Ligand-binding domains that led to the
supposition that, in vertebrates at least, these units derived from a common
ancestral gene possessing these functions (Laudet et al, 1992).
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1.5.2 The Roles of the Functional Domains in the NR Superfamily.
N-Terminus (regions A & B)
The N-terminal domain exhibits a degree of variability amongst the NR's
and is believed to participate directly - in conjunction with the DNA-binding domain
and sub-domains within the C-terminal region - in so-called "frans-activation" (the
regulation of target gene expression by a protein expressed by a different gene).
These regions of the receptor are proposed to interact, via protein-protein
interactions, with other components of the transcriptional machinery (either other
transcription factors or RNA polymerase II directly) in the formation of the pre-
initiation complex. Indeed, members of the NR superfamily, for example COUP-TF
and the oestrogen receptor, are known to make direct and specific contacts with
the general transcription factor TFIIB (Baniahmad and Tsai, 1993).
How trans-activation domains direct protein inter-relationships and what
features direct their function is as yet uncharacterised. What is becoming apparent
is that transcriptional activation domains appear to be conserved within the NR
superfamily much in keeping with the other major domain structures. Consider the
oestrogen receptor which possesses two trans-activation domains termed TAF-1
(constitutively active) and TAF-2 (ligand-dependent) locating to the N- and C-
termini respectively (Lees etal, 1989). Sequence alignment studies have
demonstrated conservation of certain residues in TAF-2 amongst a number of
nuclear receptors, notably the glucocorticoid, progesterone and androgen
receptors (Danielian etal, 1992). These residues are believed to form an
amphipathic a-helix that may directly contact other transcription factors.
C-Terminus (regions C,D & E)
The C-terminal portion of the nuclear receptors participates in many and
varied activities including ligand-binding, nuclear localisation and dimerisation.
The ligand binding domain (LBD) on average encompasses around 210
amino acids and binds the ligand in a hydrophobic pocket, potentially via multiple
specific contacts. For example, within the glucocorticoid receptor at least three
different amino acids within a ~150 amino acid region come into close proximity
with the ligand molecule. Furthermore, Forman and Samuels (1990) have identified
two regions within the LBDs of the retinoic acid and thyroid hormone receptors
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termed Ligand 1 and Ligand 2 which they believe direct ligand binding. These two
domains are almost identical among receptors of the same binding specificity.
Two further domains have been identified by Forman and Samuels. These locate
between Ligand 1 and Ligand 2, one being involved in receptor dimerisation and
the other, a domain conserved amongst all the NRs, termed xh is believed to be a
ligand-sensitive transcriptional inactivating domain. The dimerisation domain
consists of nine heptad repeats of hydrophobic amino acids that form into a coiled-
coil a-helix possessing a dimerisation interface along one surface. The
juxtaposition of these repeats and ij with Ligand 1 and Ligand 2 ensures that
receptor dimerisation and suppression of transcriptional inactivation are
inextricably linked to ligand binding.
The C-terminus is also implicated in the binding of heat-shock proteins
(hsp's) and a number of other so-called receptor associated proteins (RAPs) to
hormone-free receptors in the inactive state (for review see Smith and Toft, 1993).
These include hsp90, hsp70, hsp56, p60, p54, p50 and p23. The ligand-free
steroid hormone receptors exist in a 8-1 Os complex with hsp90, hsp70 and hsp56
(Baniahmad and Tsai, 1993). Binding of the ligand transforms the receptor into a
transcriptionally active state through release of the hsp's from the receptor
molecule. It is clear however that removal of the hsp's does not render the receptor
constitutively active and hormone-binding is still required for full function (Bagchi et
al, 1990). Although the fate of the hsp's seems fairly clear, the exact roles of these
proteins within the inactive receptor is highly controversial. Theories range from
molecular chaperones to inhibitors of unliganded receptor degradation and it is
often proposed that hsp90 interacts with receptor molecules such that
transcriptional activation domains e.g. the DNA-binding domain are masked (Smith
and Toft, 1993). Hormone-binding is postulated to alter the conformation of the
receptor such that the hsp's dissociate.
DNA-binding Domain (Region C)
The DNA-binding domain of the NR superfamily comprises a highly
conserved 66 amino acid stretch of high cysteine content within the interior of the
protein sequence. This region contains 9 cysteine residues, 8 of which have been
demonstrated to form 2 zinc fingers akin to those first observed in Xenopus laevis
transcription factor IIIA (for review see Schwabe and Rhodes, 1991; Freedman and
Luisi, 1993). 4 cysteine residues associated with each zinc finger give rise to a
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C2-C2 motif consisting of a stretch of a-helix and an N-terminal loop stabilised by a
tetrahedrally co-ordinated zinc ion located toward the N-terminus of the helix. The
N-terminal zinc finger is believed to contact the DNA in the major groove via
specific amino acid residues on the lower surface of its a-helix (recognition helix).
The second zinc finger determines the orientation of the recognition helix through
protein-protein interactions (Figure 1.07 a.). The recognition helix possesses only
three discriminatory amino acids that recognise one half of a palendromic cis-acting
consensus sequence termed the Hormone Response Element (HRE)
(Figure 1.07 b.). Shortcomings in terms of specificity offered by so few protein-DNA
contacts are overcome through the correct orientation of the recognition helix in the
major groove by the second C2-C2 motif.
It is clear that many questions relating to the activity of the NR superfamily
remain as yet unanswered, with much emphasis being placed on the role of protein
phosphorylation and the involvement of putative nuclear localisation domains in
receptor activity. As long as such insights are denied to us, the precise
mechanisms underlying NR-regulated gene transcription will remain unclear.
1.5.3 Androgen Receptor - Structure and Function.
The androgen receptor cDNA, cloned in the late 1980's by a number of
groups (Trapman etal, 1988; Lubahn et al, 1988; Chang et al, 1988; Tillet etal,
1989), demonstrates an open reading frame of 2751 nucleotides encoding a
protein of 917 amino acid residues with a calculated molecular weight of
98,845 Da. The androgen receptor gene is located on the X chromosome in the
Xq11-12 region (Brown et al, 1989) and is of a size in excess of 90kb (Kuiper et al,
1989). Kuiper demonstrated that the information for the AR is divided over 8 exons.
The first exon, which contains the ATG translation start codon, encodes the entire
N-terminal domain of the receptor protein (1586bp)(Faber et al, 1989). The first
zinc finger is encoded by exon 2 (152bp) while exon 3 (117bp) encodes the second
of the two motifs. The ligand-binding domain coding region is divided over exons 4-
8 (288bp, 145bp, 131 bp, 158bp and 153bp respectively). The sizes of exons 1 and
8 are considerably greater than those quoted due to the large 5' (1.1 kb) and 3'
(6.8kb) untranslated regions (UTRs).
The promoter for the AR gene is unusual in that it lacks the typical "TATA"
and "CAAT" sequence motifs. Transcription initiation occurs at 2 sites within a 13bp







Amino Acids : cGS ckV
HRE consensus : ^AGAACA nnn TGTTCT*
Note : the discriminatory amino acids on the recognition helix are written in bold text.
Figure 1.07 DNA-binding by Nuclear Receptors.
a. A schematic representation of the protein-DNA complex formed
between the DNA-binding domain of the two receptor molecules and their
palendromic recognition sequences, (taken from Schwabe and Rhodes,
1991).
b. The symmetrised DNA response element and contacting amino acids of
the glucocorticoid-like nuclear receptors.
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frame (Tilley et a/, 1990; Faber et al, 1991). These two sites have been termed
AR-TIS I (+1/2/3) and II (+12/13). The promoter is characterised by a short GC-box
(-59/-32) and a longer homopurine region (-117/-60), the former directing
transcription from AR-TIS II exclusively (Faber et at, 1993). Interestingly, the GC-
box contains a single binding site for the transcription factor Sp1, mutation of which
abolishes initiation from AR-TIS II. It would appear that the initiation of AR mRNA is
somewhat idiosyncratic, nevertheless, it is clear from the work of Tilley that this
promoter region is preferentially used for AR gene expression in many and varied
tissue types.
Transcription initiated at either AR-TIS I or II yields two major RNA
transcripts of approximate sizes 10kb (9614 bases) and 7kb (6682 bases)(Tilley et
at, 1990a.). These two RNA species are believed to have the same hnRNA
progenitor, however, an alternative splice event occurring in the 3' UTR removing
approximately 3.3kb gives rise to the smaller transcript (Faber et at, 1991). A third
AR mRNA, 4361 bases in length, is also commonly detectable in the LNCaP cell
line and prostatic tissue (Tilley et al, 1990a.; Bonnet et at, 1993), although it would
appear that this transcript is merely a degradation product of the larger mRNAs
(Blok et al, 1991).
The protein product arising from translation of the AR mRNA transcripts
exists as two different isoforms which migrate as a closely spaced doublet of 110-
112 kDa on SDS-PAGE (Kuiper et al, 1991). Most receptor is present in the larger
of the two forms although it is evident that both will bind hormone and undergo
transformation to a nuclear binding form. Kuiper et al (1991 and 1992)
demonstrated that the AR is synthesised as the 110kDa protein but is rapidly
converted to the larger isoform in a hormone-independent phosphorylation step.
Further receptor phosphorylation occurs in presence of androgens, with over 90%
occurring in the N-terminal transactivation domain (Kuiper et al, 1993). The role of
this hormone-dependent phosphorylation remains to be elucidated.
Testosterone and dihydrotestosterone exert different actions during the
embryogenesis and post-natal life of the male but it is evident that their separate
influences are mediated by the same androgen receptor. Although testosterone
and DHT both bind to the AR, they differ markedly in their androgenicity. Deslypere
et al (1992) demonstrated that DHT/AR complex is -10 times more powerful as a
transcriptional activator than the testosterone/AR complex. Such amplification of
the androgenic signal results from a significantly higher affinity of the AR for DHT
(Grino et al, 1990). Clearly, the action of 5areductase allows full androgenic
potential within the prostate.
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Sequence alignment coupled with mutational analysis demonstrates that
the functional domain structure of the AR is comparable to that of the
glucocorticoid and progesterone receptors (Jenster et al, 1992). Clearly the AR
possesses domains for steroid- and DNA-binding in addition to sequences that
direct transcriptional activation and nuclear import (Simental et al, 1991). It has
recently been shown that nuclear localisation (determined by residues 608-625
within the DNA-binding domain) of the AR in addition to receptor dimerisation and
binding to the androgen response element (ARE) are androgen-dependent
(Jenster et al, 1993; Wong et al, 1993). Such hormone-induced transformations
may relate to the dissociation of heat shock proteins, including hsp90, 70 and 56,
from the receptor complex following androgen-binding (Veldscholte et al, 1992a.).
Only a small number of cellular genes have thus far been characterised
which are regulated by androgens through direct interaction of the AR with a
localised ARE. Amongst these are the genes for human glandular kallikrein-2
(hKLK2), PSA (hKLK3), the components C1, C2 & C3 of rat prostatic binding
protein and latterly the gene for rat probasin (Riegman et al, 1991; Murtha et al,
1993; Claessens et al, 1993; Rennie et al, 1993). Two response elements have
been identified in the PSA and C3 gene with the sequences AGAACAgcaAGTGCT
and AGTACGtgaTGTTCT respectively. These sequences are extremely similar to
the glucocorticoid response element (GRE) consensus (Figure 1.07b.) and indeed
it has been demonstrated that the GRE can mediate induction by androgens in the
mouse mammary tumour virus long terminal repeat (MMTV-LTR)(Darbre et al,
1986; Ham et al, 1988). Despite Roche et al (1992) having described a highly
specific ARE consensus sequence, it is becoming clear that AR specificity is
provided not only by the palindromic consensus but also by other juxtaposed
sequences within the enhancer (Adler et al, 1993). It is such combinatorial function
which may allow specific gene regulation by androgens in tissues containing a full
range of steroid hormone receptors.
1.5.4 Anti-androgens - Flutamide.
Anti-androgens are used to block the action of testosterone and DHT at the
target tissues through direct interaction with the androgen receptor such that
formation of the activated receptor complex is abolished. The most widely used
non-steroidal anti-androgen is flutamide (a-a-a-trifluoro-2-methyl-4'-nitro-m-
propionotoluidine) marketed by Schering Plough (Sch-13521) as Drogenil.
Flutamide is metabolised within the cell to an activated a-hydroxy metabolite,
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hydroxyflutamide (Sch-16423; a-a-a-trifluoro-2-methyl-4'-nitro-m-lactotoluidide),
which interacts with the AR such that the receptor complex cannot bind to the ARE
and influence the expression of target genes (Neri, 1977; Simard et al, 1986; Wong
et al, 1993; Veldscholte et al, 1992b.). Symes et al (1978) demonstrated that
hydroxyflutamide will displace testosterone at a 1000 to 10000 molar excess.
These findings are in keeping with the observation that DHT-induced transcription
from the MMTV-LTR promoter is inhibited by a 100-1000 molar excess of anti-
androgen (Warriar et al, 1993).
The exact mechanism underlying the inhibition of DNA-binding by the AR
following interaction with hydroxyflutamide is not yet clear, however, such
information is only now becoming available from studies performed with other
receptor systems and alternative anti-androgens. Baniahmad and Tsai (1993) in a
review of recent literature support the theory that differences in transcription
activation potential of hormone/receptor and anti-hormone/receptor arise because
of varying protein conformations. Such differences have been observed in the
progesterone receptor, and the suggestion is that anti-progesterones act
antagonistically because of a different conformation at the C-terminus of the
protein, which may mask transactivation domains or even the DNA-binding domain.
A similar situation appears in the AR, where a 30kDa protease-resistant fragment
observed upon androgen binding does not arise in the presence of either steroidal
or non-steroidal anti-androgens (Kallio et al, 1994).
1.5.5 The Androgen Receptor in the Benign and Malignant Prostate.
The androgen receptor is essentially an epithelial phenomenon.
Immunohistochemical and steroid-binding analyses demonstrate that in the normal
and hyperplastic prostate, glandular epithelia demonstrate high levels of nuclear
AR, with basal epithelial cells and stromal exhibiting similar but lower intensities of
staining (Hulka et al, 1987; Masai et al, 1990; Chodak et al, 1992; Miyamoto et al,
1993). In carcinoma, it appears that the extent of nuclear AR is lower than in
hyperplasia and that the staining decreases with the increasing histological grade
of the tumour. Well differentiated tumours (Gleason scores 1 and 2) generally have
a higher number of AR-positive than poorly differentiated tumours (Gleason scores
4 and 5). It is also apparent that AR staining exhibits greater heterogeneity in
cancer specimens compared with BPH. Indeed, Sadi and Barrack (1993) have
correlated this variation in staining intensity with response to endocrine therapy and
demonstrated that poor responders (<20 months to tumour progression) exhibit
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greater variance in intensity than good responders (>20months to tumour
progression).
In endocrine management of metastatic prostate cancer, it is aimed to
prevent AR activation by androgens and/or to block its function as a transcriptional
activator. As discussed previously, such therapies rarely cure the disease with the
response generally lasting for 2-3 years prior to relapse of the tumour to androgen-
independent growth. In the rat Dunning model of prostate cancer it has been
demonstrated that tumour progression into hormone escape is associated with the
outgrowth of androgen-independent cells from an initially heterogeneous mixture of
cells (Isaacs and Coffey, 1981). The nature of this heterogeneity and the intrinsic
features of the androgen-independent cells are still controversial. Quarmby et al
(1990) demonstrated that progression to hormone escape in the Dunning R-3327
tumour is associated with alteration of the level of expression of the AR. These
findings are very much in keeping with those of Diamond and Barrack (1984) who
demonstrated that the androgen-independent sublines of the Dunning tumour have
low or undetectable levels of AR. In addition to these observations in the Dunning
tumours, Rennie et al (1990) observed that the androgen-independent stem cells
and their progeny obtained in the Shionogi model after androgen ablation also do
not express detectable AR. Masai et al (1990) observed that in untreated human
prostate adenocarcinomas, clusters of cancer cells contain both receptor-positive
and receptor-negative clones. This group observed that endocrine management
induced a lowering of the percentage of AR-positive cells to levels below, but not
significantly below, those exhibited by poorly differentiated, untreated prostate
neoplasms. The suggestion is that the transition to hormone-independence is
coupled with the preferential growth of AR-negative epithelia. This view of hormone
escape in advanced CaP is extremely contentious. Furuya et al (1992) have
demonstrated that an androgen-independent subline of the androgen-independent
mouse mammary adenocarcinoma Shionogi carcinoma-115 (SC-115) possesses a
fully functional androgen receptor identical to that in the parent subline. In addition
to these findings, van der Kwast et al (1991) have observed that in the majority of
human adenocarcinoma under endocrine management, there is no preferential
increase in AR-negative tumour. In these instances there is a possibility that the AR
detected has altered function resulting from mutation and indeed only now are
such mutations becoming apparent in androgen-deprived prostate tumours.
Partial and complete androgen insensitivity syndrome (AIS) is an X
chromosome-linked disorder preventing normal development of the male
phenotype in 46,XY individuals. AIS arises from defects in the AR. Mutations have
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been observed in all 8 exons of the AR gene (Brinkmann and Trapman, 1992) and
indeed in one published case, deletion of the entire AR gene has been
demonstrated (Quigley et al, 1992). A number of groups have analysed relapsed
prostate tumours in an attempt to identify AR mutations that may account for the
androgen independence.
The LNCaP model of hormone-sensitive advanced metastatic CaP
expresses high levels of AR (Horoszewicz et al, 1983; Tilley etal, 1990a. and b.). It
is well documented that the LNCaP AR carries a point mutation (A to G; thr868 to
ala) in its ligand-binding domain that alters the steroid specificity such that it
demonstrates higher affinity for progestagenic and oestrogenic steroids and altered
response to the anti-androgen flutamide/hydroxyflutamide (Brinkmann et al, 1991;
Veldscholte et al, 1990a. and b.; Culig et al, 1993; Veldscholte et al, 1992b.). In
prostatic tumours very few such mutations have been detected.
In early, organ-confined prostatic tumours, mutations have been observed
in the ligand binding domain coding regions of the AR gene and in exon 1. In 1 of
40 tumour specimens examined, Schoenberg et al (1994) recognised an alteration
in the number of CAG repeats in exon 1 from 24 down to 18. The consequence of
this microsateliite mutation is an apparent agonist response to flutamide, however,
it remains to be seen whether this alteration of the AR gene or another coincident
mutation are responsible for the observed activity. Substitution of a valine residue
with a methionine residue, resulting from a G to A exchange in codon 730, has
been demonstrated in an untreated prostate adenocarcinoma (Newmark et al,
1992). This mutation was present in approximately 50% of the DNA in the
specimen, indicating a possible relationship with ceils exhibiting growth advantage.
Perhaps more significantly, analysis of the AR gene in endocrine therapy-resistant
tumours has also revealed somatic mutation (Culig et al, 1993; Suzuki et al, 1993).
Culig et al (1993) detected a G to A substitution at codon 715 in a patient who had
undergone orchiectomy. This mutation correlates with enhanced receptor function,
illustrated by activation, not only by testicular androgens, but also by the adrenal
androgens, DHEA and androstenedione, and by progesterone. It is therefore
conceivable that this mutant AR will be functionally active in the androgen ablated
patient. The AR mutation found by Suzuki et al (1993) in metastatic tissue is
identical to that in the LNCaP cell line and must presumably demonstrate activation
by progestagens, oestrogens and indeed anti-androgens.
Rundlett etal (1990) demonstrated that constitutive activity could be
conferred upon the AR through truncation of the receptor protein in the carboxy
terminus by 201-234 amino acids (removing ~50% of the ligand binding domain). In
36
theory, nonsense mutations which insert aberrant termination codons in the open
reading frame of the gene and thus induce abnormal translation termination could
give rise to such a shortened AR. No such mutations have been observed in
human prostate cancer to date.
It would appear that, if anything, mutations in regressing CaP have a
predisposition for altering the binding specificity of the AR leading to increased
activation by alternative steroid hormones and by anti-androgens.
It should be borne in mind that mutation of the AR occurs very rarely in
human prostate tumours. Those alterations of the AR gene established by Culig et
al (1993) and Suzuki et al (1993) were observed in 1 of 4 and 1 of 8 hormone
refractory tumours respectively. Clearly, if it is possible to question the validity of
the no receptor theory on the grounds of a lack of conclusive evidence, by the
same token there must be an element of doubt concerning the involvement of AR
gene mutation. In van der Kwast's studies (1991) on AR expression in tumours
subject to endocrine manipulation, 1 patient exhibited almost no positive AR
staining, with a further 3 displaying considerable heterogeneity of staining.
Therefore, it would not seem unreasonable to suppose that both AR down-
regulation and receptor mutation may both result in regression of prostatic tumours.
Since evidence for alterations in the AR gene and AR gene expression is to
say the least limited, and certainly inconclusive, attention has recently turned to
other gene products which may be involved in epithelial cell death or survival under
androgen limiting conditions. Notably much interest has been focused on the bcl-2
oncoprotein whose overexpression has been demonstrated to provide protection
from apoptotic stimuli and which may, as a consequence, operate to prevent
programmed cell death in prostatic epithelia.
1.6 bcl-2.
The bcl-2 oncoprotein first rose to prominence owing to its involvement in
human follicular B-cell lymphomas (Tsujimoto et al, 1985). In this disease the bcl-2
gene on chromosome 18 recombines with a region on chromosomes 14 such that it
is juxtaposed to the immunoglobulin heavy chain locus. The net effect of this
t(14; 18) translocation is the creation of a bcl-2/lgH fusion gene that demonstrates
marked deregulation, resulting in the overproduction of bcl-2 mRNA and protein in
malignant B-lymphocytes (Bakhshi et al, 1985; Cleary and Sklar, 1985). Such
dramatic upregulation of gene expression is believed to arise from the proximity of
enhancer sequences after recombination.
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The t(14; 18) translocation is diagnostic of B-cell lymphomas and may well
upregulate bcl-2 expression, however, it has more recently and significantly been
demonstrated that this genomic reorganisation is not essential for detectable bcl-2
expression (Pezzella et al, 1990).
The bcl-2 gene consists of three exons and is transcribed into 3 overlapping
mRNA transcripts of sizes 8.5kb, 5.5kb and 3.5kb (McDonnell et al, 1993;
Tsujimoto and Croce, 1986). The 5.5kb and 3.5kb mRNAs give rise to two very
similar proteins bcl-2a (~26kDa) and bcl-2p (~21kDa), the former, which
represents the major isoform, differing from its counterpart in the C-terminal
portion. The oncogene products function to block the pathways of apoptosis in a
number of cell types (Hockenbery etal, 1990; Sentman et al, 1991; Jacobson et al,
1993) and indeed their expression appears to be restricted to tissues characterised
by apoptotic cell death (Hockenbery et al, 1991).
Hockenbery et al (1991) initially demonstrated that the anti-apoptotic onco¬
protein bcl-2 locates to the mitochondrion and although this still appears to be its
primary residence, further studies have shown that it also occupies the nuclear
envelope and endoplasmic reticulum (ER) (Jacobson et al, 1993; Krajewski et al,
1993). This sub-cellular localisation is certainly unusual for an oncoprotein and has
subsequently spawned considerable debate as to its mode of action. Perhaps the
most intriguing of these is a potential role in the regulation of the Ca2+-dependent
endonucleases whose activation is implicated in the early commitment to apoptotic
death. Richter (1993) and Krajewski etal (1993) both support this theory and
suggest that bcl-2 may inhibit endonuclease activity and consequently prevent the
onset of apoptosis through obstruction of Ca2+ release from the mitochondria and
endoplasmic reticulum (the lumen of the ER being the major site of intracellular
Ca2+ storage) into the cytoplasm. This function may be mediated by direct action
on Ca2+ pumps or channels.
bcl-2 Is highly expressed in the prostate and locates exclusively to the basal
epithelial cell layer (Hockenbery et al, 1991; McDonnell et al, 1992; Colombel et al,
1993). Both McDonnell etal (1992) and Colombel et al (1993) have analysed bcl-2
expression immunohistochemically in primary tumours, metastases and regressed
neoplasms in order to establish any correlation with progression of the disease.
Their findings are extremely similar and imply that androgen ablation therapy leads
to an increased number of bcl-2-positive cancer cells. Indeed in the rat, McDonnell
et al (1992) have demonstrated upregulation of bcl-2 mRNA in the ventral prostate
as a consequence of androgen ablation, reaching a maximum 10 days post-
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castration; and this effect could be reversed through subsequent testosterone
administration. It is also apparent that androgen-independent prostatic tumours
exhibit a significantly higher percentage of bcl-2 positivity compared to androgen-
dependent neoplasms.
The observed bcl-2 staining patterns in CaP tend to suggest that its
expression is not a primary molecular event in the tumourigenic process but rather
associates with tumour recurrence associated with endocrine management. In this
respect, expression of bcl-2 may be central to the mechanisms of hormone escape,
through the provision of apoptosis-resistance for the malignant cell population such
that they are able to survive under androgen limiting conditions. This hypothesis is
supported by work previously eluded to, which indicates that bcl-2 expressing basal
epithelia are unaffected by androgen withdrawal (English et al, 1987 and 1989).
Therefore, the malignant epithelial cells with high bcl-2 content may represent the
sub-population of androgen-independent cells originally observed by Isaacs and
Coffey (1981). However, the extent of the bcl-2 requirement of such androgen-
independent prostatic epithelia remains to be assessed.
1.7 In vitro Models of Prostatic Epithelia.
Analysis of tissues using techniques such as immuno-histochemistry, in situ
hybridisation provides the researcher with a "snap-shot" of in vivo cellular
behaviour in terms of gene expression, cell growth and cell differentiation. In vitro
cell models, although perhaps not fully representative of the in vivo situation (a
consequence of the difficulty involved in accurately reproducing the complex
molecular and cellular environment of a functional whole body), provide a means of
studying cellular action. It is their manipulable nature coupled with a general ease
of use that makes the use of such model systems so appealing.
A number of in vitro approaches are available for the study of the human
prostate including the use of cultured established cell lines, organ explant cultures
and short term primary cultures.
1.7.1 Prostatic Carcinoma Cell Lines.
A number of human prostatic cancer cell lines are available including EB-
33, PC-82, Honda, PC-EW, LNCaP, DU145 and PC3. The origins and growth
characteristics in culture of the most commonly used prostate cancer cell lines and
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those which are dealt with in the thesis, namely LNCaP, DU145 and PC3, are
summarised below.
1.7.1.1 The LNCaP Cell Line.
The LNCaP (Lymph Node Carcinoma of the Prostate) established by
Horoszewicz et al (1983) from needle biopsy from a supracavicular lymph node of
a 50 year old patient with metastatic stage D2 CaP (stage M1a). Androgens
stimulate the growth of LNCaP and induce the secretion of acid phosphatase and
PSA via a high affinity receptor (Horoszewicz et al, 1983; Wilding et al, 1989;
Schuurmans et al, 1988; Young et al, 1991; Montgomery et al, 1992; Tilley et al,
1990b.). It should be noted that LNCaP cells exhibit sensitivity to androgens but
are not truly androgen-dependent. As previously discussed the LNCaP AR
possesses a mutation in its ligand-binding domain that dramatically alters its ligand
specificity (Veldscholte et al, 1990a. and b.).
The majority of LNCaP cells exhibit a pseudodiploid karyotype with a modal
chromosome number of 46, however, it is apparent that a small sub-population are
near-tetraploid in nature (Gibas et al, 1984). 7 marker chromosomes (m1-7) arising
from 5 separate chromosomal translocation events are also detectable. Similar
markers are also observable in the DU145 and PC3 cell lines
A number of sub-clones of the LNCaP have been established, notably
LNCaP-FGC (fast growing colony) and the LNCaPr (resistant). The LNCaP-FGC is
very similar to the parent cell line apart from increased growth rate. The LNCaPr
sub-clone was first characterised by Hasenson et al (1985), who demonstrated
unresponsiveness to androgens, oestradiol and flutamide despite the apparent
presence of an androgen receptor.
1.7.1.2 The DU145 Cell Line.
The DU145 cell line was established from a metastatic brain lesion derived
by craniotomy from a patient who had undergone oestrogen treatment (Stone et al,
1978; Mickey et al, 1980). Cell proliferation studies have demonstrated that this cell
line is neither androgen-sensitive or androgen-dependent; a finding that correlates
with the inability to detect AR expression at either the mRNA or protein level (Tilley
et al, 1990b.). Additionally, only very weak staining for prostatic acid phosphatase
is observed (Mickey et al, 1980).
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Karyotypic analysis indicates that the DU145 cell line is aneuploid i.e. it
possesses a modal chromosome number of 64 (Mickey et al, 1980).
1.7.1.3 The PC3 Cell Line.
As with the DU145 cell line, PC3 cells, which originate from a bone
metastasis of prostatic adenocarcinoma treated by means of castration and
oestrogen therapy, are karyotypically aneuploid (modal chromosome number
between 55 and 62) and do not display androgen-sensitivity or -dependence
(Kaighn et al, 1979 and 1980). Unsurprisingly, since PC3 was established from an
androgen-independent tumour, and displays such characteristics in culture, no
androgen receptors in addition to 5areductase and acid phosphatase activities are
detectable (Tilley et al, 1990b.; Kaighn et al, 1979).
1.7.2 Primary Prostatic Cell Cultures.
Established cell lines offer many advantages to the researcher yet cells
cultured long-term are prone to phenotypic/genotypic alterations and one must
surely question how representative they are of the in vivo situation. In theory, short-
term primary cell cultures should not be subject to such changes and will
subsequently have greater resemblance to their tissue progenitors.
Organ culture is the maintenance or growth of organ primordia or whole
parts of an organ in vitro. This approach is useful for the study of interrelationships
between different cell types in the same organ through preservations of a degree
of tissue architecture, however, it is not fully indicative of some of the more
complex interactions occurring in vivo. Primary cultures occupy a position
intermediate between organ culture and a true replicative tissue culture and refers
to the initial outgrowth of cells from tissue fragments or monolayer cultures of cells
derived by tissue dispersion. The clear advantages of this approach are not only
the similarity of the resulting cells to the tissue of origin but also the potential
homogeneity of the cell population and the ease of study of responses to altered
environments. Nevertheless, it should be noted that the necessary loss of
extracellular matrix favours decreased opportunity for resynthesis and organisation
in addition to possible selection of cell types perhaps not representative of the
composition of the tissue.
The establishment of prostatic primary cultures has been reported by many
groups since the first demonstration of epithelial cell outgrowth from
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adenocarcinoma by Burrows et a/in 1917. The various protocols for autonomous
culture of prostatic epithelia and fibroblasts are in general merely variations on a
theme and it is apparent that there are only two real considerations : 1. The use of
mechanical or enzymatic separation of tissues; 2. The choice of medium for
sustained growth of the different cell types.
There is no real evidence as to whether mechanical or enzymatic dispersion
improves the outcome of the consequent cell culture or indeed alters its
characteristics, however, it would appear that there is a tendency, from studies of
the literature, for the seemingly less aggressive and potentially less damaging use
of collagenase (Webber et al, 1980; Chevalier et al, 1981). In addition to this there
is some evidence to support enhanced epithelial cell growth and/or suppression of
fibroblasts using collagenase to prepare essentially fibroblast-free acini (Kaighn et
al, 1975).
It is generally believed that cell culture media supplemented with foetal calf
serum (FCS) will support both prostatic epithelial and fibroblastic growth and
subsequently the use of such media necessarily leads to overgrowth of epithelia by
fibroblasts (Webber, 1980). Although this phenomenon is certainly not true in all
cases, a great deal of emphasis has been placed upon the development of serum-
free media containing defined components that will only support epithelial cell
growth. The pursuit of such culture conditions lead to the development of a serum-
free medium by Chaproniere and McKeehan (1986), notably containing cholera
toxin and bovine pituitary extract, both of which stimulate epithelial cell growth, the
former probably via elevation of intracellular cAMP.
In contrast to the observed stimulation of primary epithelial cells by human
fibroblasts, of both prostatic and non-prostatic origin (Kabalin etal, 1989), efforts to
demonstrate a response to androgens have yielded equivocal results. Schroeder et
al (1974) showed that both BPH- and CaP-derived epithelial cells do not respond
favourably to testosterone and DHT. These findings are very much in keeping with
those of McKeehan etal (1984) and Merchant (1990), however, conflicting data
has been presented by both Syms et al (1982) and Hallowes et al (1991). The
latter group not only demonstrated stimulation of prostatic organoid-derived
epithelia by testosterone, but also a dose-dependent inhibition of cell growth by
flutamide and hydroxyflutamide.
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1.8 Aims and Objectives.
The mechanisms underlying hormone escape in human prostatic
adenocarcinoma are very poorly understood. In animal models and humans, it
would appear that the most credible theory of tumour relapse following androgen
ablation is the outgrowth of androgen-independent cancer cells. However, if we are
to believe this hypothesis, the nature of these androgen-independent cells must be
ascertained.
The available in vitro models of benign and malignant prostatic epithelia
display marked differences in their ability to respond to androgens and anti-
androgens. The aim of this work was to analyse the characteristics of established
prostatic carcinoma cell lines and primary epithelial cell cultures with respect to
their responsiveness to androgenic stimuli. Consequently, the expression of the
androgen receptor and the anti-apoptosis oncogene bcl-2, both of which have been






The LNCaP cell line [clone FGC (fast growing colony)] was obtained from
the American Type Culture Collection (A.T.C.C.), Rockville, U.S.A.. This cell line
was established from a metastatic lesion of human adenocarcinoma and presents
many of the malignant properties characteristic of neoplastic epithelial cells in CaP
( Horoszewicz et al., 1980 & 1883 ). Cells between passage numbers 80-85 were
utilised for all experiments.
The cell line DU145 was kindly donated by Dr. D.D.Mickey, Department of
Urology, University of North Carolina, Chapel Hill, U.S.A.. DU145 was originally
derived from a brain metastasis identified as a moderately differentiated prostatic
adenocarcinoma ( Mickey et al, 1980). In all experiments, cells between passage
numbers 80-90 were used.
The PC3 cell line was isolated from a poorly differentiated bone metastasis
of prostatic adenocarcinoma ( Kaighn et al, 1979 ), and was obtained from the
European Collection of Animal Cell Cultures, PHLS Centre for Applied Microbiology
and Research, Porton, Salisbury, England. The passage number of the cells was
unknown, but for the purpose of our experiments, only cells passaged up to 10
times were employed.
Note : The cell lines were regularly screened for mycoplasma contamination
using a mycoplasma detection kit supplied by Boehringer Mannheim UK.




All plasticware, including tissue culture flasks, Universal flasks, Erlenmeyer
flasks and pipettes, was obtained from Bibby Sterilin Ltd., Staffordshire, UK. All
media and solutions were sterile-filtered before use, with 0.2pm bottle-top filters
and 0.2pm sterile Acrodiscs supplied by the Sigma Chemical Company Ltd., Poole,
Dorset, UK. and Gelman Sciences, Northampton, UK. respectively.
Oxoid Dulbecco 'A' phosphate buffered saline was purchased from Unipath
Ltd., Basingstoke, Hampshire, UK. 10xTrypsin-EDTA (0.5%w/v trypsin; 0.2%w/v
EDTA; 0.85%w/v NaCI) was purchased from Gibco BRL, Paisley, Renfrewshire,
U.K..
Unless otherwise stated, all chemicals used in tissue culture procedures
were obtained from the Sigma Chemical Company Ltd..
2.1.2.2 Cell Lines - media/supplements.
RPMI 1640 medium was obtained from Gibco BRL, Paisley, Renfrewshire,
UK.. Dulbecco's Modified Eagles Medium and Ham's F12 medium were purchased
from ICN Biomedicals Ltd., High Wycombe, UK.. All media were supplemented with
foetal calf serum (FCS), L-glutamine (200mM), penicillin (10,000unitsml"'') and
streptomycin (10,000pgml"''), acquired from Gibco BRL.
2.1.2.3 Epithelial and Fibroblast Primary Culture - media/supplements.
Collagenase was obtained from Worthington Biochemical Corporation,
Freehold, New Jersey, U.S.A..
WAJC 404 medium was acquired from Kyokuto Pharmaceutical Industrial
Co. Ltd., Tokyo, Japan. HEPES, zinc-stabilised insulin, cholera toxin and
dexamethasone were all purchased from Sigma. Sodium hydrogen carbonate and
epidermal growth factor were obtained from Fisons Scientific Equipment,
Loughborough, Leicestershire, UK. and Universal Biologicals Ltd., London, UK.
respectively. Fungizone was procured from Gibco BRL.
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2.1.2.4 Cell Proliferation.
Phenol red-free versions of the cell culture media used were obtained from
the suppliers listed in 2.1.2.2.. [ Note : Phenol red-free Ham's F12 is not normally
supplied by ICN Biomedicals Ltd. and must be requested ]
The MTT ( 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) and
dimethylsulphoxide were purchased from Sigma and the Aldrich Chemical
Company Ltd., Gillingham, Dorset, UK. respectively.
The activated charcoal and Dextran T70 used in the removal of
endogenous steroids from foetal calf serum were resectively obtained from Sigma
and Pharmacia Biotech Ltd., Milton Keynes, UK.. Dihydrotestosterone (5a-
androstan-17p-ol-3-one) was purchased "cell culture tested" from Sigma.
Hydroxyflutamide (a-a-a-trifluoro-2-methyl-4'-nitro-m-lactotoluidide; SCH 16423)
was kindly donated by the Schering Corporation, Bloomfield, New Jersey, U.S.A..
2.1.3 Molecular Biology.
2.1.3.1 General Consumables.
The majority of chemicals employed in molecular biology procedures were
obtained from the Sigma Chemical Company Ltd., and were, wherever possible of
molecular biology grade.
NaCI, f/7-sodium citrate, NaOH, 37% formaldehyde (12.3M, pH>4.0),
ethanol, Tris-saturated phenol (20mM, pH8.0) and glacial acetic acid were all
purchased from Fisons Scientific Equipment.
Isopropanol (2-propanol), isoamylalcohol (3-methyl-1-butanol) and
formamide were obtained from the Aldrich Chemical Company Ltd..
Agarose NA and DNA gel loading buffer (Bio 101 Inc.) were purchased from
Pharmacia Biotech Ltd. and Stratech Scientific Ltd., Luton, Bedfordshire, UK.
respectively.
Nuclease-free water was acquired from the Promega Corporation,
Southampton, Hampshire, UK..
Sterile screw-cap Eppendorf tubes were purchased from Sarstedt Ltd.,
Beaumont Leys, Leicester, UK.. Sterile pastettes were obtained Alpha Laboratories
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Ltd., Eastleigh, Hampshire, UK.. Whatman 3MM paper was acquired from
Whatman International Ltd., Maidstone, UK..
Hybond C extra (nylon supported nitrocellulose) was obtained from
Amersham International pic., Aylesbury, UK.. The Fastrad Autoradiography
cassettes (Hoefer Scientific Instruments) and accompanying intensifying screens
were acquired from Scottish Biotechnology Instrumentation, Auchterarder,
Perthshire, UK..
2.1.3.2 Plasmid Constructs.
pCMV/ARcom and pMMTV/SPAP were kindly provided by Dr. Don
Wallace, Biochemical Targets, Glaxo Research and Development, Greenford,
Middlesex. pRc/CMV (Invitrogen Corporation ) was purchased from British
Biotechnology Ltd., Abingdon, Oxfordshire, UK.. The three plasmid constructs used
are illustrated in Figure 2.01.
Note : All three plasmids carry a beta-lactamase gene for ampicillin
selection.
pAM41 carrying the mouse non-muscle p-actin cDNA was kindly donated by
Professor A.H.Wyllie, Department of Pathology, University of Edinburgh.
pCMV/ARcom.
Expression of the androgen receptor cDNA is controlled by upstream
promoter/enhancer sequences from the immediate early gene of human
cytomegalovirus, ensuring high level constitutive transcription in mammalin cells.
Polyadenylation and transcription termination sequences are provided by the
human growth hormone gene.
pMMTV/SPAP.
Transcription of the secreted placental alkaline phosphatase (SPAP) cDNA
is directed by a portion of the mouse mammary tumour virus long terminal repeat
(MMTV-LTR). The MMTV-LTR weakly promotes transcription, but contains an
androgen response element that on binding functional androgen receptor,
significantly increases the promoter activity (Cato et al, 1987; Ham et al, 1988).
47
Figure 2.01 Plasmid Constructs.
pCMV/ARcom. (from Lubahn et al (1988). Science 240, 32)
pMMTV/SPAP.
pRc/CMV. (from the Invitrogen Corporation catalogue 1992)
48
SV40 provides polyadenylation and transcription termination sequences.
MAX Efficiency DH5a™ competent E.coli were obtained from Gibco BRL.
The TOPIOf strain was supplied from the Invitrogen Corporation with the pRc/CMV
vector as a stab culture. Ampicillin an tetracycline were both purchased from the
Sigma Chemical Company Ltd..
DOTAP transfection reagent was acquired from Boehringer Mannheim UK
(Diagnostics and Biochemicals) Ltd., Lewes, East Sussex, UK.. Sigma 104
phosphatase substrate was obtained from the Sigma Chemical Company Ltd..
2.1.3.3. Isolation and Analysis of Nucleic Acids.
Guanidine isothiocyanate was purchased from Northumbria Biologicals Ltd.,
Cramlington, Northumberland, UK..
All materials employed in first strand cDNA synthesis were obtained from
the Promega Corporation. PCR reactions were carried out using Promega Taq
DNA polymerase and Taq 10xbuffer, with dNTP's and mineral oil supplied by
Pharmacia Biotech Ltd. and the Sigma Chemical Company Ltd. respectively.
All primers were synthesised on an Applied Biosystems PCR Mate DNA
synthesiser within the Department of Molecular Science, Glaxo Research and
Development.
The de-ionised formamide (Clontech Laboratories) for denaturing RNA gel
electrophoresis was obtained from Cambridge Bioscience, Cambridge, UK..
The Megaprime™ DNA labelling system (RPN 1606), [a-32p]dCTP
(~3000Ci/mmol) and Hyperfilm™-MP were purchased from Amersham
International pic.. NICK™ columns were obtained from Pharmacia Biotech Ltd..
2.1.3.4. Analysis of Proteins.
The ECL Western blotting detection system and Hyperfilm™-MP was
supplied by Amersham International pic..
The mouse monoclonal anti-human bcl-2 oncoprotein antibody was
purchased from DAKO Ltd., High Wycombe, Buckinghamshire, UK..
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The mouse monoclonal anti-human androgen receptor antibody was





2.2.1.1a. Cell Culture Media.
The LNCaP and DU145 cell lines were routinely cultured in RPMI 1640
Medium and Dulbecco's Modified Eagles Medium respectively. The media were
supplemented with 10%v/v foetal calf serum (FCS), L-glutamine (2mM) and with
penicillin (100 unitsmM) & streptomycin (100 ^gml~1).
PC3 cells were maintained in Ham's F12 containing 7%v/v FCS,
L-glutamine (2mM), penicillin (100 unitsml"'') and streptomycin (100 |.igml~).
2.2.1.1b. Culture of Cell Lines.
The cell lines were grown in monolayer culture, in 75cm2 tissue culture
flasks, in a humidified incubator( T305GF Assab; Kebo Assab AB, Solna,Sweden. )
supplied with an atmosphere of 95% air and 5% CO2 at 37°C. All tissue culture
procedures were carried out aseptically in a laminar flow cabinet ( Microbiological
Class II; Howarth Air Engineering Ltd., Farnworth, Bolton, UK. ) using sterile
disposable plastic pipettes and pipette tips. To ensure that a sterile environment
was preserved, the laminar flow cabinet was thoroughly cleaned before, during and
after all operations with a solution of 70% ethanol. In addition, all handling of cell
lines was performed using disposable latex gloves.
Continuous cell growth was sustained through regular subculture. Upon
achieving approximately 90% confluence, cells were harvested through
trypsinisation, diluted 1:3 in medium and delivered into 3 fresh flasks. The process
of subculture involved the aspiration of spent medium from the cells, followed by 2
washes with Dulbecco 'A' phosphate buffered saline and a 5 minute incubation at
37°C in 5ml 1xTrypsin-EDTA (0.5ml of 10xTrypsin in 4.5ml of Dulbecco 'A' PBS).
The cells were detached through gentle agitation and 15mls of the appropriate
medium added to the subsequent cell suspension. Following centrifugation at
1500r.p.m. for 5 minutes and resuspension in 36 ml of medium, repeated pipetting
ensured a single cell suspension, 12 ml of which were delivered to each flask. The
cells were allowed to adhere over a 24 hour period before being supplemented with
fresh medium. Thereafter the medium was changed every 48 hours.
2.2.1.2 Culture of Epithelial Cells and Fibroblasts from Human Prostatic Tissue.
The primary culture of epithelial cells from prostatic acini in serum-free
medium was first described by Chaproniere et al (1986). The protocol described
here for the autonomous culture of epithelial and fibroblast cells is based on that
developed by Chaproniere.
Prostate tissue was obtained from patients undergoing transurethral
resection of the prostate (TURP) to treat the symptoms of BPH. The prostate chips
were immediately placed in 20ml of transport medium [ RPMI 1640 medium
supplemented with 5%v/v FCS ], and could be stored at 4°C for up to 5 days
before use. Pathology was determined by routine examination of representative
samples of excised tissue by the Department of Pathology, Western General
Hospital, Edinburgh.
Note : The handling of epithelial and fibroblast cell cultures was essentially
the same as that for the immortalised cell lines, as described in section 2.2.1.1b..
2.2.1.2a. Enzymatic Dissociation of Epithelial and Stromal Cells.
The prostatic chips were washed twice in 25ml of Dulbecco 'A' PBS,
weighed and cut into approximately 3mm2 cubes using scissors and forceps
sterilised in 70% ethanol. [ Note : At all stages of the procedure, the tissue was
kept moist under transport medium.]. The tissue was subsequently transferred to a
sterile Erlenmeyer flask, washed with 20ml of transport medium and finally
suspended in 5ml of transport medium per gram of tissue. A sterile-filtered solution
of collagenase (600unitsmr'1) in transport medium, equivalent to 2.5ml per gram of
tissue was mixed with the tissue, and the flask placed in a 37°C incubator/shaker (
Luckham R300; Luckham Ltd., Burgess Hill, UK..). The tissue was incubated for
20hours, with gentle shaking to maintain the integrity of the acini. The digest was
triturated by repeated pipetting, decanted into sterile Universal flasks and
centrifuged at 2,000r.p.m. for 10minutes. The supernatant was decanted and the
cells resuspended by inversion in 25ml of Dulbecco A' PBS to wash out the
collagenase. The cells were again centrifuged at 2000r.p.m. for 10minutes. The
washing and centrifugation step was repeated a further twice, prior to resuspension
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in 10ml of transport medium. The acini, containing the epithelial cells, were
sedimented by centrifugation at 800r.p.m. for 20seconds. The supernatant contains
aggregates of fibroblasts. The acini deposits were carefully aspirated using a sterile
Pasteur pipette and transferred to a fresh Universal. The acini were spun down
twice more and collected.
2.2.1.2b. Primary/Secondary Epithelial Cell Culture.
The acinar deposits were resuspended in 6mls of epithelial growth medium
(EGM) per gram of the original tissue and plated out in 75cm2 tissue culture flasks.
One flask was used for every 2grams of tissue. The cultures were incubated at
37°C for 48hours and then supplemented with 9mls of EGM. After a further 48hour
incubation the epithelial cells could be supplied with fresh medium.
Epithelial growth medium (EGM) : 1.104%w/v WAJC 404 medium.
(1 litre) 0.67%w/v HEPES.
0.12%w/v sodium hydrogen carbonate.
2mls of 0.25mgml"1zinc-stabilised insulin.
2mls of 10pgml"'1 cholera toxin.
10Opil of 3.92mgml"''dexamethasone in
ethanol.
1ml of lOpgml"'' epidermal growth factor.
0.5%v/v foetal calf serum.
10mls of penicillin/streptomycin
(10,000unitsml"''/10,000(.igml"'').
10mls of fungizone (250pgml~''), pH7.6.
The epithelial cell cultures were subcultured as per the immortalised cell
lines. Following the detachment of cells from flask, the 0.1% trypsin solution was
neutralised using LNCaP growth medium. Following centrifugation at 1,500r.p.m.
for 5minutes and resuspension in 24mls of EGM, the cell suspension could be split
into two 75cm2 flasks. In general, it was possible to passage the cells twice.
Beyond passage number 2 the cultures exhibited a rapid decline in growth rate.
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2.2.1.2c. Primary/Secondary Fibroblast Culture.
The supernatant from 2.2.1.2b. was centrifuged at 2,000r.p.m. for
10minutes and the resulting cell pellet resuspended in 12mls of LNCaP growth
medium, supplemented with 2.5pgml"1 fungizone, per gram of tissue. The
fibroblastic suspension was seeded into one 75cm2 flask per gram of tissue and
grown in monolayer culture at 37°C for 48hours. Subsequent to this incubation
period, the attached cells were washed with 12mls of Dulbecco 'A' PBS and
supplemented with fresh medium until 90% confluent. Sub-culture was performed
as described in 2.2.1.1b..
2.2.1.3 Spectrophotometric Determination of Viable Cell Numbers.
The proliferative rates of cultured cell lines and primary epithelial cells was
determined using the MTT ( 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) assay.
Cells were grown in 96well plates, supplemented with 100^1 of the
appropriate medium per well. 50^1 of MTT solution at a concentration of 1.5mg per
ml of culture medium, was aliquoted into each test well using a multi-channel
pipette (Titertek plus; ICN Biomedicals Ltd., and the cells incubated at 37°C for
2hours. Subsequently, 130^1 of the assay mixture could be carefully aspirated from
each well. The formazan crystals, produced as a result of the activity of intracellular
dehydrogenases, could be solubilised by suspension in 150pl of
dimethylsulphoxide containing 0.5%v/v FCS. The plates were shaken at room
temperature on an orbital shaker for 30minutes to ensure complete dissolution of
the crystals and the absorbance of resulting solution measured at 540nm on a
microplate reader (model 450; Bio-Rad Laboratories, Hemel Hempstead,
Hertfordshire, UK.).
The viability of the MTT assay as a determinant of prostatic epithelial cell
number was assessed using the DU145 cell line.
DU145 cells were plated in 96 well tissue culture plates at an initial plating
density of 1000 cells per well. 5 plates, corresponding to days 0-4, were used for
both the MTT assay and cell counts, with 8 wells employed in each. 48 hours post-
seeding, the medium was removed and replaced with 100pl of fresh medium. At
this time, and at 24 hour intervals subsequently, the cell number was assessed


































Figure 2.02 Measurement of the Proliferation ofDU145 Cells by Cell Counting and MTT Assay.
Cells were plated in DMEM supplemented with 10% FCS at an initial density of 10OOcells/well in 96 well
plates. 48 hours post-seeding (day 0) the medium was replaced and the cell numbers determined using a
haemocytometer with concomitant performance of an MTT assay. Subsequently, cell numbers were assessed in this
manner at 24hour intervals up to day 4. Each data-point represents the mean of 8 wells +/- SEM.
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Cells to be counted were washed twice in PBS 'A', incubated with 20pl of
1xtrypsin-EDTA for2minutes at 37°C, mixed with 80pl of DU145 growth medium
and cell numbers determined using both chambers of a haemocytometer (five 1mm
squares in each chamber).
Figure 2.02 exhibits the growth pattern of DU145 cells as assessed by both
cell counting and by the MTT assay. Clearly both approaches demonstrate similar
trends in DU145 growth, however, it is also apparent that the experimental error
associated with cell counting performed using the haemocytometer is considerably
greater than those with the MTT assay. These findings would tend to support the
use of the MTT assay for the assessment of cell proliferation.
2.2.1.4 Measurement of the Androgenic Responses of Cultured Cells.
The responses of LNCaP, DU145, PC3 and primary epithelial cells to
dihydrotestosterone (DHT) and hydroxyflutamide were determined as outlined in
2.2.1.3.. All media employed were purchased phenol red-free and the FCS
supplements were rendered steroid hormone-free through treatment with Dextran
Coated Charcoal (DCC).
All cells were grown in 96well tissue culture plates.
2.2.1.4a. Preparation of DCC-Stripped FCS.
50ml of DCC suspension was pelleted by splitting into two 25ml aliquots
and centrifuging at 4000r.p.m. for20minutes (4°C) in a Denley BS400 centrifuge.
DCC suspension (50ml): 1%w/v activated charcoal.
1ml of 5mgml"1 Dextran T70.
0.5ml of 1M tris-HCI, pH7.5.
0.5ml of 0.1M EDTA.
The charcoal pellets were mixed with 100ml of FCS pre-warmed to 37°C in a
Erlenmeyer flask, and the mixture shaken in a 37°C incubator for 1hour.
Subsequent to this period of incubation, the charcoal was removed by




The growth of LNCaP, DU145 and PC3 cells over a 4 day period was
assessed after exposure to a range of concentrations of DHT and
hydroxyflutamide. The concentrations employed were 10nM, 1nM, 0.1 nM, 0.01 nM,
0.001 nM and OnM (control). 1mM stock solutions of DHT and hydroxyflutamide in
ethanol were prepared and diluted down to 0.21 pM. The addition of 5pl of 0.21 pM
DHT/hydroxyflutamide to 10Optls medium gave a final concentration of 10nM. The
0.21 pM solution was serially diluted 10 fold to achieve the desired well
concentrations. The control wells were supplemented with 5pls of ethanol.
Five 96well plates corresponding to days 0-4 were employed. A total of 8
wells per plate were used for each androgen/anti-androgen concentration, with an
initial plate density of 1000cells per well for DU145 & PC3 and 4000cells per well
for LNCaP.
Cells grown in monolayer culture in 75crr)2 tissue culture flasks were
harvested through trypsinisation, as described in 2.2.1.1b., and resuspended in
10mls of their normal growth medium. The cell number was determined using a
haemocytometer and the cells diluted to the desired final concentration per 100pl
of medium in a total volume of 25mls. 100pls of the cell suspension was delivered
to each test well and the cells allowed to adhere to the plastic over a 24hour period
in a 37°C incubator. [ Note : 100pl of medium was aliquoted into all unused wells to
limit the loss of medium by evaporation from the test wells. ]. The medium was
subsequently aspirated from the test wells and replaced with 100pl of phenol red-
free medium containing DCC-treated FCS. The cells were incubated for a further
48hours at 37°C prior to the addition of DHT or hydroxyflutamide to the desired
concentration in 5pl ethanol. [ Note : DU145 and PC3 cells had their spent medium
replaced with 100pl of fresh medium prior to the addition of the androgen/anti-
androgen ]. The cell numbers were determined on DayO using the MTT assay
described previously (2.2.1.3.) and subsequently measured every 24hours up to
96hours.
2.2.1.4c. Primary Epithelial Cells.
The protocol for measurement of epithelial cell proliferation in response to
DHT and hydroxyflutamide was essentially the same as that described for the cell
lines (2.2.1.4b.). 4 wells were used for each concentration of drug per plate and the
cells were plated at a density of 5,000 cells per well in EGM. After 24hours at
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37°C, the media was replaced with 10Opil of phenol-red free LNCaP medium
supplemented with 10%v/v DCC-stripped FCS. 48 hours later the medium was
replaced with 100pl of fresh medium and the androgenic responses measured as
per 2.2.1.4.b..
2.2.2 Extraction and Purification of Plasmid DNA.
2.2.2.1 Preparation of Competent E. coli Using Calcium Chloride.
Using a sterile inoculating loop (Sigma Chemical Company LTD.) the
TOP10F' strain was streaked onto an LB agar plate supplemented with 15mgmM
tetracycline, and subsequently grown for 16hours in a 37°C incubator.
LB medium (Luria-Bertani medium) : 1% w/v tryptone;
0.5% w/v select yeast extract.
0.17M NaCI. pH 7.0.
Note : The LB medium was autoclaved for 20minutes at 15lb/sq.in. on liquid
cycle before use.
LB agar was prepared by the addition of select agar to LB medium to a final
concentration of 15gL~1, and autoclaving at 15lb/sq.in. for 20minutes.
A single colony was picked from the plate and transferred to a sterile Falcon tube
containing 2ml of LB medium, and the tube shaken at 225r.p.m. in a 37°C
incubator/shaker ( Model 625; New Brunswick Scientific Co. Inc., Edison, New
Jersey, U.S.A..) for 16hours overnight. 1ml of the overnight culture was diluted into
40ml of LB medium and grown in the 37°C in an incubator/shaker until it achieves
an A600 between 0.4 and 0-8. The bacterial culture was pelleted through
centrifugation at 6,000r.p.m. for 5minutes (4°C) and subsequently resuspended
gently in 10ml of ice-cold 0.1M CaCI2. The cells were incubated on ice for 1hour
and then spun for a further 5minutes at 6,000r.p.m. (4°C). The pellet was
resuspended in 2ml of 0.1 M CaCl2. After 2hours on ice, the cells were ready for
transformation with pRc/CMV.
2.2.2.2 Transformation of Competent E. coli.
MAX Efficiency DH5oJ"M competent E. coli were transformed with both
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pCMV/ARcom and MMTV/SPAP. TOP10F' were transformed with pRc/CMV
(Invitrogen Corporation). The transformation protocol adopted was identical for both
strains of E.coli.
The DH5a cells should be stored at -70°C and prior to transformation must
be thawed slowly on ice.
Competent cells were mixed gently by hand and two 10Optl aliquots
transferred to pre-chilled 15ml Falcon tubes. 1.7pl of a solution of 1.5M p-
mercaptoethanol was delivered to each aliquot, the cells swirled gently and
incubated on ice for 10minutes. The cells were swirled gently every 2minutes.
Subsequently 50ng of plasmid DNA was aliquoted into one Falcon tube and an
equivalent volume of autoclaved deionised water placed in the other to serve as a
"no DNA" control. The cells were swirled gently and left on ice for 30minutes. The
transformations were then heat pulsed at 42°C for 45seconds, followed by a
2minute incubation on ice. 0.9ml of SOC medium, preheated to 42°C, was added
to each tube. The tubes could then be shaken at 225r.p.m. for 1 hour in a 37°C
incubator/shaker.
SOB medium : 2% tryptone.
0.5% select yeast extract.
8.56mM NaCI.
2.5mM KCI. pH 7.0.
The medium was autoclaved at 15lb/sq. in. for20minutes and immediately
prior to use, sterile MgCl2 added to a final concentration of 10mM. SOC medium
was prepared through the mixing of glucose, sterilised by filtration, with SOB
medium, to 20mM.
200pl of both transformation mixtures were plated onto LB agar plates
supplemented with 50|^gml"'' ampicillin, and the plates incubated at 37°C for 16
hours.
2.2.2.3 Large-Scale Preparations of Plasmid DNA.
2.2.2.3a. Growth of Bacterial Cultures.
Note : All bacterial cultures were supplemented with ampicillin at a
concentration of 50^gml~1 to maintain the selection for transformed bacteria.
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A single bacterial colony from an ampicillin selection plate was used to
inoculate 5ml of ampicillin-supplemented LB medium in a sterile 15ml Falcon tube.
The culture was then incubated overnight at 37°C in a shaking incubator set at
225r.p.m.. 4ml of the overnight culture was delivered to a further 50ml of LB
medium and grown as before until an ODggo of ~0-6 (corresponding to late log
phase) was achieved. Subsequently, 500ml of LB medium in a 2L flask was
inculated with the entire late-log-phase culture, and shaken at 225r.p.m. in the
37°C incubator/shaker for 16hours. The bacteria were harvested from the culture
by splitting the culture into two 250ml Nalgene centrifuge pots and centrifuging at
5000r.p.m. for 5minutes in a Sorvall GS3 rotor. The spent medium could then be
decanted and treated with one 2.5g Presept disinfectant tablet (Surgikos LTD.,
Livingstone, UK.) for 1hour prior to disposal. Any residual medium in the pots was
removed using tissue paper.
The remaining 1ml of the overnight culture was used to prepare a stock
culture of bacteria, containing glycerol, that could be stored at -70°C indefinitely.
0.15ml of sterile glycerol was added to 0.85ml of the bacterial culture and
dispersed evenly by vortexing. The culture was transferred to a screw-cap
Eppendorf tube, snap frozen in liquid nitrogen and then stored.
The bacteria could be recovered, when needed, by scraping the surface of
the frozen culture using a sterile inoculating needle and streaking the adhering
bacteria onto an ampicillin-containing LB agar plate. The plate could then be
incubated at 37°C overnight.
2.2.2.3b. Lysis of Bacterial Cultures by Alkali.
The protocol described here, for the alkaline lysis of large scale bacterial
cultures, is a modification of that described in Maniatis et al (1989; 1.38-1.39).
The bacterial pellets from 2.2.2.3a. were completely resuspended in 5ml of
sterile, ice-cold solution 1. each, by stirring with a sterile, plastic 100ml pipette. The
5ml suspensions were pooled, delivered to a fresh centrifuge pot and mixed with
1 ml of a freshly prepared solution of 10mgml "1 lysozyme in 10mM Tris.CI.
Subsequently a 20ml aliquot of freshly prepared solution 2. was added and the
bacteria lysed through repeated inversion of the pot. The preparation was stored
on ice for 5minutes and then mixed, by shaking, with 15ml of ice-cold solution 3.,
forming a flocculent white precipitate. Following a 10minute incubation on ice, the
bacterial lysate could be centrifuged at 5000r.p.m. for 10minutes, and the resulting
supernatant decanted into a fresh centrifuge pot through four layers of
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cheesecloth. The supernatant was mixed with 0.6 volume of isopropanol, stored at
room temperature for 30minutes and centrifuged at 10,000r.p.m. for 5minutes. The
supernatant was discarded, and the pellet dried in a 37°C for 20minutes before
resuspension in 2ml of Tris-EDTA buffer (10mM Tris, 1mM EDTA; pH 8.0).
Solution I. : 50mM glucose;
25mM Tris-CI, pH 8.0;
10mM EDTA, pH8.0.
Solution 2. : 0.2N NaOH;
1% w/v sodium dodecylsulphate.
Solution 3. : 3M potassium acetate;
11.5% v/v glacial acetic acid.
2.2.2.3c. Purification of Plasmid DNA by Equilibrium Centrifugation in CsCI-
Ethidium Bromide Gradients.
2.5g of CsCI was added to the plasmid preparation ( 2.2.2.3b.) and the
solution warmed to 30°C to facilitate complete dissolution of the salt. A 0.2ml
aliquot of lOmgml"'' ethidium bromide was mixed with the solution, which could
subsequently be placed in a Beckmann Quickseal tube (13x32mm), the tube
topped up with Imgml"'' CsCI, sealed and spun at 100,000r.p.m. for 4hours at
22°C in a Beckmann Optima Ultracentrifuge TLX (rotor TLA 100-3). Following the
insertion of a 21-gauge hypodermic needle into the top of the tube, a syringe fitted
with an 18-gauge needle was used to remove, firstly, the upper band of nicked
circular or linear DNA followed by the lower band of intact plasmid DNA. The
linearised DNA could be discarded and the plasmid DNA transferred to a 15ml
Falcon tube.
2.2.2.3d. Removal of Ethidium Bromide and CsCI from Purified Plasmid DNA.
An equivalent volume of isoamylalcohol was mixed with the solution of
plasmid DNA ( 2.2.2.3c.) by vortexing, and the resulting mixture centrifuged at
1,500r.p.m. for 3minutes at room temperature. The lower aqueous phase,
containing the plasmid DNA, was removed using a DNase-free Pastette to a fresh
Falcon tube. This extraction process was repeated until the pink colouration was
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removed from both the aqueous and organic phases.
The DNA was purified from the CsCI by dialysis for 48hours against 3
changes of 2L of Tris-EDTA buffer (pH8.0) [ Note : The dialysis was performed
using Spectra-Por Molecularporous dialysis membrane ( molecular weight cut-off
3,500; Spectrum, Houston, Texas, U.S.A..)].
A 5pl aliquot of the plasmid DNA preparation was diluted in 2.995ml of Tris-
EDTA buffer (pH8.0) and the concentration determined spectrophotometrically at
260nm. An OD26O °f1 corresponds to a plasmid concentration of approximately
50pgml"'' (Maniatis et al, 1989). The plasmid solution was diluted to a final
concentration of 1mgml"1 in Tris-EDTA buffer.
2.2.2.3e. Analysis of Plasmid DNA by Agarose Gel Electrophoresis.
100ng of plasmid DNA was separated electrophoretically on 0.8% agarose
gels (50ml) containing 1xTris-Borate-EDTA (TBE) buffer. Electrophoresis was
performed using submarine mini-gel apparatus supplied by Hoefer Scientific
Instruments ( Scottish Biotechnology Instrumentation, Auchterarder, Perthshire,
UK.).
The 0.8% agarose gel was prepared by melting 0.4g of Agarose NA in 50ml
of 1xTBE using a microwave oven. The molten agarose was cooled to ~40°C
before adding 1^1 of lOmgmMof ethidium bromide and subsequently pouring into a
level gel tray carrying a comb of well dimensions 1.5x2.6mm.
5xTBE : 5.4% w/v Tris-base.
2.75% w/v boric acid.
10mM EDTA (pH8.0).
9pl of the plasmid preparation, at a concentration of 10ngpl"'1 was mixed
with 1pl of DNA gel loading buffer.
The gel tray carrying the 0.7% agarose gel was placed in the pre-chilled gel
apparatus, covered with 250ml of 1xTBE and the plasmid sample loaded alongside
10(j.l of Lambda DNA Hindlll fragments (~0.1mgml~1; Gibco BRL ). The gel was run
at 80volts for 1hour prior to examination with a U.V. transilluminator.
2.2.3 Transfection of Plasmid DNA into Prostatic Epithelia.
All transfections were performed with the DOTAP ( N-[1-(2,3-
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Dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulphate) transfection
reagent. DOTAP is a cationic lipid that, after sonication, forms liposomes which
interact with DNA, establishing stable complexes. These complexes can adhere to
the cell surface, fuse with the cell membrane and release the DNA into the
cytoplasm.
2.2.3.1 Transfection of pMMTV/SPAP into LNCaP, DU145, PC3 and Primary
Epithelial Cells.
Cells were transfected with pMMTV/SPAP and the control vector pRc/CMV.
Cells were grown in monolayer culture in eight 25cm2 tissue culture flasks
until approximately 60% confluence was achieved. 30fil of the transfection reagent
was diluted up to 10Opil with HBS in a bijou bottle. 5(xg of plasmid DNA was
separately diluted up to 100|u.l with HBS.
HBS : 20mM HEPES;
0.15M NaCI. pH7.4.
Sterilised by autoclaving for 15minutes at 15lb/sq.in. on liquid
cycle.
Both solutions were mixed by repeated pipetting and incubated at room
temperature for 10minutes, prior to the addition of 6mls of the appropriate cell
culture medium. The medium was mixed with the DNA by gentle pipetting. After
aspiration of the old cell culture medium, the cells could be incubated with the
mixture for 16hours in a 37°C incubator.
The response of the transiently transfected cell lines to DHT (10nM) and
hydroxyflutamide (10nM) in terms of their production and secretion of SPAP was
assessed. SPAP transfected cells and control transfections were given 6mls of
phenol red-free medium containing DCC-stripped FCS and the following
supplements :
Control: 12pil ethanol;
DHT 6^1 10|aM DHT and 6^1 ethanol;
Hydoxyflutamide : 6jliI 10^M hydroxyflutamide and 6(xl ethanol;
DHT/hydroxyflutamide : 6jj.I 10|aM DHT and 6fxl 10fiM
hydroxyflutamide.
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The cells were incubated in a 37°C incubator for 48hours before harvesting the
medium for immediate assay or storage at -20°C.
2.2.3.2 Co-transfection of pCMV/ARcom and pMMTV/SPAP into LNCaP and PC3
Cells.
LNCaP and PC3 cells were transfected with pCMV/ARcom plus
pMMTV/SPAP or pRc/CMV plus pMMTV/SPAP.
The cell lines were grown in eight 25cm2 flasks until 60% confluence was
achieved. The plasmids were complexed with the DOTAP reagent as outlined in
2.2.3.1. and mixed with 6mls of cell culture medium. The plasmid mixtures were
combined with their transfection partners and added to the cultured cells. The cells
were incubated in a 37°C incubator for 16hours. The cotransfected cells could
subsequently be supplemented as described in 2.2.3.1. and incubated at 37°C.
The medium was harvested after 48hours.
2.2.3.3 Assay of Secreted Placental Alkaline Phosphatase (SPAP).
Each medium sample was assayed in quadruplicate. Immediately prior to
assay, IxPNPP (p-nitrophenylphosphate) was prepared through dilution of
20xPNPP in DEA buffer.
The medium was mixed through brief vortexing and 50fils aliquoted into a
96well plate and heat-inactivated by incubation at 65°C for 1hour. 200^1 of
IxPNPP was delivered to each well and the plate incubated at 37°C for 30minutes
prior to measurement of the absorbance at 415nm on a microplate reader. The
absorbance of each medium sample was blanked against 4 wells containing 200^1
of IxPNPP only.
DEA buffer: 10.72mls 98%w/v diethanolamine;
(100ml) 1.636g NaCI;
50jj.Is 1M MgCI2. pH9.85.
Stored at 4°C.
20xPNPP : 371mg Sigma 104 phosphatase substrate in 10mls of
DEA buffer.
Store at -20°C in a glass universal shielded from light
by wrapping in foil.
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The concentration of SPAP in each sample in unitsml-1 was calculated
using the equation below.
[SPAP] in medium = OD415nm /1 x 18.5 x v unitsmh1
t = time of reaction (minutes),
v = volume of medium assayed (ml).
2.2.3.4 bcl-2 Expression in LNCaP and PC3 Cells Transfected with pCMV/ARcom.
The cell lines were grown to 60% confluence in three 25cm2 tissue culture
flasks and transfected with pCMV/ARcom as outlined for pMMTV/SPAP and
pRc/CMV in 2.2.3.1..
Two flasks of cells were transfected with pCMV/ARcom, with the remaining
flask providing a control for normal cellular expression of bcl-2. The cells were
transfected for 16hours, after which the medium form the three flasks was replaced
with phenol red-free medium containing DCC-stripped FCS. One flask of
transfected cells was supplemented with 10nm DHT and the cells incubated at
37°C for 24hours. Protein was isolated from the cultured cells as outlined in
2.2.6.1..
2.2.4 Isolation of Nucleic Acids
2.2.4.1 Isolation of Total RNA from Cultured Cells.
Total RNA was extracted from cultured cells using a modification of the
AGPC(acid-guanidinium-phenol-chloroform) method of Chomczynski and Sacchi
(1987).
In order to minimize RNAase contamination of the RNA preparation, all
solutions were prepared using RNAase-free glassware & plasticware, water and
chemicals. Wherever possible, the solutions were treated with 0.1% DEPC for 24
hours at room temperature and subsequently autoclaved for 15 minutes at
15lb/sq.in. on liquid cycle.
Solution D was prepared through the addition of 2-Mercaptoethanol to the
GTC solution to a final concentration of 0.1M.
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GTC solution : 4M guanidine isothiocyanate;
25mM sodium citrate, pH7.0.
0.5% N-lauroylsarcosine.
Cells were grown in monolayer culture to 80% confluency in 75cm2 tissue culture
flasks, washed in DEPC-treated phosphate buffered saline and lysed in 2.5mls of
solution D per flask. The tissue culture flask was shaken, at 4°C, for 10 minutes to
ensure complete cell lysis. 500pl Aliquots of the cell lysate were placed in
Eppendorf tubes and 50jnl of 2M sodium acetate (pH4.0) delivered to each. The
tubes were vortexed for 10 seconds prior to the addition of 500pl of water
saturated phenol (pH4.0) plus 10Opil of chloroform-isoamylalcohol (49:1). The
resulting suspension was vortexed for 10 seconds and then incubated on ice for 15
minutes. The samples were subsequently centrifuged at 13,000 r.p.m. for 20
minutes at 4°C in a microcentrifuge and the upper, aqueous phase transferred to a
fresh Eppendorf tube where it was mixed with 1 volume of isopropanol. The RNA
was precipitated overnight at -20°C. The RNA precipitate was sedimented, through
further centrifugation, at 13,000 r.p.m. for 20 minutes (4°C). The pelleted RNA was
resuspended in 60pl of solution D, the samples pooled and precipitated with 1
volume of isopropanol at -20°C for 2 hours. The RNA sample was centrifuged at
13,000 r.p.m. for 10 minutes (4°C) and the resulting pellet washed in 200^1 of 75%
ethanol prior to a further spin for 5 minutes. The supernatant was carefully
aspirated and the RNA air dried for 30 minutes at room temperature before
resuspension in 50pl of nuclease-free water.
A 5pl aliquot of the RNA solution was diluted in 2.995ml of DEPC treated
water and the concentration and purity of the preparation determined
spectrophotometrically. In order to quantify the amount of RNA, readings were
taken at 260nm and 280nm. An OD26O of 1 corresponds to an RNA concentration
of approximately 40pgml-1(Maniatis etal).The ratio between the readings at 260nm
and 280nm (OD26O /OD28O) provides an estimate of the purity of the RNA
preparation, with a ratio of 2 corresponding to a pure sample. If the OD26O/OD28O
ratio was less than 2, the RNA sample was extracted again with phenol-chloroform.
45pl of phenol: chloroform (1:1) was added to the RNA solution, the
suspension vortexed and spun at 13,000 r.p.m. for 5 minutes (4°C). The aqueous
phase was transferred to a fresh Eppendorf tube, and mixed with 45pl of
chloroform prior to a further spin at 13,000 r.p.m. for 5 minutes (4°C). The aqueous
phase was removed and the RNA precipitated by addition of 3 volumes of ethanol
and 3M sodium acetate to 0.3M. The RNA precipitate was pelleted and
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subsequently resuspended in 50pl of nuclease-free water. The concentration and
purity of the prepared RNA could be reassessed, spectrophotometrically, as
before.
2.2.4.2 Isolation of Total RNA from Snap-Frozen Tissue.
Prostatic tissue obtained by TURP was promptly snap frozen in liquid
nitrogen, and either used immediately in the preparation of RNA or stored at -70°C
for use within 7days of resection. Up to 1gram of frozen tissue could be used per
preparation.
The frozen tissue was disaggregated using a Mikro-Dismembrator II
( B. Braun Biotech International GmbH, Melsungen, Germany.) fitted with a 7ml
teflon shaking flask and accompanying stainless steel grinding ball, both of which
were pre-chilled in liquid nitrogen. The Mikro-Dismembrator II was operated at full
power for 15seconds, and the resulting tissue powder scraped into 5mls of solution
D (2.2.4.1.) using a pre-chilled micro-spatula. The stainless steel grinding ball was
also placed into the aliquot of solution D, since a significant amount of the
powdered tissue was seen to adhere to the ball. The RNA preparation was
continued as outlined in 2.2.4.1..
2.2.4.3 Isolation of Genomic DNA from Cultured Cells.
The cells in two 75cm2 flasks were washed once in PBS 'A', subsequently
scraped into 10mls of PBS A' and pelleted by centrifugation at 1500 r.p.m. for 5
minutes. The cell pellet was resuspended in 1ml of lysis buffer and incubated on
ice for 20 minutes with occasional swirling.




The resulting lysate was spun for 20 minutes at 2500 r.p.m. at 4°C to sediment the
nuclei. The nuclear pellet was resuspended in 4.5ml of resuspension buffer, mixed
immediately with 0.5ml of a solution of 5% SDS and 2mgml"1 proteinase K and
incubated at 37°C for 2-12 hours.
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Resuspension buffer: 0.075M NaCI;
0.024M EDTA, pH8.0.
5ml of phenol saturated with 20mM tris (pH8.0) was added to the preparation and
mixed gently by inversion- The mixture was spun at 2,000 r.p.m. for 10 minutes and
the upper aqueous phase transferred to a fresh tube using a wide-bore Pasteur
pipette. 5ml of chloroform-isoamylalcohol (24:1) was mixed with the aqueous phase
and the suspension spun as before. The aqueous phase was extracted once more
with phenol and chloroform-isoamylalcohol, prior to the addition of 0.5ml 3M
sodium acetate and 11ml ethanol at room temperature. After mixing, the DNA
precipitate was lifted out using a bent Pasteur pipette and delivered to 500ml of
Tris-EDTA buffer (pH 8.0). The DNA was stored at 4°C and allowed to dissolve
over 48 hours with occasional stirring.
A 5^1 aliquot of the DNA solution was diluted in 2.995ml of Tris-EDTA buffer
and the concentration of the preparation determined spectrophotometrically at
260nm. An OD26O °f 1 corresponds to a double-stranded DNA concentration of
approximately 50ngml~1.
2.2.5 Analysis of Nucleic Acids.
2.2.5.1 Reverse Transcription of Total RNA.
The protocol for first strand cDNA synthesis from samples of total RNA is a
modification of that described in the Promega Protocols and Applications Guide
(2nd Edition, 1991). 5|^g of total RNA was diluted in nuclease-free water up to
49.5pil and aliquoted into a 500^1 micro-test tube. The tube was heated to 85°C for
5minutes and subsequently cooled on ice for 3minutes. The tube was pulsed in a
microfuge and the following ingredients added to the RNA solution :
2.5pil of rRNasin ribonuclease inhibitor (40units^l"1);
20fxl of 25mM MgCI2;
1 Ojj-I of 10x reverse transcription buffer;
10p.l of 10mM dNTP mixture;
5.0(^1 of oligo(dT)-|5 (0.5|xgial"'1);
3.0|al of AMV reverse transcriptase (HC; 25unitS(il"1).
The tube was vortexed, pulsed in a microfuge and then incubated at 42°C for
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60minutes. Following the polymerisation step, the reverse transcription mixture was
heated to 99°C for 5minutes followed by a 5minute incubation on ice.
When using random primers for first strand cDNA synthesis, the reaction
was first incubated at room temperature for 10minutes prior to the 60minutes at
42°C. This pre-incubation ensures that the primers remain hybridised when the
temperature is raised to 42°C.
2.2.5.2 Analysis of Genomic DNA and cDNA by the Polymerase Chain Reaction
(PCR).
2.2.5.2a. Amplification of Genomic Androgen Receptor DNA Sequences.
The androgen receptor gene was analysed using a series of primers that
span each of its 8 exons. All primers except I.CAGs and I.CAGas were described
in Marcelli et al (1990). The positions of the primers on the androgen receptor gene
are indicated in Figure 2.03.
Primers.
Note : The primer sequences are written 5' to 3' with their locations on the
sequenced regions of the androgen receptor gene bracketed. The primers were
designed using sequence information obtained from Genebank EMBL. The
accession numbers for each sequence are quoted. Primers that locate to intron
sequences are indicated with an asterix.
Exon 1 (AC. No. : M35844)
Region 1 (AR1.1 product size 354bp)
AR1,1s 5'TGG AAG ATT CAG CCA AGC TCA AG3' (139-162)
AR1,1as TTC CTC ATC CAG GAC CAG GTA GCC T (492-468)
Region 2 (AR1.2 product size 534bp)
AR1,2s GCG CAG CAC CTC CCG GCG CCA GTT T (299-323)
AR1,2as CTA AGT AAT TGT CCT TGG AGG AAG T (832-808)
Region 3 (AR1.3 product size 325bp)
AR1.3s GCA GCA GCT GCC AGC ACC TCC GGA C (591-615)
AR1.3as CAA CGC CTC CAC ACC CAG GCC CAT G (915-891)
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Region 4 (AR1.4 product size 710bp)
AR1,4s TCC TTC AGC AAC AGC AGC AGG AAG C (731-755)
AR1.4as GGC TGA GGG TGA CCC AGA ACC GGG T (1440-
1416)
Region 5 (AR1.5 product size 233bp)
AR1,5s AGC CTG CAT GGC GCG GGT GCA GCG G (1390-
1414)
AR1.5as AGC CCC TGA GGG GGC CGA GTG TAG (1622-1599)
Region 6 (AR1.6 product size 153bp)
AR1,6s CAC CTG ATG TGT GGT ACC CTG GCG G (1649-1673)
*AR1,6as CGA AAG CGA CAT TTC TGG AAG GAA A (1801-1777)
CAG Repeat (1 .CAG product size 198bp)
1 .CAGs TGC GCG AAG TGA TCC AGA AC (251-270)
1 .CAGas CTT GGG GAG AAC CAT CCT CA (429-448)
Exon 2 (AC. No.: M35845) (AR2 product size 269bp)
*AR2s CAT TCA GTG ACA TGT GTT GCA TTG G (1-25)
*AR2as TGA AAG GTT AGT GTC TCT CTC TGG AA (269-244)
Exon 3 (AC. No.: M35847) (AR3 product size 185bp)
*AR3s AAC TTA TTA TCA GGT CAA TCA ACT C (1-25)
*AR3as AGG AAG AGA AAG AAA AGT ATC TTA C (185-161)
Exon 4 (AC. No. : M35847) (AR4 product size 371 bp)
*AR4s TGA TAA ATT CAA GTC TCT CTT CCT T (8-32)
*AR4as CAC TAA ATA TGA TCC CCC TTA TCT C (378-354)
Exon 5 (AC. No.: M35848) (AR5 product size 284bp)
*AR5s CCC AAC AGG GAG TCA GAC TTA GCT C (3-27)
*AR5as CCA ACC AGG TCT GGC CAA GCT GCT GT (286-261)
Exon 6 (AC. No.: M35849) (AR6 product size 245bp)
*AR6s TAT TGT AAA CTT CCC CTC ATT CCT T (1-25)
*AR6as AAT GGC AAA AGT GGT CCT CTC TGA A (245-221)
Exon 7 (AC. No.: M35850) (AR7 product size 266bp)
*AR7s TCT AAT GCT CCT TCG TGG GCA TGC T (1 -25)
*AR7as GCT CTA TCA GGC TGT TCT CCC TGA T (266-242)
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Exon 8 (AC. No.: M35851) (AR8 product size 294bp)
*AR8s CAG AGG CCA CCT CCT TGT CAA CCC T (1-25)
AR8as AGA GGA GTA GTG CAG AGT TAT AAC A (294-270)
PCR Reaction.
Genomic DNA isolated from the LNCaP, Du145 and PC3 cell lines and
male human placental DNA were analysed. DNA was diluted to a concentration of
lOOngpl"''.
All PCR reactions were carried out in 500pl micro-test tubes on a Hybaid
thermal reactor. [Note : In general, if multiple samples were to be analysed bulk
solutions containing the Taq DNA polymerase, reaction buffer, dNTPs and water
would be prepared. 79pl of this mixture could then be delivered to the DNA and
primers. In this way, a degree of consistency between tubes could be maintained.]
PCR reaction mix : 1pl of genomic DNA (lOOngpl"'');
10(ul of sense primer (50pgml~'');
10pl of antisense primer (SOpgml'"1);
10pl of 10x Reaction Buffer (containing 1.5mM
MgCI2);
16pl of dNTP mix (1.25mM of each dNTP);
0.2pl of Taq DNA polymerase (5unitspl"'');
52.8pl of nuclease-free water.
The components of the PCR reaction were thoroughly mixed through brief
vortexing , the mixture overlaid with 50pls of mineral oil and the tube subsequently
pulsed in a microfuge. Note : The tubes should be evenly distributed over the block
of the thermal reactor.
In all PCR reactions 35 amplification cycles were employed.
PCR cycles : a. Exons 1 (except the CAG repeat), 2, 5, 6, 7 and 8.




Figure 2.03 Locations of the Primer Pairs for the Analysis of Androgen Receptor Genomic DNA and cDNA.
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The PCR products were analysed by electrophoresis in 2% agarose gels.
75mls of 2% agarose was prepared using 1xTBE buffer as outlined in
2.2.4.5. 1pl of 10mgml"1 ethidium bromide was added prior to pouring the agarose
into a sealed, level midi-gel tray carrying a 5.5x1.5mm 16 well comb. The gel was
run in 750ml of 1xTBE in midi-gel apparatus ( Northumbria Biologicals Ltd.). 18pi of
each PCR reaction with 2pl of DNA loading buffer could be loaded per well,
alongside 20pl of 100bp ladder (~0.1mgml~1). [ Note : After removing aliquots of
the PCR reaction from the reaction tube, the pipette tip was wiped on the rim of the
tube to limit carry-over of mineral oil ]. Electrophoresis was performed for 4hours at
50volts, after which the gel was examined and photographed under U.V.
transillumination.
2.2.5.2b. Amplification of Androgen Receptor and bcl-2 cDNA Sequences.
cDNA was prepared as described in 2.2.5.1..
Primers.
Note : The primer sequences are written 5' to 3' with their locations on the
gene bracketed. All sequence information was obtained from Genebank EMBL.
The accession numbers for the bcl-2 sequences are quoted.
a. Androgen Receptor.
Two sets of primers were used to analyse the androgen receptor cDNA
locating to exons 2 & 3 and exons 7 & 8. The former set span intron 2 (>9kb) and
the latter set intron 7 (~13kb). [Note : The accession numbers for exons 2, 3, 7 and
8 of the androgen receptor gene are quoted in 2.4.2.1..]. The locations of the
primers for the analysis of androgen receptor cDNA are shown in Figure 2.03.
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2.3 (AR2.3 product size 265bp)
AR2.3S (Exon 2) S'GGA GAC TGC CAG GGA CCA TGT3' (48-68)
AR2.3as (Exon 3) TCC CAG AGT CAT CCC TGC TTC (159-139)
7.8 (AR7.8 product size 228bp)
AR7.8S (Exon 7) GAT GAA CTT CGA ATG AAC TAC (94-114)
AR7.8as (Exon 8) CAC TTG CAC AGA GAT GAT CTC (159-139)
b. bcl-2
The bcl-2 gene is believed to be transcribed into at least 2 mRNA's
(Tsujimoto and Croce, 1986). Sets of primers specific to the 5.5kb (bcl-2a) and
3.3kb (bcl-2p) transcripts of the bcl-2 gene and which span a putative intron located
at positions 2043bp and 732bp respectively were employed. The primer sets share
the same sense oligonucleotide. The positions of each primer pair on their
respective transcripts are indicated in Figure 2.04.
bcl-2a (AC. No. N81292) (5.5 product size 247bp)
5.5s CAC ACC TGG ATC CAG GAT AAC (2014-2034)
5.5as ATG GTA CAT CAC TGA CAA TGC A (2260-2239)
bcl-2p (AC. No. 81293) (3.5 product size 199bp)
3.5s CAC ACC TGG ATC CAG GAT AAC (702-722)
3.5as AGT GAA CGC TTT GTC CAG AGG (900-880)
C.HGPRT
Primers directed against the hypoxanthine-guanine phosphoribosyl
transferase (HGPRT) gene were used in the control PCR reactions. HGPRT is a
housekeeping protein that catalyses the conversion of the free purines,
hypoxanthine and guanine to IMP and GMP respectively. For each cDNA sample
examined, no DNA and HGPRT control PCR reactions were run in parallel. HGPRT
primers were used in both controls.
HGPRT (product size ~31 Obp)
HGPRTs CTT GCT CGA GAT GTG ATG AAG
HGPRTas GTC TGC ATT GTT TTG CCA GTG
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The procedure for the amplification of cDNA sequences was essentially the
same as that described for genomic DNA (2.4.2.1), with the reaction mixture being
described below.
PCR reaction mix : 20jxl of reverse transcription reaction;
10^1 of sense primer (50ngmr'');
10ptl of antisense primer (SOp.gml"'1);
8pil of 10x reaction buffer (containing 1.5mM
MgCI2);
16pl of dNTP mix (each dNTP at 1.25mM);
0.2fxl of Taq DNA polymerase (5unitsjj.l"1);
35.8pl of nuclease-free water.
35 amplification cycles were used in all PCR reactions.





















The PCR products were analysed by agarose gel electrophoresis as
outlined in 2.2.5.2a..
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2.2.5.2c. Restriction Endonuclease Digestion of Amplified Androgen Receptor and
bcl-2 cDNA.
The products of the PCR reactions form 2.4.2.2. were cut with appropriate
restriction enzymes to determine the efficacy of the amplification.
AR2.3, AR7.8, 5.5 and 3.5 were digested with Hind III (restriction site -
A/AGCTT), Dra III (restriction site CACN3/GTG), Alu I (restriction site - AG/CT) and
EcoRII (restriction site - /CC(aj)GG) respectively. The restriction sites and digest
product sizes are listed below.
AR2.3 (Hind III): restriction site - base 125 (exon2).
product sizes - 187bp and 78bp.
AR7.8 (Dra III): restriction site - base 108 (exon8)
product sizes - 177bp and 51 bp.
5.5 (Alu I) restriction site - base 2140.
product sizes - 127bp and 120bp.
3.5 (EcoRII) restriction site - base 805.
restriction site - 104bp and 95bp.
Restriction Digest: 10pil of PCR reaction;
2.5(xl of 10x Palette™ reaction buffer;
0.5^1 of restriction endonuclease;
12ptl of nuclease buffer.
Note : Blue, yellow and green Palette™ buffers were used with Hind III,
Alu I and EcoRII respectively.
The digestion products were analysed by electrophoresis through 2%
agarose gels as outlined as in 2.2.5.2a..
2.2.5.3 Northern Analysis.
The protocol described here for the analysis of RNA by electrophoresis
through formaldehyde gels followed by Northern transfer, is an adaptation of that
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described in Maniatis (1989; 7.43-7.48).
All solutions were prepared using RNAase-free glassware & plastic ware,
water and chemicals. Wherever possible, the solutions were treated with 0.1%
DEPC for 24 hours at room temperature and subsequently autoclaved for 15
minutes at 15lb/sq.in. on liquid cycle.
2.2.5.3a. Denaturing RNA Gel Electrophoresis.
Up to 20(xg of each RNA sample were separated electrophoretically on 1%
agarose gels (75ml) containing 2.2M formaldehyde and 1x gel buffer.
Electrophoresis was performed using midi-gel apparatus supplied by Northumbria
Biologicals LTD.. [ Note : The electrophoresis tank and gel tray were cleaned
thoroughly with a weak detergent solution, rinsed in water and soaked in a solution
of 3% hydrogen peroxide for 10 minutes. The apparatus was then rinsed
exhaustively in DEPC-treated water. ].
The gel was prepared by melting 0.75g of Agarose NA (Pharmacia Biotech
LTD., Milton Keynes, UK.) in 54ml of DEPC-treated water using a microwave oven.
The molten agarose was allowed to cool to approximately 60°C prior to the
addition of 1pl of lOmgrnr^ethidium bromide, 7.5ml of 10x gel buffer and 13.5ml of
37% formaldehyde (12.3M, pH>4.0). Following thorough mixing of the gel
components, the agarose could be poured into a sealed, level gel tray carrying a
comb of well dimensions 2 x 1.5mm thick.
10x gel buffer: 0.2M MOPS, pH7.0.
0.05M sodium acetate.
0.01M EDTA, pH8.0.
Note : The gel buffer was autoclaved before use and should achieve
a pH of between 5.5 and 7.0.
An aliquot of each RNA sample corresponding to 20p.g of total RNA was
dried down in a vacuum oven at 60°C and the pellet resuspended in 4.5pl of
nuclease-free water. The samples were incubated on ice for 30 minutes with
occasional vortexing to ensure complete dissolution of the RNA and subsequently
mixed with 2.0pil of 10x gel buffer, 3.5^1 of 37% formaldehyde and 10.0(il of
deionised formamide (Clontech Laboratories) The specimens could then be
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incubated at 55°C for 15 minutes, cooled on ice for a further 5minutes and pulsed
in a microfuge, ready to be loaded onto the gel immediately.
The gel tray carrying the formaldehyde gel was placed in the
electrophoresis apparatus, covered with ~800ml of 1x gel buffer and the total RNA
samples loaded alongside 20pl of undenatured 1kb DNA ladder (~0.1mgml~'';
Gibco BRL, Paisley, UK.). [ Note that the RNA samples were run without the
addition of loading buffer ]. The gel was run at 18volts for 16 hours, after which it
could be examined with a U.V. transilluminator and photographed under
illumination.
2.2.5.3b. Northern Blotting.
RNA separated on formaldehyde gels was transferred immediately to
nitrocellulose filters by capillary elution using 20xSSC as the transfer buffer.
The blotting apparatus consists of a basin straddled by a glass plate, both
of which should be thoroughly cleaned with detergent and rinsed with de-ionised
water prior to use. A piece of Whatman 3MM paper, of sufficient length to reach the
bottom of the basin when suspended over the glass support, was pre-wet in
20xSSC for use as a wick.
20xSSC : 3M NaCI.
0.3M tri-sodium citrate. pH7.0.
Sufficient 20xSSC must be placed in the basin to maintain a supply to the wick
over a 24 hour period.
After trimming off the unused portions and cutting off one corner to facilitate
orientation, the gel was soaked twice in 500ml of DEPC-treated water for 5minutes
each, to remove excess formaldehyde that might otherwise interfere with the
transfer. The gel was placed on the wick with its upper surface facing downward,
and surrounded completely with Saran wrap. A piece of nylon-supported
nitrocellulose (Hybond C extra), ~1mm larger than the gel in both dimensions,
initially wetted with DEPC-treated water and then soaked in 20xSSC for 5minutes,
was placed directly on top of the gel and the appropriate corner removed to orient.
Two pieces of 3MM paper, cut to the same dimensions as the nitrocellulose filter
and soaked in 2xSSC, were then positioned above the membrane. At each stage,
air bubbles were excluded by gently rolling each layer flat. A stack of tissues ~8cm
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high were placed above the 3MM papers, a glass plate located on top and the
entire stack weighed down with a 500g weight. As the tissues became, wet they
were replaced. The transfer of RNA was allowed to proceed for 24hours, after
which the apparatus was dismantled, the nitrocellulose filter soaked in 6xSSC for
5minutes-to remove any adherent agarose-and then dried at room temperature for
30minutes on a piece of 3MM paper. Finally, the filter was placed between two
fresh pieces of 3MM paper, and baked for 1hour at 80°C in a vacuum oven in
order to irreversibly bind the RNA to the nitrocellulose. Filters were stored sealed in
Saran wrap at room temperature until use.
2.2.5.4 Southern Analysis.
cDNA prepared using LNCaP, DU145 and PC3 mRNA and amplified, by
PCR, with the AR7.8 primer pair was examined.
The gel used to analyse the products of the PCR reaction was trimmed, one
corner removed to aid orientation and subsequently immersed in 500ml of a
solution of 1.5M NaCI, 0.5N NaOH to denature the DNA. The gel was gently
agitated on an orbital shaker for 45minutes. Following a brief rinse in deionised
water the gel could be neutralised by soaking for 30minutes in 500ml of 1M Tris
(pH7.4), 1.5M NaCI at room temperature, with gentle agitation. The neutralisation
solution was replaced with another 500ml volume and the gel soaked for a further
15minutes. The DNA was blotted onto Hybond C extra as described in 2.2.5.3b..
2.2.5.5 Preparation of Radiolabeled Probes.
2.2.5.5a. Production of Androgen Receptor Probes.
Two probes directed against androgen receptor sequences were
synthesised by PCR. These are referred to as 1.1 ARp and AR7.8p, and were
respectively used in the analysis of Northern blotted RNA, and 7.8 PCR products
blotted onto nitrocellulose as outlined in 2.2.5.3b.. The locations of the probes on
the androgen receptor cDNA are indicated in Figure 2.05.
Note : The PCR reactions for the synthesis of both probes were performed
as outlined in 2.2.5.2a. and used pCMV/ARcom (Ingpl""1) as template DNA. 35
cycles were used both reactions.
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1.1ARp. (product size 1093bp)
Primers : AR2.3s and AR7.8as.
PCR cycle : Denaturation 94°C, 1 minute.
Annealing 50°C, 1 minute.
Polymerisation 72°C, 4minutes.
AR7.8p. (product size 166bp)
Primers : AR7.8ps 5CAA GGA ACT CGA TCG TAT CA3' (117-136)
AR7.8as GTC CAC GCT CAC CAT GTG (120-183)
PCR cycle : Denaturation 95°C, 1 minute.
Annealing 55°C, 1 minute.
Polymerisation 72°C, 2minutes.
2.2.5.5b. p-Actin.
pAM41 (0.1pg|il-1) was linearised through EcoRI digestion.
Restriction Digest: 10pl of pAM41;
2.5pl of 10xSuRE/Cut buffer H;
0.5pl of EcoRI,
12pJ of nuclease-free water.
2.2.5.5c. Purification and Analysis of Probes.
The androgen receptor probes were purified from the PCR reaction
components by electrophoresis through 2% agarose gels prepared using low
melting point agarose and 1xTBE (2.2.4.5.) Electrophoresis was performed using
submarine mini-gel apparatus and the gel was formed with a preparative comb of
dimensions 1.5mmx47mm.
60pl of the PCR reaction was mixed with 10pl of DNA gel loading buffer and
subsequently loaded along the entire length of the preparative well. 15pl of either a
1kb DNA ladder (-O.lmgmMil.lARp) or a 100bp ladder (-O.lmgmM; 7.8ARp)
was loaded alongside the PCR reaction. The gel was run at 80volts for 1hour prior
to examination under U.V. illumination.
The appropriate band was excised from the gel using a clean scalpel, the
agarose slice cut into three equally sized fragments and transferred into three
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Eppendorf tubes. The agarose was melted at 70°C and subsequently mixed with
10Opil of tris-saturated phenol (pH8.0) per tube. The tubes were incubated at -70°C
for 10minutes, thawed and then centrifuged at 13,000 r.p.m. for 5minutes in a
microfuge. The preparation was removed, transferred to fresh tubes and extracted
sequentially with 100pl of tris-saturated phenol, 100pl of tris-saturated phenol +
100p.l of chloroform-isoamylalcohol and finally 100pl of chloroform-isoamylalcohol
per tube. After each extraction step the tubes were centrifuged at 13,000r.p.m. for
Sminutes. The DNA could be precipitated at the conclusion of the extractions
through mixing with 0.15volumes of NaCI and 2.5volumes of 100% ethanol. The
DNA precipitate was pelleted by a further spin at 13,000r.p.m. for 10minutes, dried
at room temperature for 30minutes and resuspended in 20pl of nuclease-free water
per tube. The resuspended DNA was pooled and mixed thoroughly by vortexing.
The probes were analysed by restriction endonuclease digestion followed
by electrophoresis through 2% agarose gels, as outlined in 2.4.2.3..
1.1.ARp and AR7.8p were digested with EcoRI (restriction site - G/AATTC)
and EcoRII (restriction site - /CC(aj)GG) respectively. EcoRI (SuRE/Cut buffer - H)
cuts 1.1ARp at base 141 of exon 6, yielding two products of sizes 791bp and
302bp. Digestion of AR7.8p with EcoRII produces 2 bands on an agarose gel at
81 bp and 85bp. [Note : Only 5pl of the PCR reaction was digested, and the
digestion reaction, as described in 2.2.5.2c., was altered accordingly.]
The digestion products were run alongside 5pl of uncut probe DNA
(containing 1pl of DNA loading buffer).
Linearised pAM41 was purified as described for the androgen receptor
probes, with the entire digestion reaction (2.2.5.5b.) being loaded onto the
preparative gel.
2.2.5.5d. 32p_[_abe||jng 0f CDNA.
The androgen receptor and p-actin probes were 32p.|abelled using the
Megaprime™ DNA labelling system (RPN 1606) with [a-32P]dCTP. The DNA
synthesis was primed using random sequence hexanucleotides as first described
by Feinberg and Vogelstein (1983 and 1984).
10pl of purified probe (2.2.5.5c.) was diluted into 18pl of nuclease-free
water and subsequently mixed 5pl of primer solution. The DNA was denatured by
incubation at 95°C for 5minutes prior to the addition of 10pl of Megaprime reaction
buffer, 5pl of [a-32p]dQTP and 2pl of "Klenow" DNA polymerase 1. The
components of the reaction were thoroughly mixed by repeated pipetting before
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incubating at 37°C for 1 hour.
2.2.5.5e. Separation of Radio-labelled Probes from Unincorporated [a-32P]dCTP.
Labelled probes were purified chromatographically using NICK™ column
packed with Sephadex G-50 DNA Grade F.
The top cap of the column was removed, the liquid decanted and the
column then rinsed with 3ml of equilibration buffer. The bottom cap was discarded
and the Sephadex gel subsequently equilibrated with 3ml of equilibration buffer.
The buffer was allowed to completely enter the gel prior to loading the entire
labelling reaction (2.2.5.5d.). 400^1 of equilibration buffer was added to the column
and permitted to enter the gel. The purified sample was eluted through the addition
of a further 400pl of equilibration buffer and collected in a sterile Eppendorf tube.
Equilibration buffer: 10mM Tris-HCI, pH7.5;
1mM EDTA.
2.2.5.6 Hybridisation of Radio-labelled Probes to Nucleic Acids Immobilised on
Nitrocellulose Filters.
2.2.5.6a. Prehybridisation and Hybridisation.
Note : The procedures described apply to both Northern and Southern
blots.
The filters were prehybridised in a Hybritube 15 ( Gibco BRL ) containing
12.5ml of prehybridisation fluid at 42°C for 24hours.





0.125ml sonicated, denatured salmon testes DNA
(lOmgml"'').
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20xSSPE : 3M NaCI;
0.23M Monosodium phosphate (NaH2P04);
25mM EDTA, pH7.4.






1% bovine serum albumin.
(Sterilised by filtration through a 0.2^m bottle-
top filter).
The purified radio-labelled probe was denatured through heating to 95°C
for Sminutes and immediately cooling on ice. It could then be added directly to the
prehybridisation fluid. Hybridisation was performed for 24hours at 42°C, after
which the filter could be removed form the hybridisation tube and washed
sequentially in increasingly stringent washing buffers (2.2.5.6b-c.).
Washed membranes were rinsed briefly in O.lxSSC, drained and wrapped
in Saran wrap. The blots could be placed in a Fastrad Autoradiography cassette
with intensifying screens and the filter covered with a sheet of HyperfilrrP~M-MP.
The autoradiography cassette could be placed in a -70°C freezer for 24-48hours
after which the film could be developed in an RP X-Omat developer.
2.2.5.6b. Detection of Androgen Receptor mRNA using 1.1ARp.
Northern blotted total RNA was probed with labelled 1.1 ARp for androgen
receptor gene expression, as outlined in 2.2.5.6a.. Probed blots were washed at
room temperature as described below.
Note : After each washing step the blot was monitored to determine the
level of radioactivity remaining hybridised.
Wash 1 : 3xSSC, 0.1%SDS. 20minutes.
Wash 2 : 2xSSC, 0.1%SDS. 20minutes.
Wash 3 : 1xSSC, 0.1%SDS. 20minutes.
Wash 4 : 0.2xSSc, 0.1%SDS. 10minutes.
Wash 5 : O.lxSSC, 0.1%SDS. 10minutes
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2.2.5.6c. Detection of AR7.8 PCR Products using AR7.8p.
Southern blotted AR7.8 products were probed with labelled AR7.8p, as
described in 2.2.5.6a.. The blot was washed under the following conditions :
Wash 1 : 1xSSC, 0.1%SDS. 15minutes. Room temperature.
Wash 2 : O.lxSSC, 0.1%SDS. 15minutes. Room temperature.
Wash 3 : O.lxSSC, 0.1%SDS. 15minutes. 65°C.
2.2.5.6d. Detection of p-Actin.
Northern blots probed with 1.1ARp were stripped using the procedure
described in 2.2.5.6e. and re-probed with labelled mouse p-actin cDNA. The blot
was washed as described for AR7.8p with an extra 15minute wash in O.lxSSC and
0.1%SDS at 65°C.
2.2.5.6e. Removal of Radio-labelled Probes from Nitrocellulose Filters.
500ml of a solution of 0.05xSSC and 0.01m EDTA (pH8.0) was heated to
boiling, removed from the heat and 5ml of 10% SDS added. The nitrocellulose
filters were immersed in the hot stripping solution for 15minutes. The procedure
was repeated with a further 500ml of hot stripping solution. The filters could be
rinsed briefly in 500ml of 0.01xSSC, the majority of the liquid removed by placing
on a pad of paper towels and the blot re-applied to a sheet of film for 48hours
(2.2.5.6a.). If all of the probe was seen to be removed, the blot could be dried at
room temperature for 30minutes and stored. Re-stripping could be performed if
necessary.
2.2.6 Analysis of Proteins by Western Blotting.
2.2.6.1 Isolation of Protein from Cultured Cells.
Cells were grown in monolayer culture to -80% confluency in 75cm2
(25cm2) tissue culture flasks. The cells were washed twice in 12ml of Dulbecco 'A'
PBS, drained completely and subsequently lysed in 300^1 (100p.l) of 1xSDS gel-
loading buffer pre-heated to 85°C.
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1xSDS gel-loading buffer: 50mM Tris-HCI (pH6.8);
100mM dithiothreitol;
2% w/v SDS;
0.1% w/v bromophenol blue;
10% v/v glycerol.
The lysates were transferred to Eppendorf tubes and boiled in a water-bath for
10minutes. The tubes were placed on ice and sonicated in a Soniprep 150 ( MSE;
Fisons Scientific Equipment Ltd., Loughborough, Leics., UK.) set at full power for
10seconds. The tubes could then be centrifuged in a microfuge at 13,000r.p.m. for
10minutes at room temperature and the resulting supernatants transferred to fresh
tubes.
20pl of the protein preparation was mixed with 80pl of 100% ethanol and
subsequently boiled in a water-bath for 1 minute. The resulting precipitate was
pelleted through centrifugation at 13,000r.p.m for5minutes in a microfuge, dried at
room temperature for 5minutes and resuspended in 20pl of autoclaved water. The
protein was precipitated as before and finally resuspended in 80pl of autoclaved
water. The protein content of this 80pl aliquot was determined colourimetrically by
the method of Bradford (1976) using Bio-Rad protein assay reagent. 20ptl of
reagent was added to the resuspended protein and mixed by vortexing. The assay
mixture was transferred to a 96well plate, the plate read at 595nm on a microplate
reader and the protein content assessed against bovine serum albumin (BSA)
standards ranging from 40pgml~ 1to Ip.gmMof protein.
The protein samples were either used immediately for SDS-PAGE or stored
at -20°C.
2.2.6.2 Isolation of Protein from Frozen Tissue.
0.5g of human tonsil was snap-frozen in liquid nitrogen and disaggregated
using the Mikro-Dismembrator II as described in section 2.2.4.2. The powdered
tissue was immediately scraped into 200|i of ice-cold suspension buffer using a
pre-chilled micro-spatula and subsequently mixed with 200jal of 2xSDS gel-loading
buffer. The protein preparation was continued as outlined in section 2.2.6.1.
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Suspension buffer: 0.1M NaCI;
0.01M Tris.HCI (pH 7.6);
0.001 M EDTA (pH 8.0);
l^gmr'' aprotinin;
100pgml"1 PMSF.
2.2.6.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) of Proteins.
The procedure detailed is based on the discontinuous buffer system
described by Laemmli (1970). Electrophoresis was performed using the Protean II
vertical electrophoresis system (16cm configuration [ spacers 18.3cm long and
1.5mm thick ]; Bio-Rad Laboratories Ltd.).
The electrophoresis plates were washed in a weak detergent solution,
rinsed thoroughly and the side of each plate coming into contact with the gel
cleaned with 100% ethanol. The gel plates were assembled according to Bio-Rad
instructions. The resolving gel was prepared by pouring 30mls of a 15%
polyacrylamide solution into the gap between the plates. [ Note : The
polyacrylamide solutions were prepared through the addition of each component in
order, with thorough mixing ensured through swirling immediately after the TEMED
was included.]. The resolving gel was overlaid with isobutanol to a depth of
~0.5cm and polymerisation allowed to proceed for 30minutes.
15% Polyacrylamide : 10.65mls autoclaved water;
Resolving Gel (30ml). 11.25mls 40% w/v acrylamide/bis-acrylamide;
7.5mls 1.5M Tris-base (pH8.8);
0.3ml 10% w/v SDS;
0.3ml 10% w/v ammonium persulphate;
12|o.l TEMED.
The isobutanol was removed using a paper towel and the top of the gel washed
with deionised water to remove any unpolymerised polyacrylamide. 10mls of a 5%
stacking gel was poured onto the surface of the resolving gel and a 10 well Teflon
comb (10mmx1.5mm) inserted, ensuring that no air bubbles were trapped. The
stacking gel was allowed to set for 30minutes at room temperature.
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5% Polyacrylamide : 7.25mls autoclaved water;
Stacking Gel (10ml). 1.275mls 40% w/v acrylamide/bis-acrylamide;
1.25mls 1M Tris-base (pH6.8);
0.1ml 10% w/v SDS;
0.1ml 10% w/v ammonium persulphate;
i0pi temed:
After the completion of polymerisation the comb was removed and the wells
washed with de-ionised water to remove unpolymerised acrylamide. The gel could
then be mounted into the gel apparatus and Tris-glycine electrophoresis buffer
placed in the top and bottom reservoirs. Air bubbles trapped at the bottom of the
gel between the glass plates were removed.
The protein samples were boiled in a water-bath for 10minutes and
incubated on ice for 5minutes prior to loading into the bottom of the wells using
Prot/Elec tips ( Bio-Rad Laboratories Ltd.). The samples were loaded alongside
15^1 of Rainbow™ molecular weight markers (Amersham International plc. \
molecular weight range 14,300-200,000 ). The "Rainbow markers" (15pl) were
mixed with 15pl of 1xSDS gel-loading buffer, boiled for 10minutes and loaded onto
the gel.
The gel was initially run at 20mA until the bromophenol blue reached the
interface between the stacking and resolving gels. Subsequently the gel was run at
40mA until the bromophenol was seen to run off the bottom of the resolving gel.
2.2.6.4 Transfer of Proteins from SDS-Polyacrylamide Gels to Nitrocellulose.
The SDS-polyacrylamide gel was placed in 1L of transfer buffer and soaked
for 30minutes. The gel could then be measured and nitrocellulose (Hybond C extra)
plus 4 pieces of Whatman 3MM paper cut to the same dimensions. The gel,













3.75mls 10% SDS. pH9.2.
Blotting was performed with Transblot SD semi-dry transfer cell ( Bio-Rad
Laboratories Ltd.). The electrodes were carefully cleaned with 100% ethanol prior
to the blotting procedures.
2 pieces of 3MM paper were placed on top of each other on the anode. The
nitrocellulose could then be positioned above the 3MM paper with the gel placed
exactly above the membrane. The remaining pieces of 3MM paper were stacked on
top of the gel. [ Note : At each stage, air bubbles were excluded by gently rolling
each layer flat. ]. After carefully placing the cathode atop the stack, transfer was
permitted for 16hours at 5volts.
2.2.6.5 Immuno-detection of the bcl-2 Oncoprotein Immobilised on Nitrocellulose.
Proteins detection was carried out using the ECL Western blotting detection
system.
The nitrocellulose membrane was washed in 500mls of washing buffer for
10minutes and subsequently incubated in blocking solution (0.1ml solution per
cm2) for 2hours in a shallow tray. [ Note : All incubations and washing steps were
performed at room temperature on an orbital shaker. ]. The membrane was
subsequently washed for 5minutes in 500mls of washing buffer at room
temperature, placed in a heat-sealable bag and then incubated with the
monoclonal anti-human bcl-2 antibody diluted 1:200 in blocking solution (0.1ml









5g dried skimmed milk;
2g bovine serum albumin.
The components of the blocking solution were
dissolved in washing solution.
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At the conclusion of this 2hour incubation the membrane was washed in 500mls of
washing buffer for 15minutes followed by two further 5minute washes. The
membrane was then placed in a fresh heat-sealable bag and incubated with the
secondary antibody (mouse Ig, horseradish peroxidase-linked whole antibody)
diluted 1:1000 in blocking solution (0.1ml solution per cm2) for 2hours.
Subsequently, the membrane was washed as before, once for 15minutes and then
twice for 5minutes. The membrane was drained completely and incubated for
1 minute with the two ECL detection reagents (0.125mls per cm2) previously mixed
in equal quantities. The membrane was drained, wrapped in Saran wrap and
placed in an autoradiography cassette fitted with intensifying screens.
HyperfilmTM-ECL was exposed to the membrane for 30seconds, 1 minute,
2minutes and 4minutes to ensure optimum exposure.
Densitometric analysis of exposed autoradiographs was performed with a
Quantimet 970 supplied by Cambridge Instruments. The optical densities of each
band are based on that of the darkest band in a particular group and are thus
quoted in arbitrary units
2.2.7 Immunohistochemical Analysis of Androgen Receptor Expression in
Prostatic and Endometrial Tissues.
All immunohistochemistry was performed by Dr. H. O. Critchley, Department
of Obstetrics and Gynaecology, Centre for Reproductive Biology, University of
Edinburgh.
Paraffin sections of BPH and endometrial tissues were examined using a
mouse monoclonal antibody raised against a site of high antigenicity on the human
androgen receptor. Negative controls were treated with the anti-mouse IgG
secondary antibody alone. Detection of the antigen was improved through the use
of microwave antigen retrieval.
The biotinylated secondary antibody was detected using a streptavidin-
horse radish peroxidase (HRP) conjugate with 3,3'-Diaminobenzidine
Tetrahydrochloride (DAB) as the enzyme substrate. Consequently, positively
stained nuclei appeared dark brown in colour. The negative controls were counter-
stained with haematoxylin.
2.2.8 Statistical Analysis.
Statistical significance was determined using Student's t-test for comparison
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of 2 means and a modification of the t-statistic termed the Bonferroni method for
the comparison of a number of means against a control mean (Wallenstein et al,
1980). Using the Bonferroni method the critical value is obtainable from a standard
table of the t-distribution using a significance level of P/n, where n is the number of
pairwise comparisons e.g. for 5 comparisons, the P value of 0.05 would be




At the time of diagnosis, the majority of prostatic adenocarcinomas have
already progressed to a state where radical surgical approaches to treatment are
insufficient for complete tumour management. The logical course of action is then
to deny the inherently androgen-dependent tumour cells androgenic stimulation
either by chemical or surgical castration. The subsequent induction of apoptosis in
the majority of tumour cells leads to dramatic initial reductions in tumour mass with
corresponding diminution of symptoms. However, these extremely favourable
responses are only temporary and in nearly all cases there is a recurrence of
tumourigenic symptoms leading ultimately to the death of the patient.
Patient relapse results from progression of the tumour from a state of
androgen-dependent growth to androgen-independence. Such "hormone escape"
has been postulated to occur by a number mechanisms (see Introduction),
however, the net effects are essentially identical i.e. the development of a
carcinoma containing cells which will not undergo programmed cell death in an
androgen-free environment. In order to develop effective therapies which target
both androgen-dependent and androgen-independent prostate cancer cells
effectively it is preferable that the phenotype of both cell types be fully
characterised. In this respect, the available in vitro models of prostate cancer
provide ideal systems for the analysis of hormone escape owing to their inherent
ease of study.
The expression of the androgen receptor and the anti-apoptosis
oncoprotein bcl-2 is extremely cell-specific within the prostate, the former generally
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being restricted to the secretory epithelia and the latter arising almost exclusively in
the basal epithelial cells. Additionally, altered expression of both these proteins has
been implicated in the development of androgen-independent prostate cancer.
Subsequently, it was the aim of the thesis to determine the relationship between
hormone-independence in vitro and the expression of bcl-2 and the androgen
receptor. Furthermore, the possibility of liaison between the androgen signalling
networks and the bcl-2 oncoprotein was also investigated. The approach used is
summarised below:
1. Assessment of the growth responses of prostate cancer cell lines and
primary epithelial cell cultures to androgens and anti-androgens.
2. Determination of the expression of the androgen receptor in cell lines and
primary cultures at the transcriptional level.
3. Measurement of androgen receptor function.
4. Determination of the expression of the bcl-2 oncoprotein in the cell
models and its relationship with androgen responsiveness and the
androgen receptor.
3.1 The Effects of Dihydrotestosterone (DHT) and Hydroxyflutamide (HO-F) on
the Growth of Cultured Prostate Cancer Cell Lines and Primary Epithelial Cell
Cultures.
The effects of androgenic stimuli on the LNCaP, DU145 and PC3 cell lines
is well documented (Horoszewicz et at, 1983; Wilding et al, 1989; Mickey et al,
1980; Kaighn et al, 1979; Schulz et al, 1990). It was felt necessary to determine the
growth characteristics of our cell lines in order to ensure the appropriate responses
to DHT and hydroxyflutamide. This was felt to be of particular importance in LNCaP
in view of the subclones of androgen-insensitive cells (LNCaPr) known to
contaminate this cell line (Hasenson et al, 1985).
A number of groups have analysed the response of primary prostatic
epithelial cell cultures to androgens and indeed to anti-androgens (Schroeder et al,
1974; McKeehan et al, 1984; Hallowes et al, 1991). Their findings differ greatly and
it was intended, in these studies, to determine conclusively, whether or not primary
cultures retain any of the in vivo growth characteristics of secretory epithelia.
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The growth response of cultured cells to both dihydrotestosterone and also
to the non-steroidal anti-androgen hydroxyflutamide was assessed. DHT, being the
most potent and certainly the most physiologically significant androgen within the
prostate, was employed to determine hormone-responsiveness. Hydroxyflutamide
was included in the study since truly androgen-dependent cells should not exhibit
any response to such an androgen receptor antagonist.
3.1.1 Growth Response of the LNCaP, DU145 and PC3 Cell Lines to DHT and
HO-F.
3.1.1.1 LNCaP.
Figures 3.01 a. and 3.01 b. demonstrate the impact of increasing
concentrations of DHT and HO-F on the growth of the LNCaP cell line over a 4 day
period.
LNCaP cells exhibit significant (p<0.05) growth stimulation at all
concentrations of DHT used by day 2 compared to control (Figure 3.01 a.). There is
no significant difference in cell numbers between all DHT concentrations at day 2.
[ Note : the tailing-off of the growth curves for the control and the majority of the
tests after day 3 is presumably either due to medium exhaustion or due to cell
confluence ].
After 4 days, LNCaP cells supplemented with 0.001 nM, 0.01 nM and 0.1 nM
HO-F show no significant (p>0.05) increases in cell number compared to control
(Figure 3.01 b.). At day 3, the cells exhibit significant (p<0.05) growth stimulation in
the presence of 10.0nM HO-F but not 1.0 nM HO-F. Both 10.0nM and 1.0nM HO-F
stimulate LNCaP proliferation significantly (p<0.05) by day 4. There is a significant
difference between cell numbers in the 10.0nM HO-F treatment compared to the
1.0nM HO-F treatment, at day 4. Such variation is not observed at day 3.
The responses of the LNCaP cell line to DHT and the androgen antagonist
Hydroxyflutamide are very much in keeping with those observed by other groups
(Olea eta!, 1990; Wilding et al, 1989).
3.1.1.2 DU145.
As Figures 3.02 a. and 3.02 b. indicate, DHT and HO-F in the range
0.001 nM to 10.0nM, have no significant (p>0.05) influence on the rate of pro¬


























Figure 3.01 Dose Response ofLNCaP Cells to Dihydrotestosterone and Hydroxytlutamlde.
Cells were plated in RPM11640 medium supplemented with 10% FCS at a density of 4000cells/well in 96 well
plates. After 24 hours the medium was aspirated and replaced with phenol red-free RPMI 1640 containing 10% DCC-
stripped FCS. Subsequent to a further 48hour incubation, DHT [Figure 3.01 a ] or HO-F [Figure 3.01 b ] was added to a
final concentration of 0.001, 0.01, 0.1, 1.0 and 10.0nM. Control wells were supplemented with an aliquot of ethanol
equivalent to the volume given to the test wells. 8 wells were used for each dilution. Cell numbers were assessed
spectrophotometrically (540nm) using the MTT assay at days 0, 1, 2, 3 and 4. Each data point represents the mean +/-
























































Figure 3.02 Dose Response ofDU145 Cells to Dihydrotestosterone and HydroxyHutamide.
Cells were plated in DMEM supplemented with 10% FCS at a density of 1000cells/well in 96 well plates. After
24hours the medium was aspirated and replaced with phenol red-free medium containing 10% DCC-stripped FCS. 48
hours later, after replacement with fresh medium (100pl), DHT [Figure 3.02 a.] or HO-F [Figure 3.02 b.] was added to a
final concentration of 0.001, 0.01, 0.1,1.0 and 10.0nM. Control wells were supplemented with an aliquot of ethanol
equivalent to the volume delivered to the test wells. 8 wells were used for each drug concentration. Cell numbers were




PC3 cells exhibit similar responses to androgens/anti-androgens as the
DU145 cell line (Figure 3.03 a. and 3.03 b.). Over a 4 day period, there is no
significant (p>0.05) increase in the proliferative rate of cells supplemented with
DHT (0.001nM - 10.0nM) or HO-F (0.001nM - 10.0nM) compared to control. [ Note :
No obvious explanation can be offered for the observed "lag" in growth up to day 2,
but since it occurs in both control and test wells, it may indicative of adverse effects
of ethanol on this particular cell line. ]
3.1.2 Growth Response of Primary Epithelial Cells to DHT and HO-F.
Primary epithelial cells derived from specimens obtained by TUR of both
benign and malignant prostates were analysed for their response to androgen and
anti-androgen. Primary cells were used in this study since they exhibit significant
growth advantage over secondary/tertiary cultures.
Cultures derived from 2 BPH (Figures 3.04 and 3.05) samples and 1 poorly
differentiated adenocarcinoma of the prostate (Figure 3.06) were studied. It is
evident from the data that there is no significant growth stimulation of either BPH or
CaP derived epithelial cells in the presence of DHT or HO-F at concentrations of
between 0.001nM and 10.0nM.
3.2 Androgen Receptor (AR) Expression in Cultured Prostate Cancer Cell
Lines and Primary Epithelial Cells - Analysis by Northern Blotting.
Having established that the DU145 and PC3 cell lines plus all of the primary
epithelial cell cultures do not respond to either androgens or anti-androgens the
logical progression was to establish the extent of androgen receptor gene
expression, the rationale being that an inability to respond to hormonal stimuli may
be due to a lack of functional receptor.
Total cellular RNA was prepared from tissues, prostatic carcinoma cell lines
and primary epithelial cells using the approach described by Chomczynski and
Saachi (1987). 20pg of total RNA was separated electrophoretically on 1% agarose
formaldehyde gels and blotted by capillary transfer to nylon-supported
nitrocellulose. Blots were analysed for AR mRNA transcripts using a 1093bp PCR


















































































Figure 3.03 Dose Response ofPC3 Cells to Dihydrotestosterone and HydroxyHutamide.
Cells were plated in HAM'S F12 medium supplemented with 7% FCS at a density of 10OOcells/well in 96 well
plates. Following a 24hour incubation the medium was aspirated and replaced with phenol red-free medium containing
7% DCC-stripped FCS. After a further 48hours the spent medium was replaced with 100j.il of fresh medium and DHT
[Figure 3.03 a.] or HO-F [Figure 3.03 b.] added to a final concentration of 0.001, 0.01, 0.1,1.0 and 10.0nM. Ethanol was
delivered to control wells. 8 wells were used for each concentration of androgen/anti-androgen. Cell numbers were











Figure 3.04 Dose Response of BPH-derived Primary Epithelial Cells to Dihydrotestosterone and Hydroxyflutamide.
Cells (BPH 1) were plated in EGM at a density of 5000cells/well in 96well plates. Following a 24 hour
incubation the medium was aspirated and replaced with phenol red-free RPM11640 medium supplemented with 10%
DCC-stripped FCS. After a 48 hour incubation the spent medium was replaced with 100pl of fresh medium and DHT
[Figure 3.04 a ] of HO-F [Figure 3.04 b.] added to a final concentration of 0.001, 0.01, 0.1,1.0 and 10.0nM. Ethanol was
added to control wells. 4 wells were used with each concentration of androgen/anti-androgen. Cells numbers were




























Figure 3.05 Dose Response of BPH-derived Primary Epithelial Cells to Dihydrotestosterone and HydroxyHutamide.
Cells (BPH 2) were plated in EGM at a density of 5000cells/well in 96 well plates. After a 24 hour incubation
the medium was aspirated and replaced with phenol red-free RPM11640 medium supplemented with 10% DCC-stripped
FCS. After a further 48 hour period the spent medium was replaced with 1OOpI of fresh medium and DHT
[Figure 3.05 a.) or HO-F [Figure 3.05 b.) added to a final concentration of 0.001, 0.01, 0.1, 1.0 and 10.0nM. Ethanol was
added to control wells. 4 wells were used with each concentration of androgen/anti-androgen. Cell numbers were





Figure 3.06 Growth Response of CaP-derived Primary Epithelial Cells to Dihydrotestosterone and Hydroxyflutamide.
CaP derived epithelial cells were plated at a density of 5000cells/well in EGM. Following a 24 hour incubation
the medium was aspirated and replaced with phenol red-free RPMI 1640 medium containing 10% DCC-stripped FCS.
48 hours later, after replacing the spent medium with fresh medium (100pl), DHT [Figure 3.06 a ] or HO-F
[Figure 3.06 b.] was added to a final concentration of 0.001, 0.01, 0.1, 1.0 and 10.OnM. Ethanol was delivered to control
wells. 4 wells were used for each concentration of androgen/antiandrogen. Cell numbers were assessed
spectrophotometrically (540nm) using the MTT assay at days 0,1, 2, 3 and 4. Each data-point represents the mean +/-
SEM.
102
3.2.1 Synthesis and Analysis of 1.1 ARp.
The complete human AR cDNA, purified from pCMV/ARcom, was used in
initial attempts to detect Northern blotted AR transcripts. However a high degree of
non-specific binding, in particular to the 28s ribosomal RNA band, was observed
after moderately stringent washes and attempts to remove this through increasing
stringency resulted in the loss of all hybridisation. In attempts to overcome these
specificity problems a probe of smaller size was prepared spanning the AR cDNA
from the coding region for the DNA-binding domain to 3' of the Ligand-binding
domain code (Figure 2.05). The new probe, termed 1.1 ARp (1093bp), was
prepared by PCR using pCMV/ARcom as template DNA and the primers AR2.3s
and AR7.8as (Section 2.2.5.2b.). Two restriction fragments of sizes 791 bp and
302bp are diagnostic of EcoRI digestion of 1.1ARp. Prior to use, 1.1ARp was
digested with EcoRI to ensure complementarity with AR cDNA.
Digestion of 1.1 ARp with EcoRI yields two products of approximate size
800bp and 300bp as indicated in Figure 3.07. It is evident that undigested 1.1 ARp
(Lane 2) is retarded in the gel relative to purified 1.1 ARp (Lane 1). This
phenomenon may be due to the effects of the restriction buffer or the restriction
enzyme itself on the mobility of the fragments.
The ability of 1.1ARp to hybridise specifically with receptor sequences was
analysed using Northern blotted RNA derived from tissue samples of known
androgen receptor status. For the purpose of this study prostate tissue was used
as a positive and endometrium provided a receptor-negative control.
3.2.2 Detection of Androgen Receptor mRNA in Prostatic and Endometrial Tissues
by Northern Blotting.
The androgen receptor status of prostatic and endometrial tissues was
determined immunohistochemically using an anti-AR monoclonal antibody raised
against a site of high antigenicity.
Immunohistochemical analysis of tissue from a benign hyperplastic prostate
demonstrates the localisation of the majority of androgen receptors to the nuclei of
secretory epithelial cells within the glandular structures (Figure 3.08). In addition,
receptor-positive nuclei are also evident diffusely spread throughout the
fibromuscular stroma immediately surrounding the gland.





Figure 3.07 Digestion of 1.1ARp with EcoRI.
1.1 ARp was prepared in a 35cycle PCR reaction using the primers 2.3s and 7.8as and AR cDNA as template.
The PCR product was purified from a 2% agarose preparative gel by phenol-chloroform extraction and 10pl of the isolate
digested with EcoRI at 37°C for 60minutes.
Lane 1 : 1kb DNA ladder. Lane 2 :1.1 ARp. Lane 3 : 1.1ARp/EcoRl.
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Figure 3.08 Androgen Receptor fmmunostaining ofBPH Tissue.
Paraffin sections of benign prostatic hyperplasia tissue were immunostained with AR mAb. x25 magnification.




Figure 3.09 Blank Immunostain ofBPH Tissue.
Paraffin sections of benign prostatic hyperplasia tissue were immunostained without the addition of primary
antibody and were counterstained with Mayers haematoxylin. x25 magnification.
SE - secretory epithelial cell; S - fibromuscular stroma; L - glandular lumen.
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Figure 3.10 Androgen Receptor Immunostaining ofEndometrial Tissue.
Paraffin sections of endometrium were immunostained with AR mAb. x25 magnification.




Figure 3.11 Blank Immunostain ofEndometrial Tissue.
Paraffin sections of endometrial tissue were immunostained without the addition of AR mAb and were
counterstained with Mayer's haematoxylin. x25 magnification.
E - epithelia; S -stroma.
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cells of the endometrium was evident (Figure 3.10).
Northern blot analysis using 1.1ARp as probe DNA indicates that prostatic
tissue contains high levels of AR mRNA as opposed to the endometrium which
contains little or no AR transcripts (Figure 3.12 b. & c.). Exposure of probed blots
for 24 hours demonstrates the presence of the 4361 base AR transcript in both
malignant and benign prostates (Figure 3.12 b.). This transcript is proposed to be a
degradation product of larger AR mRNAs (Blok et al, 1991). At this exposure time
the ~4kb AR mRNA is undetectable in endometrial tissues. Autoradiography over a
72 hour period again indicates the presence of the 4kb transcript in BPH and CaP,
but there is also evidence to suggest the presence of higher molecular weight
transcripts, potentially the 6682 base and 9614 base species observed by Tilley et
al (1990). The endometrium possesses very low levels of 4kb AR transcript, as
indicated by the 72 hour exposure, and indeed there appears to be a faint band on
the autoradiograph of a size greater than 10kb. [ Note : The presence of blotted
RNA in each sample lane is indicated by the hybridisation of p-actin probe. ]
Clearly 1.1 ARp is specific for AR transcripts since little hybridisation is
observed with Northern blotted RNA derived from AR-deficient tissue. Similarly, the
weak signal obtained with endometrial RNA would support the claim that the
detectable 4kb band does not merely represent hybridisation with the 28s
ribosomal RNA. In addition, it would appear that using total RNA it is possible to
predict the receptor status of heterogeneous tissues such as the prostate and, by
extrapolation, cultured cells, without the need for purification of mRNA.
3.2.3 AR Gene Expression in Human Prostatic Carcinoma Cell Lines.
The extent of androgen receptor expression in the LNCaP, DU145 and PC3
cell lines, which display marked differences in their responses to androgenic inputs
as previously described, was examined by Northern hybridisation with 1.1ARp.
Figure 3.13 B. demonstrates the expression of high levels of AR mRNA in
LNCaP, a feature which correlates well with the observed androgen-sensitivity of
this cell line. 3 AR mRNA species are detectable in LNCaP : 2 major transcripts of
sizes 6682 bases and 9614 bases and the 4kb transcript, previously described in
3.2.2., which represents the minor AR gene product (Tilley et al, 1990; Brown et al,
1988). Both the DU145 and PC3 cells express little or no detectable AR mRNA as
indicated by the 24 hour and 72 hour autoradiographs and certainly appear to
contain manifestly less transcript than the LNCaP cell line.
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Figure 3.12 Androgen Receptor Gene Expression in Prostatic and Endometrial Tissue.
20mg of total RNA isolated from BPH, CaP and endometrium was electrophoresed on 1 % agarose gels
containing 2.2M formaldehyde (A.) and transferred to Hybond™-C extra transfer membrane. AR mRNA was detected
using 32P-labelled 1.1 ARp. Autoradiography was performed, with intensifying screens, for 24 (B.) and 72 hours (C.).
A. 1% Denaturing Agarose Gel. Lane 1 - BPH. Lane 2 - CaP. Lane 3 - endometrium.
B. Autoradiograph - AR. 24 hour exposure. Lane 1 - BPH. Lane 2 - CaP. Lane 3 - endometrium.
C. Autoradiograph - AR. 72 hour exposure.
D. Autoradiograph - [i-Actin. Lane 1 - BPH. Lane 2 - CaP. Lane 3 - endometrium.
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Figure 3.13 Androgen Receptor Gene Expression in the LNCaP, DU145 and PC3 Cell Lines.
20pg of total RNA isolated from LNCaP, DU145 and PC3 cells in addition to 20ug of endometrial RNA
(negative control) was electrophoresed on a 1 % agarose gel containing 2.2M formaldehyde and transferred to Hybond™-
C extra. 32P-labelled 1.1 ARp was used in the detection of AR mRNA transcripts. Autoradiography was performed,
under intensification, for 24hours (B.) and 72 hours (C.).
A. 1% Denaturing Agarose Gel. Lane 1-1° Epi. culture (CaP). Lane 2 - LNCaP. Lane 3 - DU145.
Lane 4 - PC3.
B. Autoradiograph - AR. 24 hour exposure. Lane 1-1° Epi. culture (CaP). Lane 2 - LNCaP.
Lane 3 - DU145. Lane 4 - PC3.
C. Autoradiograph - AR. 72 hour exposure.
D. Autoradiograph - (3-Actin. Lane 1 -1° Epi. culture (CaP). Lane 2 - LNCaP. Lane 3 - DU145.
Lane 4 - PC3.
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3.2.4 AR Gene Expression in Human Primary Epithelial Cell Cultures.
Five primary epithelial cultures, 4 of which were BPH-derived (BPH 1, 2, 3
and 4) and 1 CaP-derived (CaP 1), were examined for AR mRNA.
[ Note : BPH 1 and BPH 2 are the same BPH-derived cultures whose dose
response to DHT and HO-F was examined in section 3.1.2. ]. LNCaP total RNA,
serving as a positive control, was run in parallel to the primary culture samples.
It is evident from the results shown in Figure 3.14 B., that none of the
primary epithelial cultures investigated express sufficient AR mRNA to be
detectable in samples of total RNA analysed by Northern Blotting. [ Note : The poor
quality of the p-actin autoradiograph is an unfortunate feature of the stripping and
reprobing of Hybond™-C extra membranes. It appears that the harsh conditions
required to strip the membranes often causes irreversible damage leading to high
levels of background hybridisation. ].
From both the assessment of the growth responsiveness of primary
epithelial cells and the measurement of androgen receptor gene expression it
would appear that the cells obtained from cultured prostatic acini are not ideal
models of secretory epithelia in vivo. This is probably a feature of epithelial cell
growth in serum-free conditions. Therefore the influence of plating the acini in an
environment that retains some of the attributes common to the prostate gland was
briefly examined.
Prostatic acini were plated and the cells grown in EGM supplemented with
either 1nM DHT, an equal volume of medium conditioned by BPH-derived prostate
fibroblasts for 48 hours or a combination of 1nM DHT plus fibroblast conditioned
medium. Total RNA isolated from these cells was subsequently examined for AR
mRNA by Northern blotting. Figure 3.15 demonstrates that none of these
treatments gives rise to sufficient AR mRNA to be detectable by Northern blotting.
Clearly to obtain a truly representative model of prostatic epithelia requires other
factors, the exact nature of which are not entirely obvious at this juncture, and
therefore it was decided not to attempt optimisation of the culture conditions.
3.3 Androgen Receptor (AR) Expression in Cultured Prostate Cancer Cell
Lines and Primary Epithelial Cells - Analysis by Reverse Transcription-
Polymerase Chain Reaction (RT-PCR).
Northern blotting offers limited sensitivity for the detection of mRNA
transcripts. Abundant RNAs (0.1% or more of the mRNA population) can usually be
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Figure 3.14 Androgen Receptor Gene Expression in Primary Epithelial Cells.
20pg of total RNA isolated from BPH- and CaP-derived primary epithelial cell cultures was electrophoresed on
a 1% formaldehyde agarose gel (A.) and transferred to Hybond™-C extra. AR mRNA was detected using 32P-labelled
1.1 ARp. Autoradiography was performed with intensifying screens for 24hours (B.).
A. 1% Denaturing Agarose Gel. Lane 1 - LNCaP. Lane 2 - BPH 1. Lane 3 - BPH 2. Lane 4 - CaP 1.
Lane 5 - BPH 3. Lane 6 - BPH 4.
B. Autoradiograph - AR. 24 hour exposure. Lane 1 - LNCaP. Lane 2 - BPH 1. Lane 3 - BPH 2.
Lane 4 - CaP 1. Lane 5 - BPH 3. Lane 6 - BPH 4.
C. Autoradiograph - p-Actin. Lane 1 - LNCaP. Lane 2 - BPH 1. Lane 3 - BPH 2. Lane 4 - CaP 1.
Lane 5 - BPH 3. Lane 6 - BPH 4.
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Figure 3.15 Androgen Receptor Gene Expression in Primary Epithelial Cells Grown in DHT and Fibroblast Conditioned
Medium (FCM).
Acini obtained from TUR specimens from a hyperplastic prostate were seeded in 75cm2 tissue culture flasks
and epithelial cells grown in either of the following : 1. 12ml EGM + 1nM DHT; 2. 6ml EGM + 6ml FCM; 3. 6ml EGM +
6ml FCM + 1nM DHT. [ Note : The FCM was removed from BPH-derived fibroblast cultures after 48 hours. ]. Total RNA
was isolated from sub-confluent cells and 20pg electrophoresed on a 1 % formaldehyde agarose gel (A.) and transferred
to Hybond™-C extra. 32P-labelled 1.1 ARp was used to detect AR mRNA. Autoradiography was performed with
intensifying screens for 24 hours (B.).
A. 1% Denaturing Agarose Gel. Lane 1 - LNCaP. Lane 3 - 10nM DHT. Lane 4 - FCM.
Lane 5 - 10nM DHT + FCM.
B. Autoradiograph - AR. 24 hour exposure. Lane 1 - LNCaP. Lane 3 -10nM DHT. Lane 4 - FCM.
Lane 5 - 10nM DHT + FCM.
C. Autoradiograph - p-Actin. 24 hour exposure. Lane 1 - LNCaP. Lane 3 - 10nM DHT. Lane 4 - FCM.
Lane 5 -10nM DHT + FCM.
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detected by Northern analysis of 10-20pg of total cellular RNA. RT-PCR overcomes
these limitations and allows low copy-number transcripts to be observed through
amplification of specific RNA sequences.
In samples of reverse transcribed RNA, the presence of AR cDNA was
determined using 2 sets of intron-spanning primer pairs locating to exons 2 & 3
(AR2.3s and AR2.3as) and exons 7 & 8 (AR7.8s and AR7.8as) respectively.
[ Note : The use of intron-spanning primer pairs generates discrimination between
cDNA and genomic DNA contaminants ]. These primers will amplify cDNA
corresponding to the DNA-binding domains and C-terminus of the AR, allowing
detection of both full-length AR mRNA, and potentially, truncated transcripts known
to give rise to constitutively active receptors (Rundlett et al, 1990).
Control primers specific to the cDNA of the house-keeping protein
hypoxanthine-guanine phosphoribosyl transferase (HGPRT) were used with all
samples to determine the efficiency of the reverse transcription reaction. These
primers, denoted HGPRTs and HGPRTas, give rise to a product of size ~310bp.
All PCR products were visualised on 2% agarose gels.
3.3.1 Analysis of AR-Positive and AR-Negative Tissues for Androgen Receptor
mRNA.
Reverse transcribed RNA from prostatic and endometrial tissues was
examined for AR sequences. Figure 3.16 A. and B. displays the production of
AR2.3 and AR7.8, not only from BPH and CaP samples but also from endometrial
cDNA. Clearly the AR gene is transcribed in the endometrium, however, the mRNA
product would appear to be strikingly lower in abundance than in prostatic epithelial
cells in view of the data obtained by Northern analysis (section 3.2.2.). HGPRT is
present in all three cDNA samples. The mechanism underlying the observed down-
regulation of AR mRNA in the endometrium is unclear, although there may be a
role for either decreased transcription of the AR gene (arising from alterations in
the transcriptional control elements of the AR gene) or perhaps a change in the
half-life of the gene transcript.
The specificity of AR2.3s/AR2.3as and AR7.8s/AR7.8as for AR sequences
was assessed through restriction digestion of the AR 2.3 and AR7.8 PCR products.
Digestion of AR2.3 and AR7.8 with Hindlll and Dralll respectively should yield
products of sizes 187bp and 78bp from the former and 177bp and 51 bp fragments
in the latter case.
Figure 3.16 D. demonstrates the results of the digestion of AR2.3., with two
116
Figure 3.16 Androgen Receptor Gene Expression in Prostatic and Endometrial Tissue.
Total RNA (1pg per PCR reaction) isolated from BPH (A.), CaP (B.) and endometrium (C.) was reverse
transcribed and amplified by PCR for 35 cycles using HGPRTs/as, AR2.3s/as and AR7.8s/as . The PCR reactions for
the "no DNA" controls were performed without cDNA. 10ul of AR2.3 and AR7.8 from endometrium were digested at
37°C for 60 minutes with Hindlll (D.) and Drain (E.) respectively. The RT-PCR products and restriction fragments were
analysed by electrophoresis through 2% agarose gels containing -0.1 pgml"1 ethidium bromide. 10Obp molecular weight
markers were electrophoresed alongside the RT-PCR products. The gels were photographed under transillumination.
A. 2% Agarose Gel - RT-PCR BPH tissue. Lane 1 -10Obp ladder. Lane 2 - No DNA. Lane 3 - HGPRT.
Lane 4 - AR2.3. Lane 5 - AR7.8.
B. 2% Agarose Gel - RT-PCR CaP tissue. Lane 1 - 100bp ladder. Lane 2 - No DNA. Lane 3 - HGPRT.
Lane 4 - AR 2.3. Lane 5 - AR7.8.
C. 2% Agarose Gel - RT-PCR Endometrium. Lane 1 - 100bp ladder. Lane 2 - No DNA. Lane 3 - HGPRT.
Lane 4 - AR2.3. Lane 5 - AR7.8.
D. Restriction Digest (AR2.3/HindIII). Lane 1 - 100bp ladder. Lane 2 - AR2.3. Lane 3 - AR2.3/HindIII.
E. Restriction Digest (AR7.8/DralII). Lane 1 - 100bp ladder. Lane 2 - AR7.8. Lane 3 - AR7.8/HindIII.
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bands clearly evident. The largest fragment corresponds to undigested AR2.3, with
the band at ~190-200bp representing the larger of the two restriction fragments.
The 78bp restriction product cannot be visualised. Digestion of 7.8 with Dralll
produces a single restriction fragment observable on an agarose gel
(Figure 3.16 E.). The fragments appears to be running at ~190-200bp. It is evident
that restriction analysis of AR2.3 and AR7.8 results in fragments of sizes marginally
greater than that expected, as indicated by gel electrophoresis.
Both Drain and Hindlll are "rare-cutter" restriction enzymes in eukaryotic
systems. This being the case, it would seem unlikely that mis-priming of the primer
pairs used to analyse AR cDNA would yield PCR products, not only of the expected
size but also that exhibit digestion by these restriction endonucleases. It can be
concluded, therefore, that the digestion observed with both AR2.3 and AR7.8
derived from endometrium is indicative of the specificity of AR2.3s/AR2.3as and
AR7.8s/AR7.8as for their respective regions of the AR cDNA. The inappropriate
sizes of the restriction fragments observed in 3.13 D. and E. may merely represent
artefactual retardation as observed in section 3.2.1..
3.3.2 AR Gene Expression in Human Prostatic Carcinoma Cell Lines.
Figures 3.17 A. and 3.17 B. exhibit the results of PCR reactions using cDNA
derived from LNCaP, DU145 and PC3 cells with the AR primers. AR2.3 and AR7.8
sequences are both detectable in LNCaP and PC3 cDNA, although undoubtedly to
a lesser extent in the latter. AR2.3 and AR7.8 sequences cannot be detected in the
DU145 cell line.
The gel in Figure 3.17 B. was blotted onto Hybond™-C extra using the
technique of Southern and subsequently probed for AR7.8 using radiolabeled
AR7.8p, a PCR probe spanning a 166bp stretch of the AR cDNA located within
AR7.8. Thus it was possible not only to analyse the specificity of AR7.8s/as for AR
cDNA once more, but also, potentially, to detect trace amounts of AR7.8 produced
from DU145 cDNA by PCR.
Figure 3.18 A. demonstrates the results of digestion of AR7.8p with EcoRII
which cuts the probe diagnostically liberating 2 fragments of sizes 81 bp and 85bp.
These restriction fragments cannot be visualised on the gel, however, since
identical amounts of DNA were applied to both the "no digest" and "digest" lanes of
the gel, the lower intensity of the band corresponding to undigested probe in the
EcoRII digest suggests the presence of the appropriate restriction site in the PCR
product.
118
Figure 3.17 Androgen Receptor Gene Expression in the LNCaP, DU145 and PC3 Cell Lines.
Total RNA was isolated from duplicate cultures of LNCaP, DU145 and PC3 cells. Total RNA (1 pg per PCR
reaction) was subjected to reverse transcription followed by PCR for 35 cycles using HGPRTs/as (A.), AR2.3s/as (A.)
and AR7.8s/as (B.). The PCR reactions for the "No DNA" controls were performed without cDNA. The RT-PCR
products were electrophoresed, alongside 100bp molecular weight markers, through 2% agarose gels containing
~0.1 pgml"1 ethidium bromide. The gels were photographed under transillumination.
A. 2% Agarose Gel - RT-PCR. Lane 1 - 100bp ladder. Lane 2 - No DNA. Lane 3 - HGPRT/ BPH tissue.
Lane 4 - HGPRT/ LNCaP a.. Lane 5 - HGPRT/ LNCaP b..
Lane 6 - HGPRT/ DU145 a.. Lane 7 - HGPRT/ DU145 b.. Lane 8 - HGPRT/ PC3 a..
Lane 9 - HGPRT/ PC3 b.. Lane 10 - AR2.3/ LNCaP a.. Lane 11 - AR2.3/ LNCaP b..
Lane 12 - AR2.3/ DU145 a.. Lane 13 - AR2.3/ DU145 b.. Lane 14 - AR2.3/ PC3 a..
Lane 15 - AR2.3/ PC3 b.. Lane 16 - 100bp ladder.
B. 2% Agarose Gel - RT-PCR. Lane 1 - 100bp ladder. Lane 2 - AR7.8/ LNCaP a.. Lane 3 - AR7.8/ LNCaP b.
Lane 4 - AR7.8/ DU145 a.. Lane 5 - AR7.8/ DU145 b.. Lane 6 - AR7.8/ PC3 a..
Lane 7 - AR7.8/ PC3 b..
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Southern blot analysis yields the same findings as before , i.e. strong
signals are obtained for LNCaP and PC3, however, no bands are visible on the
autoradiograph corresponding to the DU145 lanes of the gel [ Figure 3.18 B.].
3.3.3 AR Gene Expression in Human Primary Epithelial Cell Cultures.
Three of the primary epithelial cell cultures examined for AR mRNA by
Northern blotting (section 3.2.4.), i.e. BPH 1 & 2 and CaP 1, were analysed for
receptor transcripts through RT-PCR [ Figure 3.19 ]. AR2.3 and AR7.8 are
detectable in the cDNAs of all three primary cultures examined. It would appear
that in terms of AR gene expression, primary epithelial cells strongly resemble the
PC3 cell line in that receptor transcripts are detectable by RT-PCR but not by
Northern blotting.
3.4 Androgen Receptor (AR) Activity in Cultured Prostate Cancer Cell Lines
and Primary Epithelial Cells.
The established prostate cancer cell lines and primary epithelial cells exhibit
striking differences in terms of their responsiveness to androgens and the extent of
androgen receptor gene transcription. Furthermore, two of the in vitro models of
prostatic epithelia which do not exhibit androgen responsive growth display
detectable androgen receptor gene expression. This prompts the question as to
whether the levels of AR mRNA revealed by RT-PCR actually give rise to functional
receptor?
It was intended, not just to demonstrate the presence or absence of
receptor protein, but to assess whether or not AR function - the binding of ligand
leading to alterations of target gene expression through protein-DNA interactions-
could be demonstrated in the presence of its normal ligand. Receptor activity was
assayed through transient transfection of cells with the plasmid construct
pMMTV/SPAP, which carries the cDNA for secreted placental alkaline phosphatase
(SPAP) downstream of the mouse mammary tumour virus - long terminal repeat
(MMTV-LTR). The MMTV-LTR contains a promoter region that directs the
transcription of 3' sequences upon induction by adjacent hormone response
elements (HREs) e.g. the response elements for the androgen, glucocorticoid and
progesterone receptors. Binding of liganded receptor is required for the activation
of these HREs. Therefore, if a pMMTV/SPAP transfected cell contains a functional
AR, added DHT will bind to the receptor, the receptor will then dimerise and bind to
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Figure 3.18 Southern Blot Analysis ofAR7.8 Derived from LNCaP, DU145 and PC3.
AR7.8p was prepared in a 35 cycle PCR reaction using the primers AR7.8ps and AR7.8pas with AR cDNA
as template. The PCR product was purified from a 2% agarose preparative gel by phenol-chloroform extraction and 10pl
of the isolate digested with EcoRII at 37°C for 60 minutes. The digest was analysed by electrophoresis through a 2%
agarose gel containing ~0.1pgml"1 ethidium bromide.
AR7.8 produced by PCR using cDNA obtained from LNCaP, DU145 and PC3 was electrophoresed on a 2%
agarose gel and capillary-transferred to Hybond™-C extra. AR7.8 was detected using 32P-labelled 1.1 ARp.
Hybridisation was assessed qualitatively through autoradiography under intensification for 24 hours.
A. 2% Agarose Gel - AR7.8p digest. Lane 1 - 100bp ladder. Lane 2 - AR7.8p. Lane 3 - AR7.8p/EcoRII.
B. Autoradiograph - AR7.8. Lane 1 - LNCaP a.. Lane 2 - LNCaP b.. Lane 3 - DU145 a.. Lane 4- DU145 b..
Lane 5 - PC3 a.. Lane 6 - PC3 b..
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Figure 3.19 Androgen Receptor Gene Expression in Primary Epithelial Cells.
Total RNA (1ug per PCR reaction) isolated from 2 BPH-derived (BPH 1 and 2) and 1 CaP-derived primary
epithelial cell culture was reverse transcribed and amplified by PCR for 35 cycles using HGPRTs/as, AR2.3s/as and
AR7.8s/as. The PCR reactions for the "no DNA" controls were performed without cDNA. The RT-PCR products were
electrophoresed through 2% agarose gels containing ~0.1|xgml"1 ethidium bromide. The gels were photographed under
transillumination.
Lane 1 - 100bp ladder. Lane 2 - No DNA. Lane 3 - HGPRT/ BPH 1. Lane 4 - AR2.3/ BPH 1. Lane 5 - AR7.8/
BPH 1. Lane 6 - HGPRT/ BPH2. Lane 7 - AR2.3/ BPH 2. Lane 8 - AR7.8/ BPH 2. Lane 9 - HGPRT/ CaP 1.
Lane 10 - AR2.3/ CaP 1. Lane 11 - AR7.8/ CaP 1.
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the androgen response element (ARE) within the MMTV-LTR. This interaction will
switch on the neighbouring promoter, resulting in transcription of the SPAP cDNA.
Alkaline phosphatase activity secreted into the cell culture medium is assayable
colourimetrically.
The SPAP activity secreted by pMMTV/SPAP transfected prostatic epithelial
cells in response to treatment with DHT, the androgen antagonist HO-F or
combined DHT & HO-F was determined with a view to assessing endogenous AR
content. Cells possessing a fully functional androgen receptor should display clear
stimulation of SPAP synthesis in the presence of the androgen and corresponding
antagonism of MMTV activation with the anti-androgen.
Cells were grown in monolayer to ~60% confluence before transfecting, by
means of the DOTAP transfection reagent (Boehringer Mannheim), with either
pMMTV/SPAP or the control vector pRc/CMV for 16hours. Subsequently, the
medium was replaced with medium containing DCC-stripped FCS and
supplemented with either 10nM DHT, 10nM HO-F or 10nM DHT plus 10nM HO-F.
48 hours later, the medium was removed, heat inactivated to denature endogenous
alkaline phosphatase, and subsequently assayed for SPAP activity through
spectrophotometric measurement (415nm) of the conversion of p-Nitrophenyl
phosphate (phosphatase substrate) to p-Nitrophenol.
3.4.1 Detection of AR Function in the LNCaP, DU145 and PC3 Cell Lines.
Figure 3.20 demonstrates the SPAP profiles obtained from the prostate
cancer cell lines.
Transfection of LNCaP cells with control plasmid (pRc/CMV) does not result
in a significant increase in the levels of secreted alkaline phosphatase activity over
control, following administration of either DHT or the androgen antagonist
HO-F at 10nM (3.20 a.). However these cells do respond to the addition of 10nM
DHT plus 10nM HO-F with a significant (p<0.05) rise in the levels of alkaline
phosphatase secreted. There is apparently no difference between the abilities of
DHT and HO-F, at the concentrations employed, to direct MMTV-LTR-mediated
transcription in pMMTV/SPAP-transfected LNCaP. Similarly, HO-F, when given to
cells in conjunction with DHT does not antagonise the effects of the androgen, but
rather acts synergistically with it, to significantly (p<0.05) increase the rate of
MMTV-LTR-driven SPAP transcription, not only over control but also over that
observed with DHT or indeed HO-F alone. These observations support the findings




































Figure 3.20 SPAP Activity Secreted by pMMTV/SPAP Transfected Prostate Cancer Cell Lines in Response to DHT
andHO-F.
LNCaP, DU145 and PC3 cell lines were grown to ~60% confluence in 25cm2 tissue culture flasks prior to
transfection with 5pg of either pMMTV/SPAP or the control vector pRc/CMV. The transfections were allowed to proceed
for 16 hours before aspirating the medium and replacing with medium containing DCC-stripped FCS and supplemented
with 10nM DHT, 10nM HO-F or 10nM DHT + 10nM HO-F. Control cells were given medium containing ethanol only.
After a 48 hour incubation the cell culture medium was harvested, heat inactivated (65°C for 1 hour) and the SPAP
content determined through spectrophotometric assessment (415nm) of the conversion of p-Nitrophenyl phosphate to
p-Nitrophenol over a 30 minute period at 37°C. The SPAP activities are given in Unitsml"1. Each bar represents the
mean of 4 separate SPAP assays +/- SEM. Statistical significance (p<0.05) over control values is indicated by an
asterisk.
a. LNCaP. b. DU145. c. PC3.
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HO-F (section 3.1.1.1) in which it was observed that growth is significantly
stimulated by 10nM HO-F. pMMTV/SPAP transfected cells display significantly
(p<0.05) higher levels of secreted alkaline phosphatase than pRc/CMV
transfectants in all treatment groups and additionally in the control group. The
levels of SPAP produced by untreated pMMTV/SPAP transfectants is presumably a
consequence of endogenous steroids present within the cells prior to treatment.
Ideally, the cells would have been rendered steroid hormone-free before
experimentation. However, it was found that the rate of transfection was drastically
reduced in LNCaP using medium containing DCC-stripped FCS and it was not
possible to give the cells 48 hours in steroid hormone-free medium post-
transfection due to the finite duration of transient transfectants and the limitations
imposed by the time to 100% confluence.
The significantly increased levels of alkaline phosphatase produced by
pRcCMV-transfected LNCaP in response to DHT plus HO-F may be representative
of high levels of endogenous alkaline phosphatase synthesised in response to
androgenic stimuli.
As Figure 3.20 b. indicates, in both pMMTV/SPAP- and pRc/CMV-
transfected DU145 cells, the addition of DHT, HO-F or DHT plus HO-F does not
significantly (p>0.05) increase the alkaline phosphatase released by this cell line
compared to controls.
As was observed with the DU145 cell line, PC3 cells transfected with
pMMTV-SPAP do not exhibit significant (p>0.05) increases in SPAP secretion in
any of the treatment groups compared with control (Figure 3.20 c.). Similar
responses are observed in cells carrying pRcCMV. However, it is noticeable that
within treatment groups the general trend is for the pMMTV/SPAP-transfected cells
to liberate higher levels of alkaline phosphatase than their counterparts. Indeed, in
3 of the 4 groups - the control, hydroxyflutamide and combined DHT &
hydroxyflutamide groups - there was significantly (p<0.05) higher levels of alkaline
phosphatase in pMMTV/SPAP-transfected cells [ Note : The critical values of the 4
groups are very close to that quoted for the 95% confidence interval, indicating
only marginal significance in the relevant groups ]. This phenomenon may arise
due to the presence of basal levels of AR, or more likely, either due to basal
promoter activity or the function of other steroid hormone receptors (This being
indicative of the promiscuity of these proteins for other ligands.) In respect of the
latter speculation, it should be borne in mind that the MMTV-LTR also possesses
HREs for the progesterone and glucocorticoid receptors.
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Comparison of the SPAP activities released by the pMMTV/SPAP-
transfected cell lines would seem to indicate that of the three it is only the LNCaP
cell line which contains sufficient functional receptor to activate the MMTV-LTR
promoter.
It is unusual that the androgen antagonist hydroxyflutamide given to LNCaP
cells not only promotes cell growth but also induces upregulation of the
transcription rate from the MMTV-LTR in pMMTV/SPAP transfectants. Does this
arise due to interaction with other members of the nuclear hormone receptors or is
it a function of the mutation known to exist within the ligand-binding domain coding
region of the LNCaP AR gene (Brinkmann et a/, 1991)?
3.4.2 Co-transfection of the LNCaP and PC3 Cell Lines with pMMTV/SPAP and
pCMV/ARcom.
In order to establish whether the observed response of pMMTV/SPAP-
transfected LNCaP to hydroxyflutamide was due to the mutated AR endogenous to
this cell line, normal AR was introduced into cells via pCMV/ARcom and the ability
to activate the MMTV-LTR promoter through treatment with DHT and HO-F
reassessed. It was hoped that the AR constitutively produced by pCMV/ARcom
would swamp the mutated LNCaP receptor and downregulate its expression.
pCMV/ARcom was also transfected into PC3 cells in order to assess the SPAP
profiles from a cell in which there appears to be little or no functional receptor
protein.
Figure 3.21 a. demonstrates that LNCaP cells transfected with pRc/CMV
and pMMTV/SPAP display identical responses to DHT and hydroxyflutamide as
illustrated previously (Figure 3.20). DHT and HO-F at 10nM, stimulate a significant
(p<0.05) rise in alkaline phosphatase synthesis over control cells. These responses
are clearly not as pronounced as those observed in cells transfected with
pMMTV/SPAP alone. This is presumably a feature of transfection with more than
one plasmid, with cells less likely to accept pMMTV/SPAP in the presence of the
control vector. DHT and HO-F together significantly (p<0.05) increases SPAP
production over control levels and over that observed with DHT and HO-F given
separately. LNCaP co-transfected with pCMV/ARcom and pMMTV/SPAP exhibit
altered profiles of SPAP production to the pRc/CMV + pMMTV/SPAP transfections.
10nM DHT significantly (p<0.05) increases SPAP production compared to control
cells. However cells incubated with 10nM HO-F for 48 hours do not secrete SPAP
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Figure 3.21 SPAP Activity Secreted by LNCaP and PC3 Cells Co-transfected with pCMV/ARcom & pMMTV/SPAP in
Response to DHT and HO-F.
LNCaP and PC3 cells were grown to -60% confluence in 25cm2 tissue culture flasks prior to transfection with
5mg each of either pRcCMV & pMMTV/SPAP or pCMV/ARcom & pMMTV/SPAP. Transfection was carried out for 16
hours before replacing the medium with fresh medium containing DCC-stripped FCS and supplemented with 10nM
DHT, 10nM HO-F or 10nM DHT + 10nM HO-F. Control cells were given medium containing ethanol alone. After 48
hours the cell culture medium was harvested, heat inactivated (65°C for 1 hour) and the SPAP content determined
through spectrophotometric determination of the conversion of p-Nitrophenyl phosphate to p-Nitrophenol over a 30
minute period at 37°C. The SPAP activities are given in Unitsml-1. Each bar represents the mean of 4 separate SPAP
assays +/- SEM. Statistical significance (p<0.05) over control values is indicated by an asterisk,
a. LNCaP. b. PC3.
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enhanced in cells given DHT and HO-F together. It is also noteworthy that in the
control and 10nM DHT treatment groups, the pCMV/ARcom transfectants secrete
significantly greater quantities of alkaline phosphatase than their pRc/CMV-
transfected counterparts.
The results obtained with the PC3 cell line are in good agreement with the
observations from LNCaP. Again DHT and DHT + HO-F supplements significantly
(p<0.05) increase SPAP release by pCMV/ARcom + pMMTV/SPAP
cotransfectants. Such a response is not exhibited by cells given HO-F alone. In
contrast to LNCaP, pCMV/ARcom transfectants display significantly increased
SPAP production compared to pRc/CMV transfectants in all treatment groups.
In both the LNCaP and PC3 cell lines we might have anticipated that, with
the introduction of normal AR, repression of DHT induced SPAP synthesis by
simultaneous addition of HO-F would eventuate. However, this outcome is quite
evidently not furnished by either cell line. The only explanation that can be offered
in this respect is that the concentration of HO-F employed is insufficient to
antagonise the DHT. In competitive binding studies testosterone and DHT displace
labelled testosterone from the AR maximally in 100-fold excess (Symes et at,
1978). In contrast, maximal displacement by hydroxyflutamide is achieved at 1,000
to 10,000-fold excess. Clearly, with DHT and HO-F combined and at the same
concentration, the DHT is 10-100 times more likely to occupy the ligand binding
domain of the AR.
It can be concluded from these co-transfection studies that the effects of
hydroxyflutamide on MMTV-LTR-mediated gene transcription in LNCaP is a
function of the mutated AR endogenous to this cell line.
3.4.3 Detection of AR Function in Primary Epithelial Cells.
The primary epithelial culture BPH 4, which was examined for AR mRNA by
Northern blotting in section 3.2.4., was transfected with pMMTV/SPAP and
subsequent responses to DHT and HO-F assessed. Figure 3.22 demonstrates that
the SPAP profile obtained using this BPH-derived culture is similar to that of the
PC3 cell line.
Cells transfected with pRc/CMV exhibit no significant (p>0.05) increases in
alkaline phosphatase synthesis over controls when grown in the presence of either
DHT, HO-F or combined DHT and HO-F. Identical responses to these treatments
are demonstrated by cells transfected with pMMTV/SPAP. The suggestion is























Figure 3.22 SPAP Activity Secreted by pMMTV/SPAP Transfected Primary Epithelial Cells in Response to DHT and
HO-F.
BPH-derived primary epithelial cells (BPH 4) were grown to ~60% confluence in 25cm2 tissue culture flasks
prior to transfection with 5pg of either pMMTV/SPAP or pRc/CMV in epidermal growth medium (EGM). Transfection
was performed for 16 hours before aspirating the medium and replacing with EGM without dexamethasone and
supplemented with 10nM DHT, 10nM HO-F or 10nM DHT + 10nM HO-F. Control cells were given medium containing
ethanol only. After a 48 hour incubation period the cell culture medium was harvested, heat inactivated (65°C for 1 hour)
and the SPAP content determined through spectrophotometric assessment (415nm) of the conversion of p-Nitrophenyl
phosphate to p-Nitrophenol over a 30 minute period at 37°C. The SPAP activities are given in Unitsml"1. Each bar
represents the mean of 4 separate assays +/- SEM.
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lines, contain insufficient AR to influence ARE-driven transcription.
3.4.4 Summary of the pMMTV/SPAP Transfection Studies.
Androgen receptor function is detectable using the SPAP system only in the
LNCaP cell line and is not detectable in either DU145, PC3 or primary epithelial cell
cultures. AR mRNA is undetectable in DU145 cells by Northern blotting or indeed
by RT-PCR and therefore it is unsurprising that AR function cannot be discerned
through transfection with pMMTV/SPAP. AR mRNA is detectable in PC3 and
primary epithelial cells by RT-PCR, however, the extent of AR gene expression in
these cells is clearly insufficient to have any significant influence on the
transcription rate of androgen responsive genes.
3.5 Analysis of the Androgen Receptor Gene in the LNCaP, DU145 and PC3
Cell Lines.
The established prostate cancer cell lines exhibit marked differences in their
AR mRNA levels and it is evident that 3 tiers of AR gene expression exist. In the
LNCaP cell line AR mRNA is detectable by both Northern blotting and RT-PCR. AR
transcripts can be identified by RT-PCR but not by Northern blotting in PC3 cells.
AR gene expression is undetectable by both Northern blotting and RT-PCR in the
DU145 cell line. In an attempt to determine the underlying features of these
observed variations, the AR gene was examined by PCR using primers spanning
each of its 8 exons to determine whether or not there are any gross differences in
gene structure between the 3 cell lines. Male genomic DNA isolated from human
placenta was analysed in parallel.
Figure 3.23 demonstrates that exons 2-8 of the AR gene are present in
samples of genomic DNA isolated from LNCaP, DU145 and PC3 cells. AR1.1,
AR1.2, and AR1.3 are also detectable in the cell lines. In all the samples analysed
AR1.4, AR1.5 and AR1.6 could not be amplified using the primers quoted in
Marcelli et al (1990). Altering the conditions of the PCR cycle used did not increase
the specificity of the PCR reaction such that the appropriate fragment could be
visualised. Such difficulties were experienced by Marcelli and it was felt
inappropriate to attempt to further optimise the PCR reactions for AR1.4s/as,
AR1.5s/as and AR1.6s/as.
Clearly, AR1.1 and AR1.2 [Figures 3.23 a. and 3.23 b.] demonstrate
variability in size amongst the three cell lines and indeed the human placental DNA.
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Figure 3.23 Amplification ofExons 1-8 of the Androgen Receptor Gene using the Polymerase Chain Reaction.
100ng of genomic DNA from LNCaP, DU145, PC3 and human placenta (male) was analysed for AR
sequences using primers spanning each of the 8 exons of the AR gene (section 2.2.5.2.a.). The PCR reactions were
carried out for 35 cycles. The PCR products were examined electrophoretically on 2% agarose gels containing
~0.1p.gml"1 ethidium bromide. 10Obp molecular weight markers were electrophoresed in parallel. The gels were
photographed under transillumination. A. AR1.1 (354bp). Lane 1- 100bp ladder. Lane 2 - placenta. Lane 3 - LNCaP.
Lane 4 - DU145. Lane 5 - PC3. B. AR1.2 (534bp). Lane 1 - placenta. Lane 2 - LNCaP. Lane 3 - DU145. Lane 4 - PC3.
Lane 5 - 100bp ladder. C. AR1.3 (325bp). Lane 1 - 100bp ladder. Lane 2 - placenta. Lane 3 - LNCaP. Lane 4 - DU145.
Lane 5 -10Obp ladder. D. AR2 (269bp): Lane 1 -10Obp ladder; Lane 2 - placenta; Lane 3 - LNCaP; Lane 4 - DU145;
Lane 5 - PC3. AR3 (185bp): Lane 6 - placenta; Lane 7 - LNCaP; Lane 8 - DU145; Lane 9 - PC3; Lane 10 - 100bp
ladder. E. AR4 (371bp): Lane 1 - 100bp ladder; Lane 3 - placenta; Lane 4 - LNCaP; Lane 5 - DU145; Lane 6 - PC3.
AR5 (284bp): Lane 7 - placenta; Lane 8 - LNCaP; Lane 9 - DU145; Lane 10 - PC3. F. AR6 (245bp): Lane 1 - 100bp
ladder; Lane 2 - placenta; Lane 3 - LNCaP; Lane 4 - DU145; Lane 5 - PC3. AR7 (266bp): Lane 6 - placenta;
Lane 7 - LNCaP; Lane 8 - DU145; Lane 9 - PC3; Lane 10 - 100bp ladder. G. AR8 (294bp): Lane 1 - 100bp ladder.
Lane 2 - placenta. Lane 3 - LNCaP. Lane 4 - DU145. Lane 5 - PC3.
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Figure 3.23 continued overleaf >
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Both these regions encapsulate the longest of two CAG repeat regions
(nucleotides 333 to 426) within exonl of the AR gene which gives rise to a
polyglutamine stretch in the receptor protein. AR1.1 possesses an Aval restriction
site 5' of the CAG repeat region which will allow determination of whether it is
variation in the sizes of the repeat region that accounts for the observed
differences in the PCR products. From the published sequence of the AR gene,
digestion with Aval yields 2 fragments of sizes 132bp and 222bp. The latter
fragment contains the CAG repeat which spans a 94bp portion. Digestion of AR1.1
from the four genomic DNA samples with Aval yields in all cases the 132bp
fragment [Figure 3.24 A.]. The larger fragment indicates variability amongst the
samples, similar to that observed in AR1.1. This would suggest that the differences
in AR1.1 from the LNCaP, DU145 and PC3 is due to disparity in the numbers of
CAG triplets. Amplification of the CAG repeat using flanking primers (1.CAGs/as)
supports the findings of the Aval restriction digest [Figure 3.24 B.]. In normal
individuals the length of the polyglutamine region varies from 17 to 26 residues with
an average repeat number of 21 (La Spada et al, 1991). Variations in the numbers
of glutamine residues from the normal range have been demonstrated to be
associated with AR-linked disorders e.g. increased thermolability associated with
partial androgen insensitivity syndrome (12 glutamine residues) and X-linked spinal
and bulbular muscular atrophy (La Spada etal, 1991; McPhaul et al, 1991). From
the published sequence, I.CAGs and I.CAGas will produce a 198bp PCR
fragment with 19 CAG triplets. Genomic DNA from human placenta and DU145
cells yields PCR products of the expected size (~200bp). Clearly the products
obtained from the LNCaP and PC3 cell lines are larger in size but would appear to
lie within the accepted normal range i.e. a normal product may be up to a size of
219bp. Further the PC3 cell line has an approximately equivalent number of
repeats to LNCaP which contains a fully functional AR, despite having a mutation
in its ligand binding that alters its binding characteristics.
3.6 Overview of the Androgen Receptor Studies.
The data presented supports the idea that the hormone-independence
characteristic of relapsed prostate cancers is associated with a down-regulation of
the androgen receptor. All of the cells which exhibit androgen-independent growth
also display a level of receptor protein which is insufficient to significantly influence
the transcription of target genes. Furthermore, the alteration of androgen receptor
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gene expression is clearly manifest at the DNA level where three tiers of gene
transcription are in operation.
Whether these observations on the androgen receptor are truly
representative of the in vivo situation in humans is at best extremely debateable
judging by the contradictory results obtained in immunohistochemical analyses.
Less controversy surrounds the relationship between the bcl-2 oncoprotein and
hormone-independence in vivo. There is little doubt that a strong correlation exists
between the extent of cellular expression of this oncogene and resistance to
androgen ablation therapy. Indeed, in the normal prostate bcl-2 is exclusively
localised to the basal epithelial cells which are resistant to androgen deprivation
and which coincidentally do not generally exhibit androgen receptor expression.
Therefore the expression of bcl-2 in the cell models was examined to ascertain
whether there is any relationship with androgen responsiveness, and thus by
association, the androgen receptor.
3.7 bcl-2 Expression in Cultured Prostate Cancer Cell Lines and Primary
Epithelial Cells.
The bcl-2 oncoprotein acts to block the pathways of apoptosis in many
tissues, including prostatic epithelia, which characteristically undergo programmed
cell death. Epithelial cells in the normal prostate will suffer apoptosis under the
androgen limiting conditions consequent of androgen ablation therapy. The
hormone escape characteristic of the prostate during such therapy may result from
promotion of a subset of epithelial cells resistant to apoptosis perhaps due to
upregulated bcl-2 oncoprotein. Indeed it has been demonstrated in the rat ventral
prostate that following castration, bcl-2 mRNA levels rapidly increase reaching a
maximum at around 10 days (McDonell et al, 1992).
The prostate cancer cell lines and primary epithelial cells were examined for
bcl-2 expression both at the RNA and protein levels.
3.7.1 Detection of bcl-2 mRNA in LNCaP, DU145, PC3 and Primary Epithelial
Cells by Reverse Transcription-Polymerase Chain Reaction (RT-PCR).
bcl-2a (5.5kb) and p (3.5kb) mRNA was detected by RT-PCR using intron-
spanning primers specific to each transcript, namely 5.5s/as and 3.5s/as
respectively. These primers share the same 5' primer, however bcl-2a and p exhibit
different sequences 3' of the putative intron and therefore discrimination between
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Figure 3.24 Analysis ofAR1.1 and the CAG Repeat Within Exonl of the Androgen Receptor Gene of the LNCaP,
DU145 and PC3 Cell Unes.
AR1.1 from human placenta plus the LNCaP, DU145 and PC3 cell lines was digested with Aval at 37°C for
60 minutes (A.). The CAG repeat of the AR gene from LNCaP, DU145, PC3 and human placenta (male) was amplified
by PCR for 35 cycles using 1 .CAGs and 1 .CAGas (B ). Digested AR1.1 and the PCR products were analysed by
electrophoresis through 2% agarose gels containing ~0.1p.gml"1 ethidium bromide. The gels were photographed under
transillumination.
A. 2% Agarose Gel - AR1.1 : Lane 1 - placenta; Lane 2 - LNCaP; Lane 3 - DU145; Lane 4 - PC3.
AR1.1/AvaI: Lane 5 - placenta; Lane 6 - LNCaP; Lane 7 - DU145; Lane 8 - PC3; Lane 9 - 100bp ladder.
B. 2% Agarose Gel - CAG repeat. Lane 1 -100 bp ladder. Lane 2 - placenta. Lane 3 - LNCaP. Lane 4 -
DU145. Lane 5 - PC3.
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the two transcripts is provided by the 3' primer. 5.5s/as and 3.5s/as yield PCR
products of sizes 247bp and 199bp respectively.
Figure 3.25 demonstrates the outcome of the analysis of reverse
transcribed mRNA from the prostate cancer cell lines and the primary epithelial
cultures BPH 1, BPH 2 and CaP 1 examined in section 3.2.4.. bcl-2a and p
sequences are detectable in all three of the cell lines and indeed in all the primary
epithelial cells examined.
5.5 and 3.5 amplified from CaP 1 mRNA were analysed by restriction
digestion with Alul and EcoRII respectively to determine the specificity of the
primer pairs employed. From the published sequences for 5.5 and 3.5, the
respective digests should generate fragments of sizes 127bp & 120bp and 104bp
& 95bp. Figure 3.26 A. indicates the results of the digestion of 5.5 with Alul which
clearly demonstrates the production of a fragment running at approximately 120-
130bp. Digestion of 3.5 with EcoRII produces a fragment of approximately 110bp
(Figure 3.26 B.). It would appear that the PCR products generated using 5.5s/as
and 3.5s/as are complementary to bcl-2 cDNA and that these primer pairs are
specific for bcl-2 sequences under the reaction conditions employed.
3.7.2 Detection of the bcl-2 Oncoprotein in LNCaP, DU145, PC3 and Primary
Epithelial Cells by Western Blotting.
Lysates from LNCaP, DU145 and PC3 cells all demonstrate bcl-2
expression by Western blotting (Figure 3.27 A.). In equivalent 10^g loadings of
lysates from the three cell lines the relative levels of bcl-2 expression as
determined by densitometry were as follows : PC3 (0.792) > DU145 (0.443) >
LNCaP (0.296). Evidently the androgen-independent cell lines express more bcl-2
oncoprotein than the hormone-sensitive cell line LNCaP. From the densitometric
analysis, it would appear that the PC3 cell line can be conservatively estimated to
express ~2.7 times more bcl-2 than LNCaP.
Primary epithelial cells express approximately equivalent amounts of bcl-2
to the PC3 cell line (Figure 3.27 B.).
It is worth noting that PC3 and primary epithelial cells are similar in terms of
their androgen receptor expression and responses to androgenic hormones. It may
be, that the unresponsiveness of these cells to androgens arising from insufficient
expression of a functional AR underlies the elevated expression of bcl-2 relative to
LNCaP. Could bcl-2 be an androgen-repressed gene? Secretory epithelial cells in
the normal prostate possess an androgen receptor but do not express bcl-2 to any
138
Figure 3.25 Detection ofbcl-2a and /SmRNA Transcripts in Prostatic Carcinoma Cell Lines and Primary Epithelial Cell
Cultures.
Total RNA (1pg per PCR reaction) isolated from the LNCaP, DU145 & PC3 cell lines and from the primary
epithelial cultures BPH1, BPH2 and CaP1 was reverse transcribed and amplified in a 35 cycle PCR using the primers
HGPRTs/as, 5.5s/as and 3.5s/as. "No DNA" control PCRs were performed without cDNA. The RT-PCR products were
analysed by electrophoresis through 2% agarose gels containing ~0.1 pgml"1 ethidium bromide. The gels were
photographed under transillumination.
A. 2% Agarose Gel - RT-PCR. Lane 1 - 100bp ladder. Lane 2 - No DNA. Lane 3 - HGPRT/ LNCaP. Lane 4 -
HGPRT/ DU145. Lane 5 - HGPRT/ PC3. Lane 6 - bcl-2oJ LNCaP. Lane 7 - bcl-2o/ DU145.
Lane 8 - bcl-2oJ PC3.
B. 2% Agarose Gel - RT-PCR. Lane 1 - 100bp ladder. Lane 2 - No DNA. Lane 3 - HGPRT/ LNCaP. Lane 4 -
HGPRT/ DU145. Lane 5 - HGPRT/ PC3. Lane 6 - bcl-2p/ LNCaP. Lane 7 - bcl-2p/ DU145.
Lane 8 - bcl-2p/ PC3.
C. 2% Agarose Gel - RT-PCR. Lane 1 -10Obp ladder. Lane 2 - No DNA. Lane 3 - HGPRT/ BPH1.
Lane 4 - bcl-2o/ BPH1. Lane 5 - HGPRT/ BPH2. Lane 6 - bcl-2oJ BPH2. Lane 7 - HGPRT/ CaP1.
Lane 8 - bcl-2al CaP1.
D. 2% Agarose Gel - RT-PCR. Lane 1 - 100bp ladder. Lane 2 - No DNA. Lane 3 - HGPRT/ BPH1.
Lane 4 - bcl-2p/ BPH1. Lane 5 - HGPRT/ BPH2. Lane 6 - bcl-2p/ BPH2. Lane 7 - HGPRT/ CaP1.
Lane 8 - bcl-2p/ CaP1.
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Figure 3.26 Analysis of 5.5 and 3.5 Produced by RT-PCR from CaP 1 Total RNA.
10pl of 5.5 (A.) and 3.5 (B.) synthesised by PCR from reverse transcribed total RNA isolated from CaP1 were
digested with Alul and EcoRII respectively. Digestion was carried out for 60 minutes at 37°C. The digestion products
were electrophoresed through 2% agarose gels alongside 10pl of undigested PCR product.
A. Restriction Digest (5.5/AluI). Lane 1 - 100bp ladder. Lane 2 - 5.5. Lane 3 - 5.5/AluI.
B. Restriction Digest (3.5/EcoRII). Lane 1 - 100bp ladder. Lane 2 - 3.5. Lane 3 - 3.5/EcoRII.
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great extent. Bearing this in mind, it was intended to determine whether by
introduction of the AR back into PC3 would similarly reduce bcl-2 expression.
3.7.3 bcl-2 Expression in pCMV/ARcom-Transfected PC3 Cells.
In LNCaP cells rendered steroid-free through growth in steroid-depleted
medium for 48hours the addition of fresh medium supplemented with 10nM DHT
for 24hours induces a reduction in bcl-2 protein content (Figure 3.28). Densitometry
expresses this down-regulation as lowering of the optical density of the protein
band from 0.783 to 0.661.
It appears that the bcl-2 oncoprotein is down-regulated in hormone-sensitive
cells and indeed bcl-2 gene expression exhibits a degree of hormone sensitivity.
pCMV/ARcom was transfected into PC3 cells and the cells subsequently treated
with or without 10nM DHT. Analysis of these cells for bcl-2 by Western blotting
indicates that compared to normal PC3, pCMV/ARcom-transfected cells do not
demonstrate any change in bcl-2 expression in the absence of DHT (Figure 3.29).
However, transfected cells given 10nM DHT exhibit a marked increase in bcl-2
expression.
These observations tend to suggest that the increased expression of bcl-2
in relapsed prostate cancer does not necessarily go hand in hand with the loss of
androgen receptor gene expression. However, it is clear that bcl-2 expression can
be influenced by androgens in both hormone-dependent cells and hormone-
independent cells expressing the androgen receptor although in a paradoxical
fashion.
3.8 Summary of Results.
The data presented can be summarised as follows :
1. Of all the in vitro models of prostatic epithelia examined, LNCaP, DU145
PC3 and primary epithelial cells, only the LNCaP cell line exhibits any
response to androgens or anti-androgens. Furthermore, LNCaP display
anomalous growth responses to 1.0 nM and 10.0nM hydroxyflutamide.
2. Northern blotting demonstrates that androgen receptor mRNA is only
detectable in LNCaP with little or no transcripts exhibited by any of the
androgen-independent cell models.
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Figure 3.27 Determination ofbcl-2 Expression in LNCaP, DU145, PC3 and Primary Epithelial Cells by Western Blotting.
The prostate cancer cell lines, LNCaP, DU145and PC3 plus the primary epithelial cultures, BPH1, BPH2and
CaP 1 were analysed. Human tonsil was included as a positive control. Cells grown to -80% confluence in 75cm2 tissue
culture flasks were lysed in 1xSDS gel loading buffer, the protein content assessed using the method of Bradford and
appropriate volumes of the cell lysates subsequently electrophoresed in 15% denaturing polyacrylamide gels. The
proteins were transferred to Hybond™-C extra by electroblotting and the blot probed with an anti-bcl-2 monoclonal
antibody. The protein bands were visualised using the ECL system. Autoradiography was performed for 1 minute.
A. Autoradiograph - Bcl-2. (1 Opg of protein per well.). Lane 1 - LNCaP. Lane 2 - DU145. Lane 3 - PC3.
Lane 4 - Human tonsil.




Figure 3.28 bcl-2 Expression in LNCaP Cells Grown With or Without Dihydrotestosterone.
LNCaP cells were grown to ~60% confluence in 75cm2 tissue culture flasks prior to replacing the medium with
RPMI 1640 containing 10% DCC-stripped FCS. The cells were incubated for 48 hours before aspirating the medium and
replacing with fresh medium containing either 10nM DHT or ethanol. 24 hours later the cells could be washed in PBS
and subsequently lysed in 300pl of 1xSDS gel loading buffer. The protein contents of both cell lysates were determined
and 40ug of protein per sample electrophoresed through a 15% polyacrylamide gel. The proteins were blotted onto
Hybond™-C extra and the blot probed with an anti-bcl-2 monoclonal antibody. The bcl-2 band was visualised using the
ECL protein detection system. Autoradiography was performed for 1 minute with intensifying screens.




Figure 3.29 bcl-2 Expression in PC3 Cells Transfected with pCMV/ARcom.
PC3 cells were grown to ~60% confluence in 25cm2 tissue culture flasks before transfecting with 5pg of
either pCMV/ARcom or pRc/CMV. Transfection was performed for 16 hours prior to aspirating the medium and
replacing with Ham's F12 containing 7% DCC-stripped FCS supplemented with either 10nM DHT or ethanol. Following a
further 24 hour incubation, the cells were washed in PBS and subsequently lysed in 1xSDS gel loading buffer. The
protein contents of the cell lysates were determined and 20p.g of protein per sample electrophoresed on a 15%
polyacrylamide gel. The proteins were blotted onto Hybond™-C extra and the blots probed with an anti-bcl-2 antibody.
The protein band was detected using the ECL protein detection system. Autoradiography was performed for 1 minute
with intensifying screens.
Lane 1 - untransfected PC3 -10nM DHT. Lane 2 - pCMV/ARcom -10nM DHT.
Lane 3 - pCMV/ARcom +10nM DHT.
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3. Using the more sensitive detection method of RT-PCR, androgen
receptor transcripts could be visualised in the LNCaP, PC3 and primary
epithelial cells but not in the DU145 cell line.
4. Transfection with the steroid receptor reporter plasmid pMMTV/SPAP
indicated that only LNCaP cells possess a functioning androgen receptor
and that this receptor is activated by both DHT and hydroxyflutamide.
5. The lack of any detectable androgen receptor mRNA in the DU145 cell
line is not due to any gross deletions in the receptor gene. The only
variation between the cell types was in the CAG repeat region of the gene
which in all cases was of a size well within what is accepted as the normal
range.
6. The bcl-2 oncoprotein is detectable in all four cell types, however, it is
markedly up-regulated in the androgen-independent species. This increase





In order to establish the phenotype of the androgen-independent epithelial
clones residing within relapsed prostatic adenocarcinoma, cell lines and primary
cultures of prostatic epithelia provide suitable, if not ideal, model systems. The
results presented in this thesis demonstrate striking differences between androgen-
sensitive and androgen-insensitive cells in terms of the expression of the androgen
receptor gene and the oncogene bcl-2. Although these findings are reasonably
conclusive, attempts to reconcile this data with those observations in vivo, would
tend to indicate that great care must taken in the conclusions drawn.
The three cell lines studied, LNCaP, DU145 and PC3, are all models of
advanced metastatic prostate cancer with marked differences in their sensitivity to
androgenic inputs. Before consideration of the features underlying the extent of
their androgen responsiveness it is worth reflecting upon the lesions from which
they were derived and the treatment these lesions had been subjected to. The
LNCaP cell line, as discussed in section 1.7.1., was derived from a lymph node of a
patient with stage D2 (stage M1a) who had undergone 6 months of treatment with
estracyt followed by a short period of chemotherapy (Horoszewicz et al, 1983).
Similarly the patients from which the DU145 and PC3 cells were obtained had
undergone oestrogen treatment and combined orchiectomy plus oestrogen
treatment respectively (Stone et al, 1978; Kaighn et al, 1979 and 1980). It is
noteworthy that ail of these cell lines were obtained from patients undergoing
endocrine therapy.
Recently, attempts have been made to determine the expression of the
androgen receptor in the LNCaP, DU145 and PC3 cell lines (Tilley etal, 1990a. &
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1990b.). The extent of bcl-2 gene expression in these cell lines has, however, not
been ascertained.
In primary cultures of the prostate the responsiveness of epithelial cells to
androgens is less clear-cut. A number of groups have analysed the hormone-
responsiveness of such cultures without establishing an unequivocal answer.
Furthermore, it is clear from the literature that little or no attempt - at least by
molecular biological approaches - has been made to establish the expression of
the androgen receptor and bcl-2 genes in primary epithelial cells.
The approach used in the study of the available in vitro models can be
summarised as follows : 1. measurement of cell growth in the presence of a range
of concentrations of androgens and anti-androgens; 2. assessment of androgen
receptor and bcl-2 expression by Northern analysis, RT-PCR and Western blotting;
3. measurement of androgen receptor function through transfection with the
reporter plasmid pMMTV/SPAP; 4. analysis of the androgen receptor gene in the
prostate cancer cell lines.
4.1 In vitro Responses to Androgens and Anti-androgens.
It is clear from the observed effects of androgens and anti-androgens upon
their growth, that all the cell lines and primary cultures examined display either
aberrant responses or indeed no response at all. At concentrations of between
0.001 nM and 10.0 nM, DHT and the flutamide metabolite, hydroxyflutamide, have
no significant influence upon the growth of either PC3 or DU145 cells. The LNCaP
cell line however demonstrates significantly increased growth in the presence of
DHT in the range 0.001 nM-10.0nM, two days post-administration. Sonnenschein et
al (1989) observed that the addition of DHT to LNCaP generates a biphasic
proliferative response with maximal stimulation at ~3x10"10M and marked inhibition
of growth at <3x10~12M and >3x10"^M. Such a biphasic response is not exhibited
in the range of concentrations employed by the LNCaP cells used in this study.
Despite the pronounced increase in growth rate consequent of androgen
administration, and as has been previously demonstrated by other workers, the
LNCaP cell line does not exhibit corresponding growth inhibition in the presence of
the anti-androgen hydroxyflutamide. After a four day period, the cells exhibit
significant increases in growth rate in the presence of 1.0nM and 10.0nM
hydroxyflutamide. It is noteworthy that the concentration of the anti-androgen and
indeed the time taken to elicit a significant response are considerably greater than
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in the case of DHT. This may be a feature of the greater affinity for DHT displayed
by the LNCaP androgen receptor.
The growth stimulatory action of hydroxyflutamide on LNCaP cells raises
the question of whether or not this model can be used as a model of hormone-
dependent malignant prostatic epithelia. Quite clearly it cannot.
All the primary epithelial cells behave in an androgen-independent manner
in culture. Using concentrations of androgen and anti-androgen which elicit a
growth response in the LNCaP cell line, no effect is observable in either BPH- or
CaP-derived epithelial cultures. These findings are very much in agreement with
those of McKeehan et al (1984) and Merchant (1990), the former group
consequently speculating that the epithelial cells obtained through culture of
prostatic acini are either undifferentiated basal cells or dedifferentiated secretory
epithelia. This theory is supported by observed androgen-independence in primary
cultures from rat ventral prostate coupled with a lack of expression of the prostatic
binding protein genes which are markers of secretory epithelium in this tissue
source (Montpetit et al, 1988).
4.2 Androgen Receptor Expression and Function in Prostatic Epithelial Cells.
A number of groups have demonstrated high levels of androgen receptor
gene expression in the LNCaP cell line, both at the mRNA and protein levels (Tilley
et al, 1990a.; Faber et al, 1991; Horoszewicz et al, 1983). Tilley et al (1990b.)
analysed the expression of the androgen receptor gene, not only in LNCaP, but
also in the androgen-insensitive cell lines DU145 and PC3. Examination of samples
of total RNA by Northern blotting with a 3' prime probe similar to that used in the
thesis, demonstrated that AR mRNA is undetectable in the DU145 and PC3 cell
lines. These observations are supported by steroid-binding and Western blot
analysis. In addition, attempts by Tilley etal (1990b.) to increase the sensitivity of
AR mRNA detection using S-| nuclease protection did not aid in the detection of
receptor transcripts in either DU145 or PC3.
RT-PCR performed with intron-spanning primer pairs demonstrates that the
androgen receptor gene is expressed in both the LNCaP and PC3 cell lines but not
in DU145. Southern blot analysis, used to improve the detection of low levels of
PCR product, fails to demonstrate the presence of AR transcripts in DU145. These
findings have recently been corroborated by Culig et al (1993). Furthermore, it is
also apparent that the transcripts detectable in LNCaP and PC3 appear to be of
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full length owing to the detection of both DNA- and ligand-binding domain coding
regions.
In primary epithelial cell cultures of both benign and malignant origin, which
have been demonstrated to be androgen-independent, androgen receptor mRNA is
undetectable by Northern blotting but can be measured by RT-PCR.
Clearly three tiers of androgen receptor gene expression exist in the in vitro
models studied. In this respect LNCaP and DU145 are polar, with the latter
apparently expressing no receptor message at all. Such a lack of AR mRNA does
not arise from any gross alterations or deletions of the receptor gene in DU145
since all 8 exons are detectable by PCR. The PC3 cell line and primary epithelial
cells fall some way between LNCaP and DU145, expressing sufficient AR mRNA to
be detectable by RT-PCR but not enough to overcome the detection limits of
Northern blotting. In view of such findings the obvious question to be addressed is
whether or not the levels of AR mRNA in the PC3 and primary epithelial cells are
sufficient to generate significant quantities of functional receptor protein.
Transient transfection of cells with the steroid receptor reporter plasmid
pMMTV/SPAP indicates that only LNCaP of the three cell lines studied possesses
significant androgen receptor function. Administration of 10nM DHT to
pMMTV/SPAP-transfected DU145, PC3 and LNCaP cells induces an increase in
the secreted alkaline phosphatase activity only in the latter case. No significantly
higher levels of SPAP activity are observed in either DHT-treated DU145 or PC3
cells over control cells. Similarly transfection with pMMTV/SPAP followed by DHT
treatment does not elevate the levels of alkaline phosphatase secreted by primary
epithelial cells. Thus it would appear that under the experimental conditions used
there is insufficient androgen receptor in either DU145, PC3 or primary epithelia to
raise the rate of transcription from the MMTV promoter. Therefore, it is reasonable
to propose that the extent of AR gene expression observed in the PC3 cell line and
primary epithelial cells does not generate, in terms of transcriptional control, a
cellularly-significant level of receptor protein. This is further borne out by the
observation that the PSA gene, which has been postulated to be under the direct
control of androgens owing to the close proximity of an androgen response
element, which is not expressed at all in the DU145 cell line, is basally expressed in
PC3 cells and primary epithelial cells (Meyer et al, 1993; Fong et at, 1991).
Additionally, Fong et al (1991) could not detect any significant increase in PSA
release from primary cultures following DHT administration.
So why is the androgen receptor mRNA down-regulated in the DU145, PC3
and primary epithelial cells compared to LNCaP? The two potential reasons for
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these dramatic alterations are either reductions in the rate of transcriDtion of the AR
gene or changes in the half-life of the receptor message itself. In the case of the
DU145 cell line we can probably discount decreased half-life of the receptor
message since it would surely be possible to detect some AR gene transcripts by
RT-PCR. More likely is that alteration of the promoter is responsible for the
complete shut-off of the AR gene in DU145. This alteration may take the form of a
direct mutation within a transcription factor binding site for example or perhaps
hypermethylation of the promoter DNA. Such site-specific methylation of cytosine
has been demonstrated to induce transcriptional inactivation in a number of
eukaryotic genes (for review see Strobl, 1990) and it is worth noting that the AR
gene promoter is very C-rich.
Whatever the mechanisms involved, it would appear at first glance that the
hormone-independence which characterises the DU145 and PC3 cell lines in
addition to the primary epithelial cells has its origins in the lack of significant levels
of fully functional androgen receptor. However the re-introduction of AR into these
cells produces unexpected results following androgen administration. Yuan et al
(1993) in their analysis of the behaviour of PC3 cells stably transfected with AR
cDNA established that the addition of DHT at a range of concentrations from 0.1 nM
to 10(xM decreased the rate of proliferation by ~40-50% compared to untransfected
and mock transfected cells. It is certainly surprising that at all of the test
concentrations examined their response should be negative, bearing in mind the
response of LNCaP to DHT. In addition to this, it is worth noting that the arrest of
cell growth associated with LNCaP maintained in steroid depleted medium is not a
feature of AR-positive PC3 cells. The transfectants demonstrate only slight and
almost certainly insignificant decreases in growth rate under these circumstances.
In view of these observations it would appear that in terms of the regulation of cell
growth at least, the AR acts as both a stimulatory and inhibitory transcription factor
in prostatic tumour cells. As a consequence, the loss of the AR in androgen-
independent cells represents the removal of a transcriptional repressor not a
transcriptional enhancer.
Using immunohistochemistry, Sica et al (1994) have recently demonstrated
that the PC3 cell line, in common with some androgen-independent tumours,
displays heterogeneous staining for the AR with a low percentage of strongly
positive cells. Interestingly, treatment with p-interferon (p-IFN) increases the
number of receptor-positive cells with concomitant decreases in growth rate.
Furthermore, the increased expression of the androgen receptor results in an
increased growth rate following the administration of the anti-androgen
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hydroxyflutamide. Evidently the paradoxical action of DHT in AR-positive PC3 cells
is paralleled by unusual responses to androgen antagonists.
These observations in the PC3 cell line raise a number of interesting
questions regarding the nature of androgen-independent prostate cancer cells. It is
likely that the AR mRNA detectable by RT-PCR originates from the small number of
AR expressing cells that contaminate PC3. The receptor protein encoded by this
mRNA is structurally normal judging by the sequence information provided by Culig
et al (1993) and therefore it must be concluded, bearing in mind the results of Yuan
et al (1993), that in AR-positive PC3 cells different genes are being regulated or
are regulated in a different manner than in ordinary receptor-positive prostate
cancer cells. In this respect it might prove interesting to determine whether there is
any differences in growth factor expression between LNCaP and PC3 and how, if
at all, this relates to androgen inputs. What is clear if one considers the apparent
basal expression of PSA in PC3, is that the changes in androgen-regulated gene
expression apparently characteristic of androgen-independent prostate cells are
extremely specific and do not necessarily involve all AR-dependent genes.
Unusual features of androgenic control are not only confined to hormone-
independent cells. The transfection studies demonstrate that the growth stimulatory
effect of hydroxyflutamide on the LNCaP cell line is paralleled by agonistic effects
upon the endogenous AR. pMMTV/SPAP-transfected LNCaP respond to the
administration of 10nM hydroxyflutamide with an increase in alkaline phosphatase
synthesis and secretion equivalent to that invoked by DHT. In addition, the anti-
androgen does not antagonise the action of DHT at this concentration but rather
acts in synergy with it to enhance the MMTV promoter activity. Veldscholte et al
(1992b.), amongst others, have published similar data to that presented here using
a reporter plasmid containing the cDNA for chloramphenicol acetyltransferase
(CAT) downstream of the MMTV-LTR. With this system Veldscholte et al (1992b.)
demonstrated that the LNCaP AR could induce CAT production when binding both
hydroxyflutamide and the synthetic androgen/progesterone receptor ligand
methyltrienolone (R1881), the latter proving to be only ~1.5-2 times more potent
agonistically.
The apparently paradoxical effects of hydroxyflutamide have been blamed
upon the thr868 to ala point mutation present within ligand binding domain of the
LNCaP androgen receptor. Certainly the introduction of wild-type AR into LNCaP
via the plasmid construct pCMV/ARcom dramatically alters the outcome of co-
transfection studies with the pMMTV/SPAP reporter. Co-transfectants exhibit
significant increases in alkaline phosphatase activity when supplied with DHT,
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however in contrast to previous findings, hydroxyflutamide cannot enhance the rate
of transcription of the SPAP gene. This profile of AR function is identical to that
obtained in the AR-negative cell line PC3. The effects of the AR mutation in LNCaP
is quite startling, however, quite why a single somatic alteration should impel a
receptor protein to completely reverse one its functional characteristics is unclear. It
seems unlikely that altered binding kinetics are relevant in this context since the
LNCaP receptor displays only a marginally higher affinity for hydroxyflutamide than
its wild-type counterpart (Veldscholte et al, 1992b.). What seems more plausible is
that the mutation somehow dictates an altered conformational response to
hydroxyflutamide binding, allowing transformation of the receptor into a DNA-
binding state. Although evidence in support of this claim is limited, normal
pathways of receptor activation appear to prevail. In particular, the shedding of the
heat shock proteins hsp90, hsp70 and hsp56, which predisposes the AR to
transcriptional activation following ligand-binding, also occurs upon interaction with
hydroxyflutamide (Veldscholte et al, 1992a.).
4.3 bcl-2 Expression in vitro.
Since its initial discovery in human B-cell lymphomas, the bcl-2 oncoprotein
has spawned much interest amongst researchers. Cell death currently being a very
fashionable topic in biological research, it is of no great surprise that an oncogene
product whose expression is so tightly restricted to tissue types characterised by
programmed cell death and which has the ability to block this form of cell death has
gained so much attention.
In the prostate bcl-2 expression, which is essentially a basal epithelial
phenomenon, has been implicated in the progression of prostate tumours to
androgen-independent growth. The rational of this hypothesis being that bcl-2
expressing cells are able to survive in circumstances which would normally initiate
apoptosis in malignant prostatic epithelia e.g. under conditions of androgen
deprivation. Data presented by McDonnell et al (1992) and Colombel et al (1993)
would tend to support such an idea, both groups having observed that the
expression of the bcl-2 oncoprotein is elevated in hormone refractory prostatic
tumours compared to androgen-dependent neoplasms.
The results presented in the thesis demonstrate that expression of the
bcl-2 oncogene, assessed at both the protein and mRNA levels, is detectable in the
three cell lines and all of the primary epithelial cell cultures examined. Western
blotting has shown that the PC3 cell line in addition to the primary epithelial cells
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contain high levels of bcl-2 protein, conservatively estimated by densitometric
analysis to be approximately 2-3 times greater than in LNCaP. Expression of bcl-2
in the DU145 cell line falls some way between LNCaP and PC3. It would therefore
appear that the bcl-2 oncoprotein is up-regulated in the hormone-independent
prostate cells compared to the androgen-dependent epithelia.
The full significance of this altered bcl-2 gene expression is not entirely
clear, however, there is strong evidence to suggest that susceptibilities to
programmed cell death are altered concurrently. Buttyan et al (1993) demonstrated
in their analysis of the behaviour of LNCaP cells stably transfected with bcl-2 cDNA
that the levels of bcl-2 oncoprotein normally present in this cell line are insufficient
to prevent cell death inducible either by culture in serum-free medium or treatment
with phorbol esters. Apoptosis cannot be induced as easily in androgen-
independent cells as confirmed by the primary epithelial cells used in the thesis
which are generated and maintained under serum-free conditions. Furthermore,
Yuan et al (1993) have demonstrated that the PC3 cell line is highly resistant to
apoptosis-inducing agents such as the calcium ionophore ionomycin in high
concentration. It may well be, in face of such evidence, that the elevated bcl-2
expression in PC3 and primary epithelia suppresses or at least contributes to the
suppression of apoptosis in these cells.
The fact that the androgen-sensitive cell line LNCaP expresses significantly
less bcl-2 than its hormone-independent counterparts, lead us to considerwhether
some relationship exists between AR expression and that of bcl-2. In LNCaP the
levels of oncoprotein are modulated by DHT such that it increases in an androgen-
deprived environment. However, re-introduction of the androgen receptor into the
PC3 cell line does not result in any dramatic reduction of bcl-2 expression in these
cells, on the contrary, administration of DHT produces a marked up-regulation. The
suggestion is that receptor loss and bcl-2 up-regulation are purely coincidental.
The paradoxical effects of DHT administration upon the levels of bcl-2 in the
AR-positive LNCaP and PC3 cells are perhaps unsurprising in light of the
observations of Yuan et al (1993) and may either represent altered gene
expression or a change in the proportion of cells expressing the oncogene. In this
context it might have proved useful to examine both cell lines
immunohistochemically to ascertain the staining patterns for bcl-2 and how these
are altered in response to androgens. It might be envisaged, for example, that
LNCaP and PC3 cells are composed of a mixture of bcl-2-positive and bcl-2-
negative cells and that cells expressing the oncogene display growth advantage in
unfavourable androgen environments and subsequently increase proportionately in
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the population. This situation may well mimic that observed by McDonnell et al
(1992) in the rat ventral prostate following androgen ablation in which increased
bcl-2 expression parallels the outgrowth of apoptosis-resistant cells.
If the cells in a hormone-independent tumour contain high levels of bcl-2
oncoprotein it may prove difficult to induce cell death through the use of non-
mitosis-dependent chemotherapeutic agents such as ionomycin or the endoplasmic
reticulum Ca2+-ATPase pump inhibitor thapsigargin (Thastrup et al, 1990).
Subsequently, specific inhibition of the bcl-2 oncoprotein or other anti-apoptosis
proteins may be necessary in order to induce programmed cell death in androgen-
independent prostate cancer cells.
Reed et al (1990) demonstrated that antisense oligonucleotides targeted
against the predicted translation-initiation site of the bcl-2 oncogene could
specifically inhibit the growth of the leukaemic cell line 697 in a dose dependent
fashion. This growth inhibition followed the near complete removal of the bcl-2
oncoprotein from the 697 cells. In theory, the cellular significance of bcl-2 in
prostate cancer cells could be assessed through its antisense-mediated
eradication.
Preliminary experiments with the bcl-2 phosphorothioate antisense
oligonucleotide 5'CAGCGTGCGCCATCCTTCCC^' - a sequence which does not
cross-react with any other human genes - and the PC3 cell line have yielded
disappointing results. After supplementing with antisense oligonucleotides at
concentrations of 50 to 300pM, Western blotting demonstrated that the levels of
bcl-2 oncoprotein was not altered over a four day period. Either the
oligonucleotides were unable to enter the cell or could not target the bcl-2 mRNA
efficiently. It is noteworthy in this respect that phosphorothioate oligonucleotides
despite offering the benefit of a degree of nuclease resistance are notoriously
difficult to transport across the plasma membrane, and to date, attempts at
improving delivery through the use of lipofection has only led to cytotoxicity
problems. If these membrane transport problems can be overcome it will be
possible to properly assess the influence of the bcl-2 oncogene in androgen-
independent prostate malignant epithelial cells.
4.4 Implications for Primary Epithelial Culture of the Prostate.
The prime concern in establishing a primary prostatic culture is that the
population of cells obtained should be a pure population of either epithelial or
fibroblast cells with little or no cross-contamination. It is generally held that the
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plating of prostatic organoids or fragments of prostatic tissue in media containing
high percentages of foetal calf serum necessarily leads to the overgrowth of the
cultures by fibroblasts (Webber, 1980). Therefore, in attempts to develop epithelial
cell cultures which are fibroblast-free, much emphasis has been placed upon the
use of serum free conditions similar to those defined by Chaproniere and
McKeehan in 1986. This group successfully cultured pure prostatic epithelia from
acinar deposits - derived from collagenase treated prostatic tissues - in a serum-
free medium which will not support fibroblastic growth. However, since at least
three varieties of cell in the prostate are epithelial in nature, there is an obvious
necessity once a successful and reproducible method of culture has been
established to determine the exact cell type. Clearly in terms of the study of
prostatic neoplasia it is the secretory epithelial cell which is of greatest interest and
consequently the ability to efficiently culture this cell type would be of immense
value. Unfortunately, as the results presented in the thesis would lay testimony to,
the cells yielded under the culture conditions of Chaproniere and McKeehan are in
no way representative of a secretory epithelial cell in vivo.
The secretory epithelial cells within a prostatic acinus are without doubt the
most significant cell type in terms of prostatic physiology and the pathogenesis of
neoplasia. They are inherently androgen-dependent, expressing high levels of
androgen receptor and displaying dramatic alterations in gene expression
dependent upon the hormonal environment. The epithelial cells obtained using the
methods of Chaproniere and McKeehan display markedly less androgen receptor
gene expression than the LNCaP cell line and do not exhibit androgen-sensitive
growth characteristics. Furthermore, previous studies in this laboratory have
demonstrated that primary cells do not secrete PSA.
The androgen-independence characteristic of the cells employed in this
study has also been observed in primary epithelial cells derived from the rat ventral
prostate and has prompted conjecture that these cultures are derived from either
basal cells or de-differentiated secretory epithelia (McKeehan et al, 1984; Montpetit
et al, 1988). Certainly in common with the primary cultures the basal epithelial cells
of the human prostate are essentially androgen receptor-negative and express high
levels of the bcl-2 oncoprotein.
We can only speculate as to the reasons why such a cell type should
predominate in primary culture. As previously eluded to, hormone-sensitive
prostate epithelia such as the LNCaP model are prone to programmed cell death
when grown in serum-free medium (Buttyan et al, 1993) and it is entirely likely that
the conditions in which the primary cultures are maintained are unsuitable for
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secretory cell propagation. It could be envisaged that when prostatic acini are
plated in serum-free medium the basal epithelia are able to survive and multiply
whereas the secretory cells are induced to undergo programmed cell death in
much the same way as they would under conditions of androgen-deprivation in
vivo. Presumably since fibroblasts are unable to survive under these circumstances
they are similarly pre-disposed to cell death. Why the basal epithelia are able to
survive when the secretory epithelia and fibroblasts do not is also unclear,
however, it is possible that the overexpression of the bcl-2 oncoprotein is involved.
Obviously primary epithelial cell culture serum-free medium requires some
refining in order to permit secretory cell outgrowth. Initial attempts to promote
secretory cell propagation by creating a culture environment that retains some
characteristics of the prostate, i.e. high levels of DHT and fibroblast-derived growth
factors, has failed to generate a cell which expresses the androgen receptor and is
therefore responsive to androgens. Fong etal (1991) have demonstrated that
epithelial cells grown in serum-free medium can be induced to secrete high levels
of PSA when grown on reconstituted basement membranes. This PSA expression
is significantly increased in the presence of DHT, fibroblast conditioned medium
and a combination of DHT plus fibroblast conditioned medium. It is unknown at this
stage whether or not this PSA secreting cell exhibits androgen-sensitive growth
and if, as suspected, it expresses the androgen receptor.
There is a school of thought that basal epithelial cells are the progenitors of
secretory epithelia. This theory propounds that basal epithelia are acting as so-
called "reserve cells" able to replace their luminal counterparts via one or more
stages of differentiation (Trump et al, 1981). It is extremely interesting that the
provision of an extracellular matrix has the potential to allow cellular progression
through such differentiation in vitro, however, further characterisation must surely
be carried out before this approach can be considered standard protocol for
primary culture of secretory prostatic epithelial cells.
Despite the fact that the primary epithelial cells used in the thesis are non-
secretory by nature, it is not necessarily the case that they are worthless as an in
vitro model in prostate research. On the contrary there are recognisable similarities
between these cells and the hormone-independent prostate cancer cell line PC3
which might be usefully exploited in the study of potential therapeutic agents for the
treatment of relapsed prostatic tumours. A good deal of emphasis has been placed
upon the development of such chemotherapeutic drugs with the ability to induce
cell death in hormone-independent prostate cancer cells. In this respect primary
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epithelial cells may provide a more in vivo-like alternative to the established cell
lines for in vitro studies.
4.5 Hormone Escape in vitro and in vivo.
How do the underlying features of hormone-independence in the cell
models compare with what is observed in the relapsed prostate tumour?
Both the DU145 and PC3 cell lines do not express functionally significant
levels of androgen receptor. However, immunohistochemical analysis of escaped
prostatic adenocarcinomas for androgen receptor staining has failed to
demonstrate that the receptor-negative phenotype characteristic of DU145 and
PC3 is typical of all androgen-independent cells in vivo. Different groups using
assorted anti-AR antibodies have demonstrated that the progression of prostatic
adenocarcinomas to androgen independence correlates well with a reduction in the
numbers of AR-positive cells (Quarmby et al, 1990; Masai et al, 1990). A similar
number of research groups have observed no alteration in receptor expression
following tumour relapse (van der Kwast et al, 1990; Furuya et al, 1992)). These
divergent findings may merely represent differences in the specificity of the
receptor antibodies, however, it is entirely likely that relapsed prostatic
adenocarcinomas display phenotypic variation. Potentially androgen-independent
tumours cells may express normal or mutated androgen receptor or indeed no
receptor protein at all. What dictates this AR status is unclear.
It is now known that PC3 cells expressing the androgen receptor do not
behave like normal prostatic epithelial cells in an androgen-deprived environment.
On the contrary, such PC3 cells are unaffected by androgen ablation but are
growth inhibited in the presence of DHT. If AR-positive cells such as this population
of PC3 existed within a prostatic tumour it might be expected that their propagation
would be suppressed in a normal androgenic environment but they would be
allowed to grow as normal at the expense of androgen-dependent cells following
androgen ablation therapy.
Since PC3 cells will grow in an androgen-deprived environment irrespective
of whether they express the androgen receptor or not, the question must be asked
as to why the AR is down-regulated. This may well be the final step in the pathways
of differentiation in androgen-independent prostate cancer cells in which they
isolate themselves completely from any androgenic influence. Such an event is
likely to be a late event in the natural history of prostate tumours. For instance, it is
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hard to envisage that AR-negative PC3 cells would be present in a pre-treatment
tumour as they would undoubtedly grow uncontrolled in any hormonal environment.
It is clear from the data presented in the thesis and from other studies that
great care must be taken when describing the LNCaP model of advanced prostate
cancer. This cell line may exhibit positive responses to androgens in terms of
propagation and transcription activation via the androgen receptor, but is no more a
model androgen-dependent CaP than the PC3 or DU145 lines. Far from it, there is
strong evidence to suggest that LNCaP cells mimic the malignant epithelial cells
predominating in a number of androgen-independent tumours.
In addition to DHT, the growth rate of LNCaP cells is increased in response
to the anti-androgens flutamide, hydroxyflutamide and cyproterone acetate plus
oestrogenic and progestagenic compounds. These unusual growth characteristics
are mediated by an androgen receptor protein mutated in the ligand-binding
domain (thr888 to ala) such that its ligand specificity is altered to accommodate
these additional ligands. The only documented example of a thr868 to ala AR
mutation within a prostatic tumour was until recently in a single metastatic lesion
analysed by Suzuki et a/in 1993. Gaddipati et al (1994) have subsequently
demonstrated that the LNCaP mutation is far more wide-spread than previous
studies would suggest. Sequence analysis of archival tumour specimens from 24
patients with advanced disease (stage C to D2) demonstrates that 6 individuals
(25% of patients) carry the thr888 to ala mutation. Undoubtedly, if these tumours
were treated in either monotherapy with oestrogens or in combination therapies
involving flutamide the cells carrying the mutated androgen receptor would have
growth advantage over normal hormone-dependent malignant epithelial cells. It
may even be the case that treatment with either oestrogens or flutamide induces
hormone escape in prostatic adenocarcinomas through promotion of LNCaP-like
cells. Unfortunately Gaddipati eta! (1994) do not include the treatment protocols
used with each individual patient studied otherwise it might be possible to validate
this theory, however, it is perhaps noteworthy that almost all the advanced prostate
tumours which were observed to be AR-positive by van der Kwast et at (1991) had
been treated with oestrogens.
All of the recent observations in the PC3 and LNCaP cell lines have forced
us to consider hormone escape in advanced prostate tumours in a completely new
light. Mechanistically it is clear that there are at present at least two distinct
possibilities for tumour relapse i.e. the complete or partial hormone-independence
characteristic of PC3 and the "hormone-promiscuity" of the LNCaP cell line. The
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ability of the PC3 cell and of potential PC3-like cells in vivo to prosper in an
androgen-free environment is proposed to demand an alteration in the control of
androgen-regulated genes rather than any alteration in the AR. In contrast, the AR
itself is central to the survivability of LNCaP-like cells through its inherent ability to
scavenge for alternative ligands. Whether different genes are targeted by the
androgen receptor in LNCaP than in truly hormone-dependent tumour cells is
unknown, although it is probably unlikely owing to the similarity of response to
ligand deprivation.
Is the phenotype of the hormone escaped prostatic adenocarcinoma
treatment-related? Evidence to support the claim that treatment protocols involving
the use of oestrogens, flutamide and cyproterone acetate pre-dispose tumours to
relapse through promotion of cells with androgen receptors carrying the thr888 to
ala mutation is at best very limited. Furthermore, whether orchiectomy induces
tumour relapse through an alternative pathway e.g. the outgrowth of PC3-like cells
is equally unclear. If a strong link between treatment type and tumour progression
could be established then it might be possible to tailor therapies such that a more
effective management protocol could be offered. Endocrine manipulation of
prostatic adenocarcinoma would subsequently take account of the potential for
PC3 and LNCaP cell outgrowth.
Akakura et al (1993) have published a treatment regime based upon the
intermittent suppression of circulating androgens. Androgen ablation therapy was
performed until such times as the serum PSA achieved normal levels before
cessation of the treatment. Thereafter, upon recovery of testicular function,
androgen-withdrawal was resumed when the serum PSA rose to ~20mgL~''. This
cycle was repeated sequentially over treatment periods of 21 to 47 months with no
loss of androgen dependence. The rationale behind this approach to tumour
management is that androgen replacement following a period of apoptotic
regression might result in the regeneration of cells with further apoptotic potential
rather than allowing therapy-resistant cells to become established. Furthermore it is
now apparent that if AR-positive PC3-like cells form part of the tumour cell
population they will be growth inhibited upon re-introduction of androgens.
Whether this novel treatment regime offers any significant benefits in terms
of survival is unclear at this juncture owing to the small numbers of patients
involved and the obvious limitations of a relatively short follow-up period.
Nevertheless, the delayed onset of hormone escape associated with this approach
is very heartening and with slight adjustment may offer the way forward for
endocrine management of prostatic adenocarcinoma.
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Akakura et a/(1993) achieved complete androgen blockade using
combinations of the non-steroidal anti-androgen cyproterone acetate and
diethylstilbestrol or cyproterone acetate plus a LHRH agonist goserelin.
Considering the potential for the outgrowth of LNCaP-like cells, this may not be the
most advisable drug cocktail. Veldscholte et al (1992) demonstrated that the
LNCaP androgen receptor is activated by cyproterone acetate in a similar fashion
to hydroxyflutamide, reaching a maximum at concentrations above 10"7M. Beyond
doubt, if cyproterone acetate or indeed diethylstilbestrol induces growth of LNCaP-
like cells in the tumour the recovery of normal androgen levels will only serve to
further promote the proliferation of these cells along with the remaining androgen-
dependent cells. The effects of subsequent administration of cyproterone actetate
and diethylstilbestrol are obvious.
The effectiveness of the intermittent suppression of circulating androgens or
indeed standard androgen ablation protocols in the treatment of advanced may be
improved by taking account of LNCaP-like cell propagation and using drugs that do
not activate the mutated androgen receptor. Oestrogens are therefore not
advisable and emphasis must be placed on the use of LHRH agonists. Of the
commonly used anti-androgens only Casodex marketed by Zeneca Ltd. efficiently
blocks the transcription activation function of the LNCaP androgen receptor
(Veldscholte etal, 1992).
Whether or not such tailoring of endocrine management protocols will
provide any long-term benefits for CaP sufferers remains to be seen. What is
apparent at this stage is that the new approaches to treatment cannot offer
complete immunity from hormone escape. Akakura et al (1993) observed in the
androgen-dependent Shionogi carcinoma that despite favourable initial responses
to intermittent androgen suppression the tumour would progress to an androgen-
independent state after the fifth treatment cycle. At this point the use of
chemotherapy represents the only course of action.
A number of chemotherapeutic agents which target mitotically active cells
have been used in the treatment of relapsed prostatic adenocarcinomas with little
benefit in terms of patient survival. The reasons underlying the failure of these
cytostatic/cytotoxic drugs is that more than 90% prostate cancer cells are in
interphase at any particular moment in time and are therefore insensitive to the
effects of chemotherapy. However, there is light at the end of the tunnel. Human
androgen-independent prostate cancer cells can undergo programmed cell death.
Kyprianou et al (1994) have recently demonstrated that the depletion of
intracellular thymidine-5-phosphate using 5-fluoro-2-deoxyuridine or
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trifluorothymidine can induce apoptosis in the highly proliferative PC3 and DU145
cell lines. Whether or not other apoptosis-inducing agents which do not rely on cell
division, such as calcium ionophores, will have similar influences on human
prostatic cells in vivo and in vitro remains to be fully elucidated. The effects of
ionomycin with hormone-independent rat prostate cancer cells are extremely
encouraging (Martikainen et al, 1991) and although the results from studies
involving such Ca^+ ionophores and human cells are to date slightly less
heartening (Yuan et al, 1993), it is easy to envisage that these drugs or other
apoptosis-targetting agents could represent the future for the treatment of
advanced prostate cancer.
4.6 Future Studies.
The cellular mechanisms underlying the hormone-independence of relapsed
prostatic adenocarcinomas are so inadequately defined that there remains a wealth
of topics for future investigation.
The loss of a functionally significant level of androgen receptor in the
hormone-independent cell lines DU145 and PC3, although probably not the step
that initially commits the prostatic epithelial cell to androgen unresponsiveness,
certainly requires further investigation. This AR down-regulation may occur by one
of two routes; either a decrease in the half-life of the androgen receptor mRNA or
an alteration of the androgen receptor promoter.
The LNCaP androgen receptor gene promoter was initially cloned and
sequenced by Tilley et al in 1990, but is only now becoming fully characterised.
Using the cloned LNCaP androgen receptor promoter it should be possible to
determine whether the DU145 and PC3 cell lines have the necessary
transcriptional machinery to allow androgen receptor gene expression. Transfection
of the hormone-independent cells with a plasmid construct containing the SPAP
gene under direct transcriptional control by the AR promoter would allow
determination of whether AR down-regulation in these cells is a consequence of
the loss of one or more transcription factors.
Assuming that the AR promoter is inactive in either the DU145 or PC3 cell
lines and the SPAP gene is not transcribed, then logically the next step must surely
be to determine the missing transcription factor or factors. In this respect, it is
essential that sequences important in transcriptional control of the receptor gene
be determined. Such information may be obtained through mutation or deletion of
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potential transcription factor binding sites in the promoter region of the AR gene.
Using band-shift assays it may then be possible to screen nuclear extracts derived
from the DU145 and PC3 cell lines with relevant sequences in an attempt to
determine the transcription factor deficiencies.
If the LNCaP AR promoter is fully functional in the hormone-independent
cell lines then the endogenous promoter regions must be examined.
There may be a case for sequencing of the androgen receptor promoter in
DU145 and PC3 cells in order to ascertain the potential disruption of transcription
factor binding sites or other translation initiation sequences. Of particular interest
in this respect is the binding site for the transcription factor SP1 residing within the
GC-box of the AR gene promoter, mutation of which results in the abolition of
mRNA synthesis from at least one of two potential transcription initiation sites
(Faber etal, 1993).
Additionally it might be possible to determine whether the AR promoter is
hypermethylated in DU145 and PC3 through the analysis of restriction fragments
obtained using restriction enzymes sensitive to CpG methylation. There are a
number of restriction endonucleases, for example Bell and MboII, which are not
sensitive to certain site-specific methylations and can therefore be used to achieve
complete digestion of modified DNA. However, almost all enzymes with CpG in the
recognition sequence fail to cleave m5CpG-rnethylated DNA (Nelson and
McLelland, 1987). Consequently, such methylation-sensitive endonucleases will
generate aberrant restriction fragments on Southern blots if the target DNA
displays hypermethylation.
The findings of Yuan et al (1993) concerning the behaviour of the PC3 cell
upon reintroduction of the androgen receptor are extremely important in terms of
the study of hormone escape. The implications of this work are that the switch from
androgen-dependent growth to androgen-independent growth may be associated
with a change in the control of gene expression and not necessarily with a change
in genes expressed. Could there be a hormone-independent transcription factor for
instance?
In an androgen-dependent epithelial cell a fine balance is maintained
between cell propagation and cell death. DHT is central to the maintenance of this
equilibrium and carries out two basic functions within the epithelial cell i.e. to
enhance the expression of growth promoting genes and to suppress the
transcription of cell death genes. Androgen ablation therefore has rather obvious
and dire consequences. Yuan's observations imply that the essential feature of
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androgen-independent prostate cancer cells is that androgen regulated gene
expression exhibits paradoxical responses to androgen ablation such that, for
example, cell death genes are not activated following androgen deprivation but
may well be upon administration of DHT. Evidence to support this theory is
exceptionally thin on the ground mainly due to the fact that only one or two genes
in humans are known to be truly androgen-responsive. Nevertheless, the elevated
levels of serum PSA in the vast majority of orchiectomised patients with relapsed
prostatic adenocarcinomas (Fossa et al, 1992) would tend to reinforce belief in a
change in the control of gene expression in androgen-independent cells.
The obvious question arising from Yuan's work is whether or not the effects
of androgens on AR-positive androgen-independent prostate cancer cells is merely
a peculiarity of the PC3 cell line. It is therefore essential the responses to
androgens of DU145 cells, stably transfected with androgen receptor cDNA, be
assessed. It might also prove useful, in view of the apparent differences in PSA
production in vivo and in vitro, to re-examine the expression of PSA in DU145 -
perhaps at the transcriptional level - and PC3 and its relationship with the androgen
receptor. At the present time this is about as far as such a study could be carried
through owing to, as previously eluded to, the lack of recognised androgen-
responsive genes and our minimal understanding of the mechanisms underlying
androgen-dependent gene expression.
There is a strong case for using the expression of the bcl-2 oncogene
prognostically as an indicator of patient performance and the time between primary
hormone treatment and relapse due to its strong correlation with the onset of
androgen-independence. However the question still remains as to the significance
of bcl-2 in androgen-independent cells. Antisense oligonucleotides offer a viable
means of ablating the bcl-2 oncogene function such that the susceptibilities to cell
death-inducing agents could be re-assessed. Either phosphorothioate or
phosphodiester oligonucleotides could be used, the former offering the advantage
of greater nuclease resistance but also displaying poorer membrane transport
properties. Lipofection or electroporation could be used to get the antisense into
the cells, however, if these approaches proved unsuccessful, it might be possible
to transfect the cells with a plasmid construct carrying the antisense sequence.
Primary epithelial cell cultures are without doubt the most desirable in vitro
model for prostate research, offering everything that the established cell lines have
in terms of ease of study but retaining more of the in vivo characteristics often lost
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through differentiation in the cell lines. A pure secretory epithelial cell population is
truly the holy grail of prostatic cell culture and all work carried out in this field is
geared toward the establishment of this cell type in vitro. Unfortunately the primary
cells used in the thesis are phenotypically more akin to basal epithelial cells.
However, some encouragement has been provided by Fong et al (1991) who have
demonstrated that the presence of an extracellular matrix allows these basal cells
to progress onto a state where they exhibit secretory attributes, notably the
synthesis and secretion of PSA. It is surely necessary to determine whether or not
these differentiated cells also express the androgen receptor and exhibit androgen-
dependence before accepting them as secretory epithelia. Establishment of
androgen-dependence in vitro would represent a monumental advance.
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